<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4261061/results/search/cochrane/results.xml">
   <result pre="plus docetaxel neoadjuvant chemotherapy from those that did achieve a" exact="pCR" post="( 22). We validated our findings by performing dose"/>
   <result pre="uM or DMSO. Viable cells were counted by trypan blue" exact="exclusion" post="5 days after the addition of drug. Results show"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4293298/results/search/cochrane/results.xml">
   <result pre="complete response after neoadjuvant therapy. 40 Concerning endocrine therapy, a" exact="meta-analysis" post="41 showed that aromatase inhibitors are significantly more effective"/>
   <result pre="44 and reported similar objective clinical responses but more hematologic" exact="adverse events" post="in the concomitant arm, with more hand–foot syndrome in"/>
   <result pre="reconstruction in this population. Age alone should not be an" exact="exclusion" post="criterion. 72 Indeed, breast reconstruction in the elderly preserves"/>
   <result pre="are under investigation. Concerning postoperative accelerated partial breast irradiation, a" exact="meta-analysis" post="96 of three randomized trials 97– 99 evaluating 1,140"/>
   <result pre="inhibitors are associated with more bone fractures 107 and musculoskeletal" exact="adverse events." post="In the exploratory analysis of ATAC (Arimidex Tamoxifen Alone"/>
   <result pre="trigger a switch to intravenous bisphosphonate therapy. 114 Finally, specific" exact="adverse events" post="predict a survival benefit in patients treated with aromatase"/>
   <result pre="tumor status. This tool helps the clinician to estimate the" exact="outcome" post="with local treatment only and the potential benefit of"/>
   <result pre="aromatase inhibitors improved PFS. Elderly everolimus-treated patients had incidences of" exact="adverse events" post="(stomatitis, infections, rash, pneumonitis, and hyperglycemia) that were similar"/>
   <result pre="183 Vascular endothelial growth factor-targeted therapy Regarding antiangiogenic agents, a" exact="meta-analysis" post="184 of the three randomized trials evaluating bevacizumab as"/>
   <result pre="well tolerated with no increase in the incidence of bevacizumab-related" exact="adverse events" post="in patients aged over 65 years. In the subgroup"/>
   <result pre="Pierga JY Girre V Laurence V et al. Characteristics and" exact="outcome" post="of 1,755 operable breast cancers in women over 70"/>
   <result pre="Diab SG Elledge RM Clark GM Tumor characteristics and clinical" exact="outcome" post="of elderly women with breast cancer J Natl Cancer"/>
   <result pre="Velde CJ Preoperative chemotherapy for women with operable breast cancer" exact="Cochrane" post="Database Syst Rev 2007 2 CD005002 17443564 37 Semiglazov"/>
   <result pre="vs tamoxifen alone for older women with operable breast cancer:" exact="Cochrane" post="review Br J Cancer 2007 96 7 1025 1029"/>
   <result pre="DJ Breast reconstruction in older women: should age be an" exact="exclusion" post="criterion? Plast Reconstr Surg 2006 118 1 16 22"/>
   <result pre="patients with early stage breast cancer: a systematic review and" exact="meta-analysis" post="Ann Surg Oncol 2014 21 3 786 24271158 77"/>
   <result pre="irradiation or whole breast radiotherapy for early breast cancer: a" exact="meta-analysis" post="of randomized controlled trials Breast J 2010 16 3"/>
   <result pre="872 18703382 110 Khan QJ O’Dea AP Sharma P Musculoskeletal" exact="adverse events" post="associated with adjuvant aromatase inhibitors J Oncol 2010 2010"/>
   <result pre="115 Fontein DB Seynaeve C Hadji P et al. Specific" exact="adverse events" post="predict survival benefit in patients treated with tamoxifen or"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="among 100,000 women in 123 randomised trials Lancet 2012"/>
   <result pre="survival in older women with hormone receptor-negative breast cancer: assessing" exact="outcome" post="in a population-based, observational cohort J Clin Oncol 2006"/>
   <result pre="HT Isaacs C Fu AZ et al. Risk of cardiovascular" exact="adverse events" post="from trastuzumab (Herceptin ®) in elderly persons with breast"/>
   <result pre="O Paesmans M et al. Bevacizumab and breast cancer: a" exact="meta-analysis" post="of first-line Phase III studies and a critical reappraisal"/>
   <result pre="21.5% No overall effect of age on AEs Abbreviations: AEs," exact="adverse events;" post="ORR, objective response rate; PFS, progression-free survival; OS, overall"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4303336/results/search/cochrane/results.xml">
   <result pre="and treatment of breast cancer have led to an improved" exact="outcome" post="and a large proportion of long-term breast cancer survivors."/>
   <result pre="radiotherapy comes from retrospective population-based studies that have compared cardiac" exact="outcome" post="after left- versus right-sided breast irradiation. In an analysis"/>
   <result pre="which will be discussed later in this review. A recent" exact="meta-analysis" post="revealed a 5.4-fold increased risk of clinical cardiotoxicity, 6.3-fold"/>
   <result pre="lower the incidence of cardiotoxicity compared to bolus therapy. A" exact="Cochrane" post="review of five randomized controlled trials found that continuous"/>
   <result pre="subclinical cardiotoxicity. 32 However, all the studies included in the" exact="meta-analysis" post="investigated the role of liposomal doxorubicin in patients with"/>
   <result pre="doxorubicin by blocking the generation of free radicals. In a" exact="meta-analysis" post="of six randomized trials, of which only three examined"/>
   <result pre="the anthracycline cardiotoxicity as has been clearly shown in a" exact="meta-analysis" post="of recent randomized trials. 52 Conversely, taxane schemes that"/>
   <result pre="decrease in the risk of cardiovascular events. 58 In a" exact="meta-analysis" post="evaluating tamoxifen and focusing on adverse effects, tamoxifen was"/>
   <result pre="incidence of myocardial infarction was observed. 59 However, in the" exact="meta-analysis" post="by the Early Breast Cancer Trialists’ Collaboration Group, no"/>
   <result pre="led to a fear of an increased risk of cardiovascular" exact="adverse events." post="In the pivotal trial for anastrozole, patients were randomized"/>
   <result pre="the treatment group with exemestane had significantly more ischemic cardiac" exact="adverse events" post="after a median follow-up of 91 months. 62 On"/>
   <result pre="62 On the other hand, no increased risk of cardiovascular" exact="adverse events" post="with AI could be observed in a large trial"/>
   <result pre="to entail a minor increase in the risk of cardiac" exact="adverse events" post="whereas tamoxifen does not seem to entail any cardiac"/>
   <result pre="cardiac risks. In most patients, this potential risk of cardiovascular" exact="adverse events" post="with AI is outweighed by the treatment’s significant improvement"/>
   <result pre="cancer patients) to a disease with comparable or even better" exact="outcome" post="than HER2-negative disease. 64 In the adjuvant setting, 1-year"/>
   <result pre="on the design of adjuvant trials in which strict cardiac" exact="exclusion" post="criteria, prospective monitoring of cardiac function, interim cardiac safety"/>
   <result pre="trastuzumab-treated arm. 68 In the real-world setting, where the cardiac" exact="exclusion" post="criteria are not as strict as those applied in"/>
   <result pre="sequential administration, was not correlated with higher risk for cardiac" exact="adverse events." post="76– 78 However, in the absence of any difference"/>
   <result pre="therefore, a concern regarding the potential risk for increased cardiac" exact="adverse events" post="when two anti-HER2 agents that both increase cardiac toxicity"/>
   <result pre="that both increase cardiac toxicity are combined. However, a recent" exact="meta-analysis" post="could not reveal any increased risk for cardiac toxicity"/>
   <result pre="careful case-by-case baseline evaluation of preexisting risk factors for cardiac" exact="adverse events" post="and the need for an appropriate and well-structured cardiac"/>
   <result pre="early breast cancer. These treatment strategies are associated with cardiac" exact="adverse events" post="through different pathophysiological mechanisms. Several guidelines recommend initial baseline"/>
   <result pre="breast-conserving surgery on 10-year recurrence and 15-year breast cancer death:" exact="meta-analysis" post="of individual patient data for 10,801 women in 17"/>
   <result pre="axillary surgery on 10-year recurrence and 20-year breast cancer mortality:" exact="meta-analysis" post="of individual patient data for 8135 women in 22"/>
   <result pre="anthracycline agents for the treatment of cancer: systematic review and" exact="meta-analysis" post="of randomised controlled trials BMC Cancer 2010 10 337"/>
   <result pre="Lotrionte M Biondi-Zoccai G Abbate A et al. Review and" exact="meta-analysis" post="of incidence and clinical predictors of anthracycline cardiotoxicity Am"/>
   <result pre="schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy" exact="Cochrane" post="Database Syst Rev 2006 4 CD005008 17054232 39 Giotta"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="among 100,000 women in 123 randomised trials Lancet 2012"/>
   <result pre="of adjuvant anthracycline and taxane chemotherapy in breast cancer: a" exact="meta-analysis" post="Breast Cancer Res Treat 2012 135 2 335 346"/>
   <result pre="61 Mouridsen H Keshaviah A Coates AS et al. Cardiovascular" exact="adverse events" post="during adjuvant endocrine therapy for early breast cancer using"/>
   <result pre="trastuzumab in the treatment of her-2-positive early breast cancer: a" exact="meta-analysis" post="of published randomized trials BMC Cancer 2007 7 153"/>
   <result pre="S et al. Trastuzumab containing regimens for early breast cancer" exact="Cochrane" post="Database Syst Rev 2012 4 CD006243 22513938 69 Bowles"/>
   <result pre="in patients with HER2-positive breast cancer: a systematic review and" exact="meta-analysis" post="Breast 2011 20 6 485 490 21784637 77 Schneeweiss"/>
   <result pre="the combination added to preoperative chemotherapy for breast cancer: a" exact="meta-analysis" post="of randomized evidence Breast Cancer Res Treat 2012 135"/>
   <result pre="of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of" exact="outcome" post="in 120 patients Ann Oncol 2002 13 5 699"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4307685/results/search/cochrane/results.xml">
   <result pre="breast, colorectal, liver and renal cancer [ 8]. Recently, a" exact="meta-analysis" post="focusing on c-Met overexpression and the prognosis of gastric"/>
   <result pre="for Elderly Esophageal Squamous Cell Cancer (NCT02016287). The inclusion and" exact="exclusion" post="criteria were as follows: Inclusion criterion: Histological confirmed stage"/>
   <result pre="the tumor microenvironment in vivo. Peng [ 9] did a" exact="meta-analysis" post="on c-Met expression in gastric carcinoma and found that"/>
   <result pre="amplification and expression in gastric cancer: a systematic review with" exact="meta-analysis" post="PLoS One 2014 9 1 e84502 10.1371/journal.pone.0084502 24416238 10."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4309158/results/search/cochrane/results.xml">
   <result pre="A (adenocarcinoma) and1/2 pts in Arm B (non-adenocarcinoma). Treatment (Tx)-related" exact="adverse events" post="(AEs) were skin and gastrointestinal disorders NSCLC ( 70)"/>
   <result pre="objective response after treatment with afatinib daily. The most common" exact="adverse events" post="were diarrhea and rash or acne Advanced lung adenocarcinoma"/>
   <result pre="unselected patients with triple-negative breast cancer. The most common treatment-related" exact="adverse events" post="were diarrhea and skin HER2-negative metastatic breast cancer ("/>
   <result pre="of chemotherapy/erlotinib/gefitinib (LUX-Lung4) ( 77– 79). The most frequent treatment-related" exact="adverse events" post="were diarrhea, mucosal inflammation, and skin rash. A pharmacokinetic"/>
   <result pre="survival and cell proliferation that HER signaling provides. One potential" exact="outcome" post="of this tissue repair event is tumor recurrence in"/>
   <result pre="Anti-EGFR mechanism of action: antitumor effect and underlying cause of" exact="adverse events." post="Oncology ( 2006) 20( 5 Suppl 2): 5– 13."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4310719/results/search/cochrane/results.xml">
   <result pre="plus tamoxifen than those who received tamoxifen alone. 56 Most" exact="adverse events" post="(AEs) were grade 1/2, and the incidence of nonhematologic"/>
   <result pre="inhibitors for treatment of advanced breast cancer in postmenopausal women" exact="Cochrane" post="Database Syst Rev 2009 4 CD003370 19821307 13 Higgins"/>
   <result pre="Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer" exact="Cochrane" post="Database Syst Rev 2003 2 CD002747 12804433 23 Johnston"/>
   <result pre="42 Tan PS Haaland B Montero AJ Lopes G A" exact="meta-analysis" post="of anastrozole in combination with fulvestrant in the first"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4315003/results/search/cochrane/results.xml">
   <result pre="with human epidermal growth factor receptor 2-positive breast cancer: A" exact="meta-analysis" post="of randomized controlled trials SUN JINZHONG 1 2 *"/>
   <result pre="factor receptor (HER) 2-positive breast cancer. Three electronic databases, MEDLINE," exact="Embase" post="and Cochrane Central Register of Controlled Trials, and the"/>
   <result pre="(HER) 2-positive breast cancer. Three electronic databases, MEDLINE, Embase and" exact="Cochrane Central Register of Controlled Trials," post="and the abstracts of major international conferences between inception"/>
   <result pre="(pCR) rate, breast-conserving surgery (BCS) rate and the occurrence of" exact="adverse events." post="Four randomized controlled trials were assessed in the present"/>
   <result pre="Compared with the patients who did not receive lapatinib, the" exact="pCR" post="rate was higher in the hormone receptor (HR)-positive [risk"/>
   <result pre="trials (n=382; RR, 1.14; 95% CI, 0.89–1.47; P=0.31). The primary" exact="adverse events," post="including diarrhea, dermatological toxicity, hepatic toxicity and neutropenia, were"/>
   <result pre="HER2-positive breast cancer improves the probability of achieving a higher" exact="pCR" post="rate, but the use of lapatinib is associated with"/>
   <result pre="use of lapatinib is associated with a higher risk of" exact="adverse events." post="lapatinib breast cancer neoadjuvant meta-analysis Introduction Neoadjuvant chemotherapy for"/>
   <result pre="a higher risk of adverse events. lapatinib breast cancer neoadjuvant" exact="meta-analysis" post="Introduction Neoadjuvant chemotherapy for the treatment of breast cancer"/>
   <result pre="neoadjuvant therapy for the treatment of HER2-positive breast cancer, a" exact="meta-analysis" post="of all relevant published RCTs was performed. Patients and"/>
   <result pre="published RCTs was performed. Patients and methods Eligibility criteria The" exact="eligibility" post="and exclusion criteria were pre-specified. Studies were considered eligible"/>
   <result pre="was performed. Patients and methods Eligibility criteria The eligibility and" exact="exclusion" post="criteria were pre-specified. Studies were considered eligible for the"/>
   <result pre="criteria were pre-specified. Studies were considered eligible for the present" exact="meta-analysis" post="if they were RCTs that evaluated the administration of"/>
   <result pre="All cytotoxic chemotherapy regimens were considered eligible for the present" exact="meta-analysis" post="if the same chemotherapy agents were administered at the"/>
   <result pre="of Renmin Hospital of Wuhan University (Wuhan, China). Search strategy" exact="MEDLINE" post="(National Library of Medicine, Bethesda, MD, USA), Embase (Elsevier,"/>
   <result pre="Search strategy MEDLINE (National Library of Medicine, Bethesda, MD, USA)," exact="Embase" post="(Elsevier, Amsterdam, Netherlands) and the Cochrane Central Register of"/>
   <result pre="Medicine, Bethesda, MD, USA), Embase (Elsevier, Amsterdam, Netherlands) and the" exact="Cochrane Central Register of Controlled Trials" post="(Cochrane Library, Hoboken, NJ, USA) were searched between inception"/>
   <result pre="Alexandria, VA, USA), were also electronically searched to avoid the" exact="exclusion" post="of unpublished recent trials using lapatinib in neoadjuvant chemotherapy."/>
   <result pre="and dose and duration of lapatinib therapy. Primary and secondary" exact="outcome" post="measures, consisting of pCR, BCS and all adverse events,"/>
   <result pre="and secondary outcome measures, consisting of pCR, BCS and all" exact="adverse events," post="were also recorded. Outcome definition The primary outcome assessed"/>
   <result pre="all adverse events, were also recorded. Outcome definition The primary" exact="outcome" post="assessed was the rate of pCR achieved. If the"/>
   <result pre="Outcome definition The primary outcome assessed was the rate of" exact="pCR" post="achieved. If the primary study reported a separate pCR"/>
   <result pre="of pCR achieved. If the primary study reported a separate" exact="pCR" post="rate for breast tissue and breast tissue plus axilla,"/>
   <result pre="for breast tissue and breast tissue plus axilla, only the" exact="pCR" post="rate for breast tissue plus axilla was included. The"/>
   <result pre="secondary outcomes assessed were the rate of BCS and all" exact="adverse events." post="The primary adverse events included grade 3–4 diarrhea, hepatic"/>
   <result pre="the rate of BCS and all adverse events. The primary" exact="adverse events" post="included grade 3–4 diarrhea, hepatic toxicity, dermatological toxicity and"/>
   <result pre="generation of allocation, allocation concealment, masking of participants, personnel and" exact="outcome" post="assessors, incomplete outcome data, selective outcome reporting and other"/>
   <result pre="allocation concealment, masking of participants, personnel and outcome assessors, incomplete" exact="outcome" post="data, selective outcome reporting and other sources of bias."/>
   <result pre="of participants, personnel and outcome assessors, incomplete outcome data, selective" exact="outcome" post="reporting and other sources of bias. The risk of"/>
   <result pre="each primary study to estimate the relative risk of each" exact="outcome" post="in patients with HER2-positive breast cancer receiving trastuzumab-based chemotherapy"/>
   <result pre="therapy. For each eligible study group, the RR for the" exact="outcome" post="measures was estimated and compared between the groups, and"/>
   <result pre="priori to investigate the effects of HR in pCR. The" exact="meta-analysis" post="was conducted using Review Manager software version 5.1 (The"/>
   <result pre="effects of HR in pCR. The meta-analysis was conducted using" exact="Review Manager" post="software version 5.1 (The Cochrane Collaboration, Copenhagen, Denmark). Begg’s"/>
   <result pre="meta-analysis was conducted using Review Manager software version 5.1 (The" exact="Cochrane" post="Collaboration, Copenhagen, Denmark). Begg’s and Egger’s tests were performed"/>
   <result pre="Copenhagen, Denmark). Begg’s and Egger’s tests were performed using the" exact="Stata" post="software package version 12.0 (StataCorp LP, College Station, TX,"/>
   <result pre="reports the characteristics of the four trials that met the" exact="eligibility" post="criteria for the present study. The four trials were"/>
   <result pre="regimens including paclitaxel in the regimen. All trials reported the" exact="pCR" post="rate and primary adverse events. To investigate the potential"/>
   <result pre="the regimen. All trials reported the pCR rate and primary" exact="adverse events." post="To investigate the potential role of lapatinib in neoadjuvant"/>
   <result pre="studies ( 11, 12) were phase III clinical trials. The" exact="pCR" post="rate and the primary adverse events were reported for"/>
   <result pre="phase III clinical trials. The pCR rate and the primary" exact="adverse events" post="were reported for all studies. According to the Cochrane"/>
   <result pre="adverse events were reported for all studies. According to the" exact="Cochrane" post="risk of bias tool, each risk of bias item"/>
   <result pre="of bias tool, each risk of bias item for each" exact="RCT" post="included in the present study was assessed, and the"/>
   <result pre="(P=0.216) and Egger’s (P=0.122) tests. Overall effect of lapatinib on" exact="pCR" post="All four trials, including 779 patients, included data for"/>
   <result pre="trials, including 779 patients, included data for pCR. The absolute" exact="pCR" post="rate was 56.78% (222 out of 391 patients) in"/>
   <result pre="lapatinib group (RR, 1.39; 95% CI, 1.20–1.60; P&amp;lt;0.0001). A subgroup" exact="meta-analysis" post="was conducted using the HR status. The probability of"/>
   <result pre="meta-analysis was conducted using the HR status. The probability of" exact="pCR" post="was significantly higher in the lapatinib group compared with"/>
   <result pre="data. Overall effect of lapatinib on the BCS rate and" exact="adverse events" post="Data on the number of patients that underwent BCS"/>
   <result pre="treatment arms (RR, 1.14; 95% CI, 0.89–1.47; P=0.31). The primary" exact="adverse events," post="consisting of grade 3–4 diarrhea, dermatological toxicity, hepatic toxicity"/>
   <result pre="all four trials. The proportion of patients that experienced primary" exact="adverse events" post="was higher in the lapatinib group compared with the"/>
   <result pre="lapatinib group ( Fig. 6). The pooled RRs for additional" exact="adverse events" post="and the 95% CI for the use of lapatinib"/>
   <result pre="breast cancer patients results in a significant increase in the" exact="pCR" post="rate. Neoadjuvant studies using anti-HER2 agents have revealed that"/>
   <result pre="rate. Neoadjuvant studies using anti-HER2 agents have revealed that the" exact="pCR" post="rate is correlated with disease-free survival ( 16, 17)."/>
   <result pre="or chemotherapy plus trastuzumab groups, demonstrated a doubling in the" exact="pCR" post="rate in the trastuzumab group compared with the chemotherapy"/>
   <result pre="with the chemotherapy group, and a strong correlation between the" exact="pCR" post="rate and event-free survival was also identified. The Taxol"/>
   <result pre="Taxol epirubicin cyclophosphamide Herceptin neoadjuvant study reported a correlation between" exact="pCR" post="and improved disease-free or overall survival ( 17). According"/>
   <result pre="use of lapatinib, as expected, was associated with two well-documented" exact="adverse events," post="diarrhea and dermatological toxicity ( 18), despite the recommended"/>
   <result pre="risk of cardiotoxicity. These results are similar to a previous" exact="meta-analysis" post="assessing the administration neoadjuvant chemotherapy containing trastuzumab compared with"/>
   <result pre="and risk of bias assessments were not performed. The present" exact="meta-analysis" post="provided more accurate information and identified certain different outcomes"/>
   <result pre="compared with the study by Valachis et al. The present" exact="meta-analysis" post="possesses certain limitations that require discussion. First, the number"/>
   <result pre="outcomes are relatively small, which affects the power of the" exact="meta-analysis" post="to reveal statistically significant results. Second, three trials ("/>
   <result pre="Second, three trials ( 9, 11, 12) reported a separate" exact="pCR" post="rate between breast tissue and breast tissue plus axilla."/>
   <result pre="between breast tissue and breast tissue plus axilla. Only the" exact="pCR" post="rate in the breast tissue plus axilla was analyzed"/>
   <result pre="the neoadjuvant setting improves the probability of achieving a higher" exact="pCR" post="rate, but is also associated with an increased risk"/>
   <result pre="JP Neoadjuvant versus adjuvant systemic treatment in breast cancer: a" exact="meta-analysis" post="J Natl Cancer Inst 97 188 194 2005 10.1093/jnci/dji021"/>
   <result pre="Wolmark N et al. Effect of preoperative chemotherapy on the" exact="outcome" post="of women with operable breast cancer J Clin Oncol"/>
   <result pre="in patients with HER2-positive breast cancer: a systematic review and" exact="meta-analysis" post="Breast 20 485 490 2011 10.1016/j.breast.2011.06.009 21784637 6 Xia"/>
   <result pre="O Clemons M Lapatinib and HER2 status: results of a" exact="meta-analysis" post="of randomized phase III trials in metastatic breast cancer"/>
   <result pre="24095300 13 Higgins JP Altman DG Gøtzsche PC et al." exact="Cochrane" post="Bias Methods Group; Cochrane Statistical Methods Group: The Cochrane"/>
   <result pre="Altman DG Gøtzsche PC et al. Cochrane Bias Methods Group;" exact="Cochrane" post="Statistical Methods Group: The Cochrane Collaboration’s tool for assessing"/>
   <result pre="al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group: The" exact="Cochrane" post="Collaboration’s tool for assessing risk of bias in randomised"/>
   <result pre="M Davey Smith G Schneider M Minder C Bias in" exact="meta-analysis" post="detected by a simple, graphical test BMJ 315 629"/>
   <result pre="the combination added to preoperative chemotherapy for breast cancer: a" exact="meta-analysis" post="of randomized evidence Breast Cancer Res Treat 135 655"/>
   <result pre="Breast and Bowel Project. Figure 6 Forest plot of primary" exact="adverse events" post="(grades 3–4). The primary adverse were statistically more frequent"/>
   <result pre="four cycles; →, followed. Table II Pooled analysis of other" exact="adverse events." post="Adverse event Number of trials Events, n/total number of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4316710/results/search/cochrane/results.xml">
   <result pre="with conventional chemotherapy, has drastically changed the patients' prognosis and" exact="outcome" post="(Piccart-Gebhart et al., 2005; Romond et al., 2005). As"/>
   <result pre="studies have reported that R521K polymorphism is associated with favorable" exact="outcome" post="in cetuximab-based and 5-FU-based chemotherapy but shows negative correlation"/>
   <result pre="therapy (Beauclair et al., 2007). Further, a systematic review and" exact="meta-analysis" post="studying ErbB2 polymorphism in over 45,000 breast cancer patients"/>
   <result pre="I655V polymorphism and breast cancer risk: a systematic review and" exact="meta-analysis" post=". Cancer Epidemiol 35, 503– 509. 10.1016/j.canep.2011.01.007 21474413 Dahan"/>
   <result pre="I. et al. . ( 2011). Pharmacogenetic profiling and cetuximab" exact="outcome" post="in patients with advanced colorectal cancer . BMC Cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4322830/results/search/cochrane/results.xml">
   <result pre="A. Morita R. Extramammary Paget's disease: treatment, prognostic factors and" exact="outcome" post="in 76 patients British Journal of Dermatology 2008 158"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4322880/results/search/cochrane/results.xml">
   <result pre="dose of 6 mg/kg) for 8 months. No significant cardiac" exact="adverse events" post="were reported. In October 2009, there was a sudden"/>
   <result pre="early breast cancer: the dark side of the moon? A" exact="meta-analysis" post="of the randomized trials Breast Cancer Res Treat 2008"/>
   <result pre="trastuzumab in the treatment of her-2-positive early breast cancer: a" exact="meta-analysis" post="of published randomized trials BMC Cancer 2007 7 153"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4323263/results/search/cochrane/results.xml">
   <result pre="engraftment is an independent and poor prognostic indicator of patient" exact="outcome" post="represents the first step towards personalized medicine. Here we"/>
   <result pre="2 ER + Engraftment as a prognostic indicator of disease" exact="outcome" post="Vaillant and colleagues [ 30], Oakes and colleagues ["/>
   <result pre="drug (Figure 3). Although limited in number, similarities between patient" exact="outcome" post="and PDX responses have been reported. High concordance was"/>
   <result pre="engraftment may serve as an independent predictor of poor patient" exact="outcome" post="[ 34]. Samples from metastatic lesions demonstrate an improved"/>
   <result pre="M Zhao H et al. Stromal gene expression predicts clinical" exact="outcome" post="in breast cancer Nat Med. 2008 14 518 27"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4325954/results/search/cochrane/results.xml">
   <result pre="breast cancer patients and from immunohistochemical analyses of tissue. PubMed/Medline," exact="Cochrane" post="and Embase databases were searched from 1 January 2014"/>
   <result pre="patients and from immunohistochemical analyses of tissue. PubMed/Medline, Cochrane and" exact="Embase" post="databases were searched from 1 January 2014 to 1"/>
   <result pre="from 1 January 2014 to 1 April 2014. Neither the" exact="Cochrane" post="library nor Embase yielded relevant results using specific search"/>
   <result pre="2014 to 1 April 2014. Neither the Cochrane library nor" exact="Embase" post="yielded relevant results using specific search criteria. Therefore PubMed/Medline"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4331616/results/search/cochrane/results.xml">
   <result pre="weeks (95 % CI 27.1, 48.0). The majority of drug-related" exact="adverse events" post="were mild to moderate (grade 1 or 2); the"/>
   <result pre="mild to moderate (grade 1 or 2); the most common" exact="adverse events" post="reported were palmar-plantar erythrodysesthesia syndrome (76 %), diarrhea (67"/>
   <result pre="(OS), time to response, duration of response, PK parameters and" exact="adverse events" post="(throughout the study period). The study consisted of two"/>
   <result pre="Good Clinical Practice guidelines and the Declaration of Helsinki. Patient" exact="eligibility" post="Eligible patients were women aged 20 years or older"/>
   <result pre="because of disease progression and 5 (10 %) because of" exact="adverse events." post="Overall, 36 deaths (71 %) were reported. The majority"/>
   <result pre="was evaluated according to the protocol, all subjects experienced drug-related" exact="adverse events," post="such as fatigue, diarrhea and pruritus. All adverse events"/>
   <result pre="drug-related adverse events, such as fatigue, diarrhea and pruritus. All" exact="adverse events" post="were grade 1 or 2 in severity with the"/>
   <result pre="which were at grade 1 or 2. The most common" exact="adverse events" post="reported were palmar-plantar erythrodysesthesia (PPE) syndrome, diarrhea and stomatitis"/>
   <result pre="and stomatitis (Table 2). In addition, all subjects experienced drug-related" exact="adverse events" post="during the study periods. Grade 4 serious adverse events"/>
   <result pre="drug-related adverse events during the study periods. Grade 4 serious" exact="adverse events" post="reported were an alanine aminotransferase increase, neutrophil count decrease,"/>
   <result pre="bone marrow failure and pericardial effusion. Table 2 Summary of" exact="adverse events" post="experienced by at least 10 % of 51 subjects"/>
   <result pre="(percent) PPE palmar-plantar erythrodysesthesia A total of two fatal serious" exact="adverse events" post="(dysphagia and respiratory failure) were reported in one subject"/>
   <result pre="to be the major cause of death. Eight additional serious" exact="adverse events" post="were reported in seven subjects (14 %). These included"/>
   <result pre="in seven subjects (14 %). These included five treatment-related serious" exact="adverse events" post="that occurred in four subjects: grade 3 vertigo and"/>
   <result pre="1+ 4 (8) 2+ 10 (20) 3+ 1 (2) HER2" exact="eligibility" post="was determined at the local laboratory. One subject was"/>
   <result pre="and trastuzumab. The safety results from 51 Japanese subjects indicated" exact="adverse events" post="were manageable and consistent with the safety profile previously"/>
   <result pre="in tumor profiles at baseline such as HER2 status or" exact="adverse events" post="observed during treatment, except the discrepancy in hormone receptor"/>
   <result pre="the study population was too small. The efficacy and safety" exact="outcome" post="of this study were consistent with previous reports on"/>
   <result pre="M Stocchi L Vidiri A Giannarelli D et al. Clinical" exact="outcome" post="of patients with brain metastases from HER2-positive breast cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4333494/results/search/cochrane/results.xml">
   <result pre="among patients treated with anti-HER2-based neoadjuvant therapy Adjuvant trastuzumab after" exact="pCR" post="Gonzalez-Angulo A M 1 2 Parinyanitikul N 1 Lei"/>
   <result pre="trastuzumab-based NST were categorised according to adjuvant trastuzumab administration and" exact="pCR" post="status. Adjuvant trastuzumab became standard of care in 2006,"/>
   <result pre="estimate survival. A test for interaction between adjuvant trastuzumab and" exact="pCR" post="was completed. Findings: Of 589 patients, 203 (34.5%) achieved"/>
   <result pre="compared with 68.8% among those who did not achieve a" exact="pCR" post="( P=0.0006). Among patients achieving pCR, adjuvant trastuzumab did"/>
   <result pre="adjuvant trastuzumab in OS and RFS among patients without a" exact="pCR" post="did not achieve statistical significance ( P=0.3 and P=0.44,"/>
   <result pre="this cohort, patients treated with trastuzumab-based NST who achieved a" exact="pCR" post="have excellent outcome regardless of whether they received adjuvant"/>
   <result pre="treated with trastuzumab-based NST who achieved a pCR have excellent" exact="outcome" post="regardless of whether they received adjuvant trastuzumab. trastuzumab neoadjuvant"/>
   <result pre="trials have shown that the use of trastuzumab-based NST increases" exact="pCR" post="rates compared with chemotherapy alone ( Buzdar et al,"/>
   <result pre="demonstrated that dual anti-HER2 therapy combined with chemotherapy further increases" exact="pCR" post="rates as compared with trastuzumab-based chemotherapy ( Baselga et"/>
   <result pre="). The impact of adjuvant trastuzumab among patients achieving a" exact="pCR" post="after trastuzumab-based NST is unknown. We therefore, aimed to"/>
   <result pre="evaluate the impact of completion of adjuvant trastuzumab according to" exact="pCR" post="status. Patients and methods A retrospective review of the"/>
   <result pre="status, progesterone receptor status, adjuvant radiation, and adjuvant endocrine therapy." exact="pCR" post="was defined as no evidence of invasive cancer in"/>
   <result pre="adjuvant trastuzumab compared with 85.5% of patients not achieving a" exact="pCR" post="( P=0.0006). At a median follow-up of 45 months,"/>
   <result pre="When comparing patients who did not or did achieve a" exact="pCR" post="after NST, the 5-year OS estimates were 90% and"/>
   <result pre="estimates of OS and RFS stratified by adjuvant trastuzumab and" exact="pCR" post="status are presented in Figure 1. On multivariate analysis,"/>
   <result pre="analysis, there was no significant interaction between adjuvant trastuzumab and" exact="pCR" post="on OS ( P=0.32) or RFS ( P=0.15). After"/>
   <result pre="(HR=1.10; 95% CI=0.52–2.33; P=0.81). As expected, patients who achieved a" exact="pCR" post="had a decreased risk of death (HR=0.23; 95% CI=0.08–0.60;"/>
   <result pre="patients with HER2-positive disease treated at our institution according to" exact="pCR" post="status. In this cohort of patients treated with trastuzumab-based"/>
   <result pre="of patients treated with trastuzumab-based NST, those who achieved a" exact="pCR" post="had an excellent outcome regardless of whether they received"/>
   <result pre="trastuzumab-based NST, those who achieved a pCR had an excellent" exact="outcome" post="regardless of whether they received adjuvant trastuzumab or not."/>
   <result pre="cancer who need less extensive or less complex therapies, and" exact="pCR" post="after adequate NST may be a good surrogate. All"/>
   <result pre="anti-HER2-based NST studies have shown that patients who achieved a" exact="pCR" post="at the time of surgery have an excellent prognosis"/>
   <result pre="caution, but they support the concept that patients achieving a" exact="pCR" post="may not receive further benefit from adjuvant anti-HER2 therapy"/>
   <result pre="therefore, toxicities may be avoided. Furthermore, if patients achieving a" exact="pCR" post="do not receive further benefit from adjuvant trastuzumab, this"/>
   <result pre="studies evaluating the benefit of adjuvant anti-HER2 therapies after a" exact="pCR" post="would be ideal to answer this important question and"/>
   <result pre="NV Bear HD 1998 Effect of preoperative chemotherapy on the" exact="outcome" post="of women with operable breast cancer J Clin Oncol"/>
   <result pre="RFS estimates ( B) according to adjuvant trastuzumab use and" exact="pCR" post="status. Table 1 Patient and tumour characteristics All patients"/>
   <result pre="diagnosis: 2001–2006 vs 2007–2012 0.78 0.34–1.79 0.56 1.13 0.59–2.17 0.72" exact="pCR" post="vs no 0.23 0.08–0.6 0.003 0.22 0.1–0.49 0.0002 Back"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4335966/results/search/cochrane/results.xml">
   <result pre="behalf of colleagues then presented an assessment of patient recorded" exact="outcome" post="measures of the SOFT trial and identified that overall"/>
   <result pre="did not cross the statistical significance threshold. Higher rates of" exact="adverse events" post="related deaths were reported for everolimus (3.6% versus 0%"/>
   <result pre="45%. However the investigators demonstrated a twofold numeric increase in" exact="pCR" post="in the 24 weeks arm over the 12 weeks"/>
   <result pre="therapy, and without chemotherapy, leads to a meaningful increase in" exact="pCR" post="rate in ER+/HER-2+ breast cancer and warrants further study."/>
   <result pre="operable breast cancer (OPPORTUNE study). They identified in their primary" exact="outcome" post="measure a mean Ki67 suppression of 83.8% versus 66%"/>
   <result pre="significantly higher than solvent based, the primary endpoint of complete" exact="pCR" post="was 38% versus 29% ( P = 0.001) respectively."/>
   <result pre="presence of a TP53 mutation was significantly associated with achieving" exact="pCR" post="(59% compared to 28% in wild type; OR ="/>
   <result pre="frequent, clinically important event in HER-2-positive disease, and it predicts" exact="pCR" post="to chemotherapy plus HER-2-targeting. Dr Bruce Tromberg from the"/>
   <result pre="mid-therapy in a DOSI-derived tissue optical index (TOI) could predict" exact="pCR" post="in breast cancer neoadjuvant chemotherapy (NACT). Using -40% as"/>
   <result pre="in tumour to normal TOI were more likely to be" exact="pCR" post="( P = 0.0586, OR = 4.667, 95% CI:"/>
   <result pre="impact of intrinsic subtype PAM50 and other gene signatures on" exact="pCR" post="rates in TNBC after NACT +/- carboplatin (Cb) or"/>
   <result pre="the HER-2 amplicon signature was uncommon and not prognostic for" exact="pCR" post="overall but was associated with reduced benefit from Cb"/>
   <result pre="mutation and low oestrogen signaling signatures were prognostic for higher" exact="pCR" post="rates and predictive of the benefits from Bev (interaction"/>
   <result pre="( P = 0.005) and suggestive of immune evasion and" exact="outcome" post="in TNBC. New approaches to breast cancer screening and"/>
   <result pre="from wire and radioisotope dependence has become more pertinent for" exact="outcome" post="measures and patient-satisfaction within breast conservation. Dr Muneer Ahmed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4339844/results/search/cochrane/results.xml">
   <result pre="with HER2-positive (HER2+) early breast cancer [ 4]. The improved" exact="outcome" post="by adding trastuzumab to chemotherapy for example is not"/>
   <result pre="that reduced levels of GREB1 are predictive of worse disease" exact="outcome" post="for breast cancer patients in general, and for ER+"/>
   <result pre="5 identifies a group of breast carcinomas with poor clinical" exact="outcome" post=". Am J Pathol 161( 6): 1991– 1996. doi:"/>
   <result pre="polymorphisms in the COX-2 gene and breast cancer risk: a" exact="meta-analysis" post=". Breast Cancer Res Treat 122: 251– 257. doi:"/>
   <result pre="-765G&amp;gt;C and 8473T&amp;gt;C polymorphisms of COX-2 and cancer risk: a" exact="meta-analysis" post="based on 33 case-control studies . Mol Biol Rep"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4341429/results/search/cochrane/results.xml">
   <result pre="associate with disease progression ( 57, 63, 64) with a" exact="meta-analysis" post="by Zhang et al. ( 10) confirming CTC presence"/>
   <result pre="are also suggested ( 65, 66). Confirming this, a defining" exact="meta-analysis" post="by Zhang et al. ( 10) showed the presence"/>
   <result pre="and mesenchymal markers. Although CTC count changes are predictive of" exact="outcome" post="in MBC, this is largely a disease where serial"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="among 100 000 women in 123 randomised trials ."/>
   <result pre="breast cancer patients after primary surgery are associated with inferior" exact="outcome" post=". BMC Cancer ( 2012) 12: 190. 10.1186/1471-2407-12-190 22640166"/>
   <result pre="human mammary stem cells and a predictor of poor clinical" exact="outcome" post=". Cell Stem Cell ( 2007) 1( 5): 555–"/>
   <result pre="L et al. HER2-positive circulating tumor cells indicate poor clinical" exact="outcome" post="in stage I to III breast cancer patients ."/>
   <result pre="CJ et al. Heterogeneous HER2 gene amplification: impact on patient" exact="outcome" post="and a clinically relevant definition . Am J Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4342830/results/search/cochrane/results.xml">
   <result pre="its ability to regulate cell survival and show that the" exact="outcome" post="of this activity impacts breast cancer resistance to HER2-targeted"/>
   <result pre="to analysis by Caspase-3 activity assay (Sigma) or trypan blue" exact="exclusion" post="and cell counting, which was performed using the cellometer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346363/results/search/cochrane/results.xml">
   <result pre="ER, PR, and HER2 expression. Basal/TNBC cancers have the worst" exact="outcome" post="and there are currently no approved targeted therapies for"/>
   <result pre="individual miRNAs or miRNA signatures to drug resistance and disease" exact="outcome" post="( Tables 3 and 4). Functional characterization of some"/>
   <result pre="miR-365, miR-502-5p, miR-520c-3p, miR-520g/h, and miRPlus-E1130) was associated with clinical" exact="outcome" post="in a patient cohort of 52 ER + cases"/>
   <result pre="expression changes in miR-30c, miR-210, and miR-519 correlated with clinical" exact="outcome" post="in independent patient cohorts treated with tamoxifen. 60– 63"/>
   <result pre="is derived. High miR-210 expression was also associated with poor" exact="outcome" post="in other patient cohorts of either all comers or"/>
   <result pre="should investigate whether any of these miRNAs can inform disease" exact="outcome" post="or treatment response within a more homogenous cohort of"/>
   <result pre="miRNA signatures or individual miRNA changes that correlate with clinical" exact="outcome" post="in TNBC cases ( Table 5). A four-miRNA signature"/>
   <result pre="represented in multiple signatures found to be associated with poor" exact="outcome" post="in TNBC. These miRNAs are known to be expressed"/>
   <result pre="an association between miR-10b levels and disease progression or clinical" exact="outcome" post="in a cohort of 84 early-stage breast cancer patients"/>
   <result pre="identifies MiR-210 associated with tumor proliferation, invasion and poor clinical" exact="outcome" post="in breast cancer PLoS One 2011 6 6 e20980"/>
   <result pre="miR-210 predicts poor survival in patients with breast cancer: a" exact="meta-analysis" post="Gene 2012 507 2 135 138 22842193 69 Camps"/>
   <result pre="between two polymorphisms in pre-miRNAs and breast cancer risk: a" exact="meta-analysis" post="Breast Cancer Res Treat 2011 125 2 571 574"/>
   <result pre="with inflammatory breast cancer and are predictive of favorable clinical" exact="outcome" post="in patients with metastatic HER2+ inflammatory breast cancer PLoS"/>
   <result pre="N Pepin F et al. Stromal gene expression predicts clinical" exact="outcome" post="in breast cancer Nat Med 2008 14 5 518"/>
   <result pre="between functional microRNA polymorphisms and breast cancer risk: a HuGE" exact="meta-analysis" post="Tumour Biol 2014 35 1 529 543 23982873 142"/>
   <result pre="W Zhao J Pre-mir-27a rs895819 polymorphism and cancer risk: a" exact="meta-analysis" post="Mol Biol Rep 2013 40 4 3181 3186 23266669"/>
   <result pre="Liu JW Yuan Y Pre-miR-27a rs895819A/G polymorphisms in cancer: a" exact="meta-analysis" post="PLoS One 2013 8 6 e65208 23762318 145 Bensen"/>
   <result pre="between common genetic variant of microRNA-499 and cancer susceptibility: a" exact="meta-analysis" post="Mol Biol Rep 2013 40 4 3389 3394 23271127"/>
   <result pre="J Redova M et al. MiR-34b is associated with clinical" exact="outcome" post="in triple-negative breast cancer patients Diagn Pathol 2012 7"/>
   <result pre="In situ hybridization Higher levels of let-7b correlate with better" exact="outcome" post="in ER + cases. 163 miR-7, miR-128a, miR-210, miR-516-3p"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346691/results/search/cochrane/results.xml">
   <result pre="cascades via phosphorylation of numerous cellular proteins [ 44]. A" exact="meta-analysis" post="of 7 studies concluded that EGFR expression correlates with"/>
   <result pre="Second-line chemotherapy versus supportive cancertreatment in advanced gastric cancer: a" exact="meta-analysis" post="Annals of Oncology 2013 24 11 2850 2854 10.1093/annonc/mdt351"/>
   <result pre="growth factor receptor in gastric cancer: a systematic review and" exact="meta-analysis" post="Archives of Medical Research 2013 44 5 380 389"/>
   <result pre="a prognostic marker in gastric cancer: a systematic review and" exact="meta-analysis" post="PLoS ONE 2013 8 11 10.1371/journal.pone.0079137 55 Iveson T."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353460/results/search/cochrane/results.xml">
   <result pre="to have metastatic lymph nodes, larger tumors, and worse clinical" exact="outcome" post="[ 1]. We also demonstrated that overexpression of DCD"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353882/results/search/cochrane/results.xml">
   <result pre="GAPDH, TFRC Statistical analysis All statistical analyses were performed using" exact="STATA" post="software version 11. Statistical significance was defined as p"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359299/results/search/cochrane/results.xml">
   <result pre="selection and combination with chemotherapy regimens may enhance the clinical" exact="outcome" post="[ 31]. In a phase II clinical trial, erlotinib"/>
   <result pre="with irinotecan and cisplatin relatively enhanced the survival and clinical" exact="outcome" post="of patients with metastatic gastric or GEJ adenocarcinoma ["/>
   <result pre="MLN8237 with standard chemotherapeutic agents could have a better therapeutic" exact="outcome" post="in upper gastrointestinal cancers. Indeed, we found that MLN8237"/>
   <result pre="for metastatic carcinoma of the esophagus and gastro-esophageal junction The" exact="Cochrane" post="database of systematic reviews 2006 CD004063 17054195 10 Mauer"/>
   <result pre="tumor cell apoptosis, migration and invasion and predicts the clinical" exact="outcome" post="of osteosarcoma patients Biochemical and biophysical research communications 2013"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4363856/results/search/cochrane/results.xml">
   <result pre="metastatic setting, we have seen the positive impact on prognostic" exact="outcome" post="with the introduction of agents that can over come"/>
   <result pre="available for women triple negative breast cancer and the prognostic" exact="outcome" post="associated with this subtype compared with other subtypes continues"/>
   <result pre="the natural history of HER2 positive breast cancer impacting prognostic" exact="outcome" post="positively in the both the adjuvant and metastatic setting."/>
   <result pre="Efforts are underway to find ways to further improve prognostic" exact="outcome" post="in this subgroup by optimally using these anti HER2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4368842/results/search/cochrane/results.xml">
   <result pre="agents or chemotherapy, these anti-HER2 agents have remarkably improved the" exact="outcome" post="of patients with HER2-positive breast cancer [ 9, 10]."/>
   <result pre="99–108. doi:10.1007/s10549-013-2444-y. 43. Bahreini F Soltanian AR Mehdipour P A" exact="meta-analysis" post="on concordance between immunohistochemistry (IHC) and fluorescence in situ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4381292/results/search/cochrane/results.xml">
   <result pre="M.J. Witteveen A.T. et al. Gene expression profiling predicts clinical" exact="outcome" post="of breast cancer Nature 2002 415 530 536 10.1038/415530a"/>
   <result pre="increase cancer cell &quot;stemness,&quot; driving recurrence, metastasis and poor clinical" exact="outcome" post="in breast cancer: achieving personalized medicine via Metabolo-Genomics Cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4385942/results/search/cochrane/results.xml">
   <result pre="subtype revealed a trend for increased KLF5 expression and poor" exact="outcome" post="in the HER2-enriched tumors (HR, 1.6; CI, 1.0–2.5, nominal"/>
   <result pre="hematological malignancies, its expression is correlates with a favorable patient" exact="outcome" post="in breast cancer. 46 Single knockdown of either KLF4"/>
   <result pre="prognostic within this subtype. Previous studies have linked adverse clinical" exact="outcome" post="to increased nuclear localization of KLF4, to elevated KLF5"/>
   <result pre="anoikis procedure and quantitation of cell death by Trypan blue" exact="exclusion" post="was previously described. 20 Alternatively, cell death was determined"/>
   <result pre="breast cancer Biologics 2012 6 289 297 22956860 Howe EN" exact="Cochrane" post="DR Cittelly DM Richer JK miR-200c targets a NF-kappaB"/>
   <result pre="HER2-enriched groups, as defined by PAM50 subtyping. ( c) The" exact="outcome" post="of patients harboring tumors with higher expression levels of"/>
   <result pre="both KLF4 and KLF5 (red, hi-hi) was compared with the" exact="outcome" post="when tumors had lower expression levels of each factor"/>
   <result pre="S.E.). ( d) Cell death was determined by Trypan blue" exact="exclusion" post="following 24 h of matrix deprivation for the indicated cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4389676/results/search/cochrane/results.xml">
   <result pre="whereas high expression of HER4 is associated with a better" exact="outcome" post="[ 2- 7]. Up to 25% of breast carcinomas"/>
   <result pre="decisions on ECD levels in routine clinical practice. A large" exact="meta-analysis" post="study [ 38] has combined the data of four"/>
   <result pre="configuration to improve the existing prognostic signatures for predicting patient" exact="outcome" post="[ 50], this protein interaction information has rarely been"/>
   <result pre="homodimer levels determined by the HERmark assay correlated with clinical" exact="outcome" post="of trastuzumab therapy better than IHC or central FISH"/>
   <result pre="First, the link between the level of HER2 amplification and" exact="outcome" post="in patients treated with trastuzumab has been proven only"/>
   <result pre="paraffin sections by using a p95-specific antibody and correlation with" exact="outcome" post="in a cohort of trastuzumab-treated breast cancer patients Clin"/>
   <result pre="al. Dynamic modularity in protein interaction networks predicts breast cancer" exact="outcome" post="Nat Biotechnol 2009 27 199 204 19182785 51. Peter"/>
   <result pre="between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient" exact="outcome" post="Diagn Mol Pathol 2009 18 88 95 19430296 97."/>
   <result pre="J Weidler J et al. Quantitative HER2 protein levels predict" exact="outcome" post="in fluorescence in situ hybridization-positive patients with metastatic breast"/>
   <result pre="NE et al. HER2 and chromosome 17 effect on patient" exact="outcome" post="in the N9831 adjuvant trastuzumab trial J Clin Oncol"/>
   <result pre="P et al. Very high quantitative tumor HER2 content and" exact="outcome" post="in early breast cancer Ann Oncol 2011 22 2007"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4391602/results/search/cochrane/results.xml">
   <result pre="low, is often used to correlate HERmark results with patient" exact="outcome" post="in clinical studies. In both Model A and Model"/>
   <result pre="HER2-targeted therapy and thus OS is a relatively reliable clinical" exact="outcome" post="in such a setting. The study has several limitations."/>
   <result pre="J Weidler J et al. Quantitative HER2 protein levels predict" exact="outcome" post="in fluorescence in situ hybridization-positive patients with metastatic breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4396883/results/search/cochrane/results.xml">
   <result pre="Haerting J et al. Chemotherapy for advanced gastric cancer The" exact="Cochrane" post="database of systematic reviews 2010 3 CD004064 20238327 5."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4403678/results/search/cochrane/results.xml">
   <result pre="with trastuzumab as a single agent [ 4]. From a" exact="meta-analysis" post="of 10 randomized control trials including 11,882 patients with"/>
   <result pre="with a 1.5-fold increase in HER2-neu expression and a worse" exact="outcome" post="[ 14]. The Ile/Val or Val/Val genotypes have been"/>
   <result pre="in risk of breast cancer [ 15]. In a recent" exact="meta-analysis" post="of 27 case–control studies of the Ile 655 Val"/>
   <result pre="of cardiac dysfunction with trastuzumab in breast cancer patients: a" exact="meta-analysis" post="Cancer Treat Rev 2011 37 4 312 320 10.1016/j.ctrv.2010.09.001"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4404037/results/search/cochrane/results.xml">
   <result pre="the various gene signatures and pathologic variables in predicting the" exact="outcome" post="of patients with early breast cancer in terms of"/>
   <result pre="with a manageable side effect profile with the most common" exact="adverse events" post="being neutropenia and fatigue. Based on these data, palbociclib"/>
   <result pre="have a better disease-free and overall survival. The hazard between" exact="pCR" post="and no pCR is largest in TNBC and HER2+"/>
   <result pre="disease-free and overall survival. The hazard between pCR and no" exact="pCR" post="is largest in TNBC and HER2+ patients [ 17]."/>
   <result pre="the long-term outcome, whereas in patients with hormone-receptor positive tumours" exact="pCR" post="is important, but the long-term outcome can be improved"/>
   <result pre="with hormone-receptor positive tumours pCR is important, but the long-term" exact="outcome" post="can be improved by adapting the therapy based on"/>
   <result pre="the gene BRCA status. Whereas in HER2+ breast cancer the" exact="pCR" post="could be increased to over 70% by using the"/>
   <result pre="trials patients with a HER2+/HR+ tumour had a significantly lower" exact="pCR" post="rate than those with a HER2+/HR− tumour. Besides the"/>
   <result pre="harbouring a mutation of the PIK3CA have a significantly lower" exact="pCR" post="rate with trastuzumab and lapatinib than those with wild-type"/>
   <result pre="infiltrating lymphocytes and immune markers significantly independently predict a higher" exact="pCR" post="rate [ 19]. Neoadjuvant endocrine therapy Neoadjuvant endocrine treatment"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4405013/results/search/cochrane/results.xml">
   <result pre="of gastric cancer by approximately one-third [ 4]. A recent" exact="meta-analysis" post="of RCTs also shows that H. pylori eradication seems"/>
   <result pre="hypermethylation in gastric cancer [ 31] ( Figure 3). Recent" exact="meta-analysis" post="revealed that the frequencies of p16 promoter methylation in"/>
   <result pre="Role of p16 gene promoter methylation in gastric carcinogenesis: a" exact="meta-analysis" post="Molecular Biology Reports 2014 41 7 4481 4492 10.1007/s11033-014-3319-y"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4406526/results/search/cochrane/results.xml">
   <result pre="The evolving field of HER2-targeted therapy has significantly improved the" exact="outcome" post="of women diagnosed with HER2-positive invasive breast cancer. In"/>
   <result pre="in Table 1. These findings were further scrutinised in a" exact="meta-analysis" post="that gathered the results of eight trials (total 11991"/>
   <result pre="[ 9]. The anticipated small absolute benefit and the expected" exact="adverse events" post="led to the exclusion of most of these patients"/>
   <result pre="absolute benefit and the expected adverse events led to the" exact="exclusion" post="of most of these patients in the pivotal studies"/>
   <result pre="(0.4%) had distant events. A 6% withdrawal rate because of" exact="adverse events" post="was also reported. The most relevant adverse events included"/>
   <result pre="because of adverse events was also reported. The most relevant" exact="adverse events" post="included grade 3 neuropathy (3.2%; 95% CI 1.7–5.4), symptomatic"/>
   <result pre="and negative respectively) is expected [ 15]. In these cases," exact="pCR" post="is a prognostic marker of favourable long-term outcomes, as"/>
   <result pre="cyclophosphamide (FEC) with or without trastuzumab. The primary endpoint was" exact="pCR" post="rate. The data and safety monitoring board stopped this"/>
   <result pre="in clinical response between arms favouring the use of trastuzumab:" exact="pCR" post="rate of 65.2% (95% CI, 43–84%) versus 26.3% (95%"/>
   <result pre="95% CI 0.38–0.90; p = 0.013) for primary endpoint. The" exact="pCR" post="rate was also higher in the trastuzumab arm (38%"/>
   <result pre="concomitant trastuzumab for a total period of one year. A" exact="pCR" post="(primary endpoint) rate of 31.7% was observed in those"/>
   <result pre="disease). In comparison, only 15.7% of the patients achieved a" exact="pCR" post="in the reference group of HER2-negative patients. These trials"/>
   <result pre="with either trastuzumab or lapatinib. The primary endpoint was the" exact="pCR" post="rate, which was of 30.3% in the trastuzumab arm,"/>
   <result pre="(46.7%, 90% CI 34.4–58.9%). The trastuzumab only arm had a" exact="pCR" post="of 25% (90% CI 13.1–36.9%) and the lapatinib only"/>
   <result pre="to either lapatinib, trastuzumab, or both. The primary endpoint was" exact="pCR" post="rate, which was higher in the group receiving combination"/>
   <result pre="difference was documented between the trastuzumab and lapatinib arms (lapatinib" exact="pCR" post="of 24.7%, 95% CI 18.1–32.3; p = 0.34 for"/>
   <result pre="afterwards completed one year of trastuzumab. The primary endpoint was" exact="pCR" post="(in the breast). The trial revealed that patients treated"/>
   <result pre="docetaxel, trastuzumab, and pertuzumab (group B) had a more favourable" exact="pCR" post="rate (45.8%, 95% CI 36.1–55.7) when compared with those"/>
   <result pre="0·014 for the difference). Groups C and D had a" exact="pCR" post="of 16.8% (95% CI 10.3–25.3) and 24.0% (15.8–33.7), respectively."/>
   <result pre="+ pertuzumab; group C) is per se effective in achieving" exact="pCR" post="in a subset of patients without any additional chemotherapy."/>
   <result pre="six months of trastuzumab. Concerning safety, similar rates of serious" exact="adverse events" post="were documented; however early stopping of trastuzumab because of"/>
   <result pre="sequence, with continued trastuzumab during FEC. No significant differences in" exact="pCR" post="in the breast (primary outcome) were noted (56.5% versus"/>
   <result pre="were continued till the completion of one year. The primary" exact="outcome" post="was pCR and serum trough concentration at a pre-dose"/>
   <result pre="till the completion of one year. The primary outcome was" exact="pCR" post="and serum trough concentration at a pre-dose cycle eight"/>
   <result pre="trough concentration at a pre-dose cycle eight before surgery. A" exact="pCR" post="rate of 40.7% versus 45.4% was obtained in the"/>
   <result pre="higher rate of patients in the SC arm had serious" exact="adverse events" post="(SAE; 21% versus 12% in the IV arm), including"/>
   <result pre="identify those patients with an increased likelihood of obtaining a" exact="pCR" post="[ 37]. This trial had a key design feature"/>
   <result pre="0.81). PET/CT responders had a two-fold likelihood of achieving a" exact="pCR" post="(week two: 42% versus 21%, p = 0.12; week"/>
   <result pre="This result contrasted with the significant improvement in terms of" exact="pCR" post="of the combination therapy in the NeoALTTO study ["/>
   <result pre="docetaxel or pertuzumab and trastuzumab or pertuzumab plus docetaxel. The" exact="pCR" post="rates between arms were 29%, 45.8%, 16.8%, and 24%,"/>
   <result pre="receiving only trastuzumab plus pertuzumab without chemotherapy that achieved a" exact="pCR" post="(16.8%), which raised the possibility that a small minority"/>
   <result pre="observation was especially valid for ER-negative patients, who achieved a" exact="pCR" post="in 29% of the cases. Other predictive biomarkers of"/>
   <result pre="L et al. Trastuzumab containing regimens for early breast cancer" exact="Cochrane" post="Database Syst Rev 2012 4 Cd006243 10.1002/14651858.CD006243.pub2 22513938 9."/>
   <result pre="JPA Neoadjuvant versus adjuvant systemic treatment in breast cancer: a" exact="meta-analysis" post="J Natl Cancer Inst 2005 97 3 188 94"/>
   <result pre="30. Procter M et al. Longer-term assessment of trastuzumab-related cardiac" exact="adverse events" post="in the Herceptin Adjuvant (HERA) trial J Clin Oncol"/>
   <result pre="neoadjuvant treatment of BC. Study Number of patients Comparison treatment" exact="pCR" post="(breast and lymph nodes) with no anti-HER2 therapy, %"/>
   <result pre="and lymph nodes) with no anti-HER2 therapy, % (95% CI)" exact="pCR" post="(breast and lymph nodes) for T, % (95% CI)"/>
   <result pre="pCR (breast and lymph nodes) for T, % (95% CI)" exact="pCR" post="(breast and lymph nodes) for anti-HER2 comparator (if applic.),"/>
   <result pre="lymph nodes) for anti-HER2 comparator (if applic.), % (95% CI)" exact="pCR" post="(breast and lymph nodes) for T plus anti-HER2 comparator"/>
   <result pre="P + T + L (prematurely closed) NA Only breast" exact="pCR" post="reported: 40 (32–49) Only breast pCR reported: 32 (22–44)"/>
   <result pre="closed) NA Only breast pCR reported: 40 (32–49) Only breast" exact="pCR" post="reported: 32 (22–44) Only breast pCR reported: 51 (42–60)"/>
   <result pre="40 (32–49) Only breast pCR reported: 32 (22–44) Only breast" exact="pCR" post="reported: 51 (42–60) Carey et al (2013) [ 53]"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4407294/results/search/cochrane/results.xml">
   <result pre="response (pCR) show more favorable outcomes. Notably, the achievement of" exact="pCR" post="varied according to BC subtype, and the prognostic value"/>
   <result pre="greatest in more aggressive subtypes. In particular, the association between" exact="pCR" post="and long-term outcomes was strongest in patients with HR"/>
   <result pre="Interestingly, Glück and colleagues [ 16] investigated the correlation between" exact="pCR" post="rate after neoadjuvant chemotherapy (NACT) and long-term outcome comparing"/>
   <result pre="correlation between pCR rate after neoadjuvant chemotherapy (NACT) and long-term" exact="outcome" post="comparing BluePrint and MammaPrint combined model versus clinical subtyping"/>
   <result pre="lymphocytes (TIL) have been associated with a higher rate of" exact="pCR" post="after NACT, and post-chemotherapy TIL presence has been linked"/>
   <result pre="linked with better outcomes in patients who did not obtain" exact="pCR" post="after neoadjuvant paclitaxel. Especially in TNBC, high levels of"/>
   <result pre="survival PAM50 Prediction analysis of microarray PARP Poly (ADP-ribose) polymerase" exact="pCR" post="pathologic complete response PFS Progression-free survival PR Progesterone receptor"/>
   <result pre="pathways: involvement of immune pathways in the therapeutic response and" exact="outcome" post="in breast cancer Clin Cancer Res. 2013 19 28"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4413633/results/search/cochrane/results.xml">
   <result pre="proliferation and apoptosis [ 10]. Moreover several studies­ (including a" exact="meta-analysis" post="conducted by us) have demonstrated that reduced p27 is"/>
   <result pre="a prognostic factor in breast cancer: a systematic review and" exact="meta-analysis" post="J Cell Mol Med 2010 14 4 944 953"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4423419/results/search/cochrane/results.xml">
   <result pre="Analysis of DFS according to HR status showed a superior" exact="outcome" post="for patients with HR+ (ER+ and/or PR+) disease, with"/>
   <result pre="patients. HR expression is thus an important determinant of long-term" exact="outcome" post="in HER2+ patients not treated with anti-HER2 therapy. Apart"/>
   <result pre="ideally by age and comorbidities, would have been the preferable" exact="outcome" post="measure as a basis for treatment decisions in health"/>
   <result pre="trastuzumab in the treatment of her-2-positive early breast cancer: a" exact="meta-analysis" post="of published randomized trials BMC Cancer 2007 7 153"/>
   <result pre="patients with HER2-positive breast cancer and tumors ≤2 cm: a" exact="meta-analysis" post="of the randomized trastuzumab trials. J Clin Oncol. 2014;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4424224/results/search/cochrane/results.xml">
   <result pre="concentration of lapatinib derived. Plasma lapatinib levels were measured and" exact="adverse events" post="noted. Results Six patients (three with brain metastases) were"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4427936/results/search/cochrane/results.xml">
   <result pre="prevention, detection or management of cancer treatment-induced cardiotoxicity. Methods Using" exact="Cochrane" post="methodology, we searched databases, citations and hand-searched bibliographies. Two"/>
   <result pre="cardiotoxicity in order to aid policy and practice decision-making. Methods" exact="Cochrane" post="methodology was used to appraise and synthesise systematic reviews"/>
   <result pre="sources and search strategy The following databases were searched: CINAHL;" exact="Cochrane" post="Database of Systematic Reviews; Joanna Briggs Institute library of"/>
   <result pre="a third independent reviewer was available for arbitration. Inclusion and" exact="exclusion" post="criteria for this meta-review are outlined in Table 1."/>
   <result pre="meta-review are outlined in Table 1. Table 1 Inclusion and" exact="exclusion" post="criteria for systematic reviews in this meta-review Inclusion criteria"/>
   <result pre="of the studies was assessed in the systematic reviews. The" exact="Cochrane" post="Collaboration specify this as an important element to include"/>
   <result pre="an important element to include in the preparation of a" exact="Cochrane" post="overview of reviews [ 19]. Our definition of ‘high-quality’"/>
   <result pre="from this meta-review. Eighteen systematic reviews fulfilled the inclusion and" exact="exclusion" post="criteria (Fig. 1). Fig. 1 Prisma flow chart -"/>
   <result pre="( n-12; 67 %) pooled results from individual studies for" exact="meta-analysis" post="[ 21– 26, 28, 30– 33]. The reviews that"/>
   <result pre="26, 28, 30– 33]. The reviews that did not use" exact="meta-analysis" post="used a narrative approach to synthesise the findings ("/>
   <result pre="chemotherapy • 11 controlled trials • Infusion duration • In" exact="meta-analysis" post="of 5 studies with 557 patients, a lower rate"/>
   <result pre="al. 2013 [ 33] P: advanced follicular lymphoma • 8" exact="RCT" post="conducted between 1974 and 2011. • ACR regardless of"/>
   <result pre="response rate, remission duration, relapse, disease control, Quality of life," exact="adverse events." post="Increased risk for cardiotoxicity associated with ACR (RR ="/>
   <result pre="ovarian cancer, sarcoma, non-Hodgkin's or Hodgkin's lymphoma, myeloma • 55" exact="RCT" post="Clinical cardiotoxicity (congestive heart failure) y 9 I: anthracycline"/>
   <result pre="al. (2008) [ 27] P: Hormone-refractory prostate cancer • 47" exact="RCT" post="published between 1977 and 2005 Drug categories included: •"/>
   <result pre="(ranged from 1 to 58 months) O: cardiotoxicity, tumour response," exact="adverse events" post="Van dalen et al. 2012 [ 28] P: children"/>
   <result pre="al. 2012 [ 28] P: children with cancer • 8" exact="RCT" post="published from 1975 to 2009 1153 treatment, 1121 control."/>
   <result pre="Rate of cardiac death was similar between treatment groups in" exact="meta-analysis" post="of two trials (RR = 0.41; 95 % CI"/>
   <result pre="et al. 2007 P: HER-2-positive early breast cancer • 5" exact="RCT" post="published in 2005 and 2006 Doxorubicin and cyclophosphamide (AC)"/>
   <result pre="2011 [ 21] P: node negative breast cancer • 19" exact="RCT" post="published from 2003 to 2010 Taxane treatment vs non"/>
   <result pre="al. 2008 [ 26] P: metastatic breast cancer • 34" exact="RCT" post="published between 1974 and 2004 • Comparison between anthracyclines"/>
   <result pre="et al. 2007 [ 22] P: breast cancer • 12" exact="RCT" post="published from 2002 to 2006 Any taxane contain regime"/>
   <result pre="containing regimens (OR 0.90, 95 %CI 0.53 to 1.55) in" exact="meta-analysis" post="of 6 studies involving 11557 patients. y 11 I:"/>
   <result pre="et al. 2012 [ 25] P: breast cancer • 4" exact="RCT" post="published between 2003 and 2009 Combinations Taxane and anthracycline;"/>
   <result pre="et al. 2011 [ 38] P: children with cancer 2" exact="RCT" post="published in 2004 and 2008 • Enalapril Vs placebo"/>
   <result pre="O: overall survival, mortality due to HF, development of HF," exact="adverse events" post="and tolerability • One intervention participant developed clinically significant"/>
   <result pre="15 days • No deaths in both groups • No" exact="adverse events" post="reported • no definitive conclusions can be drawn due"/>
   <result pre="Interval, RR Relative risk, OR, Odds ratio, HR Hazard ratio," exact="RCT" post="Randomised controlled trial. Key findings from systematic reviews Detection"/>
   <result pre="of included systematic reviews with clinical heart failure as the" exact="outcome" post="Prevention of cardiotoxicity associated with breast cancer treatment Two"/>
   <result pre="of dose-dense anthracycline-based chemotherapy in early breast cancer, comprising a" exact="meta-analysis" post="that combined n = 1,310 patients, revealed that women who received"/>
   <result pre="review, the chemotherapy regimens investigated were too dissimilar to conduct" exact="meta-analysis" post="[ 27]. No specific recommendations for the prevention of"/>
   <result pre="of observational studies [ 37]. In a further systematic review," exact="meta-analysis" post="of two randomized controlled trials revealed no statistically significant"/>
   <result pre="paediatric population [ 39]. Furthermore, only reviews registered by the" exact="Cochrane" post="Collaboration were included in van Dalen et al’s systematic"/>
   <result pre="is possible however that systematic reviews not registered with the" exact="Cochrane" post="Collaboration will meet many AMSTAR criteria, indicating that sufficient"/>
   <result pre="with the systematic review process were avoided. Therefore, including only" exact="Cochrane" post="reviews in a meta-review is not the optimal choice"/>
   <result pre="2) half of the systematic reviews not registered with the" exact="Cochrane" post="Collaboration were of high quality (n = 9; 50 % of"/>
   <result pre="met more than 7 of the AMSTAR criteria were not" exact="Cochrane" post="reviews). Based on these findings, it is recommended that"/>
   <result pre="and management of cancer treatment-induced toxicities should not include only" exact="Cochrane" post="reviews, as high-quality systematic reviews that potentially contain unbiased"/>
   <result pre="management of radiation-induced cardiotoxicity. Additional files LINK Additional file 1:" exact="MEDLINE" post="search strategy. LINK Additional file 2: AMSTAR score of"/>
   <result pre="vii155 vii66 10.1093/annonc/mds293 22997448 9. Higgins JPT, Green S, eds." exact="Cochrane" post="handbook for systematic reviews of interventions Version 5.1.0 [Updated"/>
   <result pre="systematic reviews of interventions Version 5.1.0 [Updated March 2011]. The" exact="Cochrane" post="Collaboration. 2011. Available from www.cochrane-handbook.org 10. Chu TF Rupnick"/>
   <result pre="PLoS Med 2007 4 e78 10.1371/journal.pmed.0040078 17388659 19. Collaboration TC." exact="Cochrane" post="handbook for systematic reviews of interventions version 5.1. 2011."/>
   <result pre="or without taxanes, in early or operable breast cancer: a" exact="meta-analysis" post="of 19 randomized trials with 30,698 patients PLoS One"/>
   <result pre="Nowak AK. Taxanes for adjuvant treatment of early breast cancer." exact="Cochrane" post="Database Syst Rev. 2007, Issue 4 Art No. CD004421."/>
   <result pre="trastuzumab in the treatment of her-2-positive early breast cancer: a" exact="meta-analysis" post="of published randomized trials BMC Cancer 2007 7 153"/>
   <result pre="conventional chemotherapy for early breast cancer: a systematic review with" exact="meta-analysis" post="Breast 2012 21 343 9 10.1016/j.breast.2012.02.011 22425607 26. Lord"/>
   <result pre="Simes J. Antitumour antibiotic containing regimens for metastatic breast cancer." exact="Cochrane" post="Database Syst Rev. 2004, Issue 4. Art No. CD003367"/>
   <result pre="J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer." exact="Cochrane" post="Database Syst Rev. 2006, Issue 4. Art No. CD005247"/>
   <result pre="including anthracyclines versus treatment not in-cluding anthracyclines for childhood cancer." exact="Cochrane" post="Database Syst Rev. 2011, Issue 1 Art. No.: CD006647"/>
   <result pre="HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines." exact="Cochrane" post="Database Syst Rev. 2011, Issue 6 Art No. CD003917"/>
   <result pre="L. Different anthracycline derivates for reducing cardiotoxicity in cancer patients." exact="Cochrane" post="Database Syst Rev. 2010, Issue 5. Art No. CD005006"/>
   <result pre="schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy." exact="Cochrane" post="Database Syst Rev. 2009, Issue 4. Art No. CD005008"/>
   <result pre="anthracycline agents for the treatment of cancer: systematic review and" exact="meta-analysis" post="of randomised controlled trials BMC Cancer 2010 10 337"/>
   <result pre="Anthracycline containing regimens for treatment of follicular lymphoma in adults." exact="Cochrane" post="Database Syst Rev. 2013, Issue 7. Art. No. CD008909."/>
   <result pre="and asymptomatic cardiotoxicity during and after treatment for childhood cancer." exact="Cochrane" post="Database Systematic Reviews. 2011; Issue 9: CD008011. 39. van"/>
   <result pre="of exceptional achievements: does the evidence support nurses to favour" exact="Cochrane" post="systematic reviews over other systematic reviews? Int J Nurs"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4436450/results/search/cochrane/results.xml">
   <result pre="MoAbs in cancer therapy, review all types of monoclonal antibodies-related" exact="adverse events" post="(e.g., allergy, immune-related adverse events, cardiovascular adverse events, and"/>
   <result pre="all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related" exact="adverse events," post="cardiovascular adverse events, and pulmonary adverse events), and discuss"/>
   <result pre="monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular" exact="adverse events," post="and pulmonary adverse events), and discuss the mechanism and"/>
   <result pre="pulmonary adverse events), and discuss the mechanism and treatment of" exact="adverse events." post="1. Introduction Engineered monoclonal antibodies (MoAbs) represent a significant"/>
   <result pre="(PD-1) and interleukin-6 (IL-6) are summarized in Table 1. Common" exact="adverse events" post="(AEs) include allergy (rash, infusion reactions), diarrhea, hypertension, proteinuria,"/>
   <result pre="T cells and is upregulated in malignancy [ 56]. Immune-related" exact="adverse events" post="(irAEs) can occur at any point during treatment with"/>
   <result pre="though the mechanism of pituitary injury remains unknown. Other immune-related" exact="adverse events" post="include hepatotoxicity, or failure of the thyroid gland (autoimmune"/>
   <result pre="a humanized monoclonal antibody that targets the PD-1 protein. Immune-related" exact="adverse events" post="are the most common side effects, and the skin"/>
   <result pre="neurologic events occur [ 66, 67]. 4. Cardiovascular AEs Cardiac" exact="adverse events" post="have occurred with specific MoAbs, including bevacizumab, trastuzumab, trastuzumabemtansine,"/>
   <result pre="2% patients [ 28]. 4.3. Congestive Heart Failure (CHF) A" exact="meta-analysis" post="of five randomized trials involving a total of 3,784"/>
   <result pre="and 2.5 mg/kg/week, respectively [ 25]. 4.5. Treatment To prevent cardiovascular" exact="adverse events," post="the physician should perform a pretreatment evaluation and screening,"/>
   <result pre="symptoms are generally nonspecific, the diagnosis usually remains one of" exact="exclusion" post="[ 16, 34, 35, 43, 78, 79]. Once again,"/>
   <result pre="therapy (delayed onset 15 days after methylprednisolone infusion and favorable" exact="outcome" post="with steroid therapy), rash and eosinophilia, BALF lymphocytosis, and"/>
   <result pre="MoAbs in cancer therapy, review all types of monoclonal antibodies-related" exact="adverse events" post="(e.g., allergy, immune-related adverse events, cardiovascular adverse events, and"/>
   <result pre="all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related" exact="adverse events," post="cardiovascular adverse events, and pulmonary adverse events), and discuss"/>
   <result pre="monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular" exact="adverse events," post="and pulmonary adverse events), and discuss the mechanism and"/>
   <result pre="pulmonary adverse events), and discuss the mechanism and treatment of" exact="adverse events" post="(see Table 4). Humanized monoclonal antibodies (MoAbs) have unique"/>
   <result pre="chemotherapy. With the rapid development of targeted therapy to cancer," exact="adverse events" post="of MoAbs attract increasing attention. Further research is needed"/>
   <result pre="Head and neck carcinoma ILD: Interstitial lung disease irAEs: Immune-related" exact="adverse events" post="LVEF: Left ventricular ejection fraction MoAb: Monoclonal antibody NHL:"/>
   <result pre="thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a" exact="meta-analysis" post="The Journal of the American Medical Association 2008 300"/>
   <result pre="cerebrovascular events in patients with cancer treated with bevacizumab: a" exact="meta-analysis" post="PLoS ONE 2014 9 7 26 Okines A. F."/>
   <result pre="de Azambuja E. et al. Longer-term assessment of trastuzumab-related cardiac" exact="adverse events" post="in the Herceptin Adjuvant (HERA) trial Journal of Clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439018/results/search/cochrane/results.xml">
   <result pre="for HER2-positive (HER2+) advanced breast cancer. To our knowledge, no" exact="meta-analysis" post="has evaluated HER2-targeted therapy including trastuzumab emtansine (T-DM1) and"/>
   <result pre="caner and ranked the targeted treatments. We performed a network" exact="meta-analysis" post="of both direct and indirect comparisons to evaluate the"/>
   <result pre="and examined side effects. Methods We performed a Bayesian-framework network" exact="meta-analysis" post="of randomized controlled trials to compare 6 HER2-targeted treatment"/>
   <result pre="or T-DM1-containing regimen, so there is a need for indirect" exact="meta-analysis" post="to evaluate these different HER2-targeted therapies. One of prior"/>
   <result pre="not stress on the HER2-targeted therapy [ 24]. The other" exact="meta-analysis" post="did not include the HER2-targeted agents of T-DM1 and"/>
   <result pre="of T-DM1 and pertuzumab in the study [ 25]. Network" exact="meta-analysis" post="is one of standard methods for systematic review and"/>
   <result pre="meta-analysis is one of standard methods for systematic review and" exact="meta-analysis" post="[ 26– 37]. Such analysis more comprehensively synthesizes direct"/>
   <result pre="in HER2-positive breast cancer, we performed a comprehensive systematic network" exact="meta-analysis" post="of HER2-targeted agents combined with standard treatment for HER2+"/>
   <result pre="strategy We searched for clinical trials published in English in" exact="MEDLINE" post="via PubMed and ClinicalTrials.gov ( http://www.clinicaltrials.gov) with the key"/>
   <result pre="of bias of trials was assessed as recommended by the" exact="Cochrane" post="Collaboration [ 40]. The main outcomes were OSR (overall"/>
   <result pre="effects, we extracted or derived the number of patients with" exact="outcome" post="of interest (numerator) and total number of patients in"/>
   <result pre="as an I 2 value &amp;gt;50% [ 45]. A network" exact="meta-analysis" post="was employed to synthesize direct and indirect treatment regimens"/>
   <result pre="model for advanced HER2+ breast cancer. Analysis involved use of" exact="STATA" post="12.0 (pair-wise meta-analysis and I 2 calculation), R 3.0.2"/>
   <result pre="HER2+ breast cancer. Analysis involved use of STATA 12.0 (pair-wise" exact="meta-analysis" post="and I 2 calculation), R 3.0.2 (estimation of consistency"/>
   <result pre="evidence, rank-grams, and SUCRA graphs), and WinBUGS 1.4.2 (multiple-treatments of" exact="meta-analysis" post="models). Results Eligible trials Abstract and titles of 575"/>
   <result pre="25 articles of 21 trials were included in our network" exact="meta-analysis" post="( Fig 1) and analyzed for the following HER2-targeted"/>
   <result pre="43 groups because 3 were three-group studies. The number of" exact="adverse events" post="was inconsistently reported. More reports counted the events of"/>
   <result pre="an interactive web-based response system as having no bias. Traditional" exact="meta-analysis" post="We performed a series of conventional meta-analyses to summarize"/>
   <result pre="&amp;gt;50%. In side-effect analysis, we found significant heterogeneity in the" exact="meta-analysis" post="of rash for the comparisons LC versus NST, LVEF"/>
   <result pre="diarrhea for LC versus HC ( S3 Table). For the" exact="meta-analysis" post="of diarrhea, we found I 2 &amp;gt; 75% for"/>
   <result pre="treatment-related diarrhea between LC and LC have statistical significance. Network" exact="meta-analysis" post="The ORR and OSR of the 7 treatment regimens"/>
   <result pre="rate were shown in S5 Fig. 10.1371/journal.pone.0127404.t001 Table 1 Network" exact="meta-analysis" post="comparison of the efficacy of the 5 HER2-targeted treatment"/>
   <result pre="with its confidence interval without 1. 10.1371/journal.pone.0127404.t002 Table 2 Network" exact="meta-analysis" post="comparison of the efficacy of the the 7 HER2-targeted"/>
   <result pre="of studies evaluating a specific pair of treatment regimens. Network" exact="meta-analysis" post="resolved this problem using indirect comparisons and distinguishes the"/>
   <result pre="A mixed model is as the most appropriate for multiple-treatment" exact="meta-analysis" post="[ 38, 48]. Except for a heterogeneity &amp;gt;75% for"/>
   <result pre="without stressing on the HER2-targeted therapy or did not use" exact="meta-analysis" post="for multiple-treatments [ 24, 25]. Our evidence supports adding"/>
   <result pre="added to standard treatment is not clear. In our network" exact="meta-analysis" post="and pair-wise meta-analysis, OSR and ORR was associated more"/>
   <result pre="additional data file. S2 Fig Risk of bias for each" exact="Cochrane" post="component. Review authors’ judgments (low, unclear, high) for each"/>
   <result pre="closed triangular loops (loops formed by 3 treatments) in each" exact="outcome" post="network. Inconsistent loops present inconsistent loops per network (maximum"/>
   <result pre="Salanti G , Pavlidis N , Ioannidis JP . Multiple-treatments" exact="meta-analysis" post="of chemotherapy and targeted therapies in advanced breast cancer"/>
   <result pre="with various antihypertensive therapies used as first-line agents: a network" exact="meta-analysis" post=". Jama. 2003; 289( 19): 2534– 2544. 12759325 27"/>
   <result pre="and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network" exact="meta-analysis" post="of randomised controlled trials . BMJ (Clinical research ed)."/>
   <result pre="metal stents in people with and without diabetes: collaborative network" exact="meta-analysis" post=". BMJ (Clinical research ed). 2008; 337: a1331 doi:"/>
   <result pre="Outcomes associated with drug-eluting and bare-metal stents: a collaborative network" exact="meta-analysis" post=". Lancet. 2007; 370( 9591): 937– 948. 17869634 33"/>
   <result pre="Puhan MA . Smoking cessation interventions in COPD: a network" exact="meta-analysis" post="of randomised trials. The European respiratory journal. 2009; 34("/>
   <result pre=", Lemmens R , Fieuws S . Network meta-analysis: simultaneous" exact="meta-analysis" post="of common antiplatelet regimens after transient ischaemic attack or"/>
   <result pre="coronary artery disease: a quantitative 20-year synopsis and a network" exact="meta-analysis" post=". Lancet. 2009; 373( 9667): 911– 918. doi: 10.1016/S0140-6736(09)60319-6"/>
   <result pre="F , Prins MH , Schouten JS . A network" exact="meta-analysis" post="combined direct and indirect comparisons between glaucoma drugs to"/>
   <result pre="placebo in patients with osteoarthritis of hip or knee: network" exact="meta-analysis" post=". BMJ (Clinical research ed). 2010; 341: c4675 doi:"/>
   <result pre="doi: 10.1016/j.jclinepi.2010.03.016 20688472 40 Higgins J , Green S ." exact="Cochrane" post="handbook for systematic reviews of intervention,version 5.0.0 1st ed"/>
   <result pre="handbook for systematic reviews of intervention,version 5.0.0 1st ed The" exact="Cochrane" post="Collaboration Hoboken: Wiley-Backwell; 2008. 41 Cipriani A , Furukawa"/>
   <result pre="Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments" exact="meta-analysis" post=". Lancet. 2009; 373( 9665): 746– 758. doi: 10.1016/S0140-6736(09)60046-5"/>
   <result pre="of external-beam radiation therapy for localised prostate cancer: a network" exact="meta-analysis" post=". British journal of cancer. 2014; 110( 10): 2396–"/>
   <result pre="43 DerSimonian R , Kacker R . Random-effects model for" exact="meta-analysis" post="of clinical trials: an update. Contemporary clinical trials. 2007;"/>
   <result pre=". The results of direct and indirect treatment comparisons in" exact="meta-analysis" post="of randomized controlled trials . Journal of clinical epidemiology."/>
   <result pre="V , Higgins JP . A case study of multiple-treatments" exact="meta-analysis" post="demonstrates that covariates should be considered . Journal of"/>
   <result pre="HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and" exact="meta-analysis" post=". Core evidence. 2013; 8: 69– 78. doi: 10.2147/CE.S50474"/>
   <result pre="JP . Predictive modeling and heterogeneity of baseline risk in" exact="meta-analysis" post="of individual patient data . Journal of clinical epidemiology."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439944/results/search/cochrane/results.xml">
   <result pre="that this subgroup of patients achieves a low rate of" exact="pCR" post="with chemotherapy and maintains, in any case, a favourable"/>
   <result pre="with chemotherapy and maintains, in any case, a favourable long-term" exact="outcome" post="12- 16. In addition, no prognostic advantage from the"/>
   <result pre="16. In addition, no prognostic advantage from the attainment of" exact="pCR" post="has been observed in patients with HR-positive tumors 17."/>
   <result pre="combination was more effective in reducing Ki67 labeling index. No" exact="pCR" post="was observed. The study does not provide information on"/>
   <result pre="the remaining 12 patients, RR was only 37%. Rate of" exact="pCR" post="was not reported. Imatinib, a potent inhibitor of PDGFR"/>
   <result pre="cases ( vs 7.6% in the placebo treated patients). A" exact="pCR" post="was reported in two patients treated with everolimus and"/>
   <result pre="Moreover, group A showed the highest clinical CR (10%). A" exact="pCR" post="was observed only in two (7%) patients of group"/>
   <result pre="PR (52%). Three out of 4 clinical CR were also" exact="pCR" post="(12%). Discussion We performed a systematic literature review aimed"/>
   <result pre="the investigated treatment we focused on clinical response rather than" exact="pCR" post="because of the low pCR rate achieved with endocrine"/>
   <result pre="on clinical response rather than pCR because of the low" exact="pCR" post="rate achieved with endocrine therapy, especially in a short-term"/>
   <result pre="70% 18- 21. In the impossibility to make a rigorous" exact="meta-analysis" post="of the selected studies, due to small sample size,"/>
   <result pre="therapy and without chemotherapy leads to a meaningful increase in" exact="pCR" post="rate in HR+/HER2+ breast cancer (33% with 24 weeks"/>
   <result pre="such as Ki67 reduction, depth of response, or achievement of" exact="pCR" post="could be relevant in regimens containing targeted agents. A"/>
   <result pre="38 or everolimus 43 to AI. Moreover, high rates of" exact="pCR" post="were reported using AI with trastuzumab/lapatinib or bevacizumab, 18%"/>
   <result pre="a nonchemotherapy-containing regimen, considering that hormone therapy alone rarely achieves" exact="pCR" post="56- 58. At the moment we do not know"/>
   <result pre="not know if the higher rates of Ki67 reduction or" exact="pCR" post="observed with these targeted therapies might translate in a"/>
   <result pre="hormone receptor mTOR mammalian target of rapamycin PD progressive disease" exact="pCR" post="pathologic complete response PDGFR platelet-derived growth factor receptor PR"/>
   <result pre="JP Neoadjuvant versus adjuvant systemic treatment in breast cancer: a" exact="meta-analysis" post="J Natl Cancer Inst 2005 97 188 94 15687361"/>
   <result pre="Peeters MT The relevance of breast cancer subtypes in the" exact="outcome" post="of neoadjuvant chemotherapy Ann Surg Oncol 2010 17 2411"/>
   <result pre="L Cioffi P Iacobelli S Natoli C Cianchetti E Long-term" exact="outcome" post="of neoadjuvant endocrine therapy with aromatase inhibitors in elderly"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4440424/results/search/cochrane/results.xml">
   <result pre="with hormone-receptor status has received the most extensive investigation. A" exact="meta-analysis" post="involving 26 studies found significant association between PIK3CA mutations"/>
   <result pre="to have better RFS ( Table 1). In fact, one" exact="meta-analysis" post="involving five studies listed in Table 1 27, 31,"/>
   <result pre="(hazard ratio [HR] 0.76, 95% CI 0.59–0.98; P=0.03). 30 Another" exact="meta-analysis" post="involving six studies 31, 33, 35, 39, 44, 45"/>
   <result pre="of postrecurrence treatment, which varies astronomically. As a reference, a" exact="meta-analysis" post="of seven studies indicated that PIK3CA mutations had no"/>
   <result pre="first-line tamoxifen treatment found no association of genotypes with treatment" exact="outcome" post="measured by TTP. 36 On the other hand, patients"/>
   <result pre="subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with" exact="outcome" post="in patients with early stage breast cancer Cancer 2013"/>
   <result pre="their association with hormone receptor expression in breast cancer: a" exact="meta-analysis" post="Sci Rep 2014 4 6255 25176561 31 Maruyama N"/>
   <result pre="LM Heguy A et al. PIK3CA mutation associates with improved" exact="outcome" post="in breast cancer Clin Cancer Res 2009 15 16"/>
   <result pre="et al. Hotspot mutations in PIK3CA associate with first-line treatment" exact="outcome" post="for aromatase inhibitors but not for tamoxifen Breast Cancer"/>
   <result pre="al. PIK3CA mutations, PTEN, and pHER2 expression and impact on" exact="outcome" post="in HER2-positive early-stage breast cancer patients treated with adjuvant"/>
   <result pre="prognostic biomarkers in operable breast cancer: a systematic review and" exact="meta-analysis" post="Onco Targets Ther 2014 7 543 552 24748804 47"/>
   <result pre="low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on" exact="outcome" post="in human epidermal growth factor receptor 2-positive metastatic breast"/>
   <result pre="Pathologic complete response as a potential surrogate for the clinical" exact="outcome" post="in patients with breast cancer after neoadjuvant therapy: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4444439/results/search/cochrane/results.xml">
   <result pre="injury when treating with pazopanib, sunitinib, lapatinib and regorafenib. A" exact="meta-analysis" post="published in 2013 showed that treating neoplastic patients with"/>
   <result pre="is labeled with the &quot;black box warning&quot;. In 2013 a" exact="meta-analysis" post="was published; it evaluated the range of hepatotoxicity appearing"/>
   <result pre="published in 2009 by De Matteo and partners. The above-mentioned" exact="meta-analysis" post="proved at least a twofold increase in the risk"/>
   <result pre="of tyrosine kinase inhibitors- induces hepatotoxicyty In cancer patients: A" exact="meta-analysis" post="Cancer Treat Rev 2013 39 199 206 23099278 17"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4445592/results/search/cochrane/results.xml">
   <result pre="accelerated approval was based on demonstration of an improvement in" exact="pCR" post="in patients receiving pertuzumab, trastuzumab, and docetaxel in both"/>
   <result pre="with only 29% (95% CI: 20.6–38.5) of patients who achieved" exact="pCR" post="on the trastuzumab plus docetaxel regimen ( P=0.0063). The"/>
   <result pre="assessment of pCR, all three regimens seemed active. The reported" exact="pCR" post="ranged from 57.3% to 66.2%. The highest pCR (66.2%)"/>
   <result pre="The reported pCR ranged from 57.3% to 66.2%. The highest" exact="pCR" post="(66.2%) was observed in patients who received pertuzumab, trastuzumab,"/>
   <result pre="chemotherapy. Correlation of biomarker subgroups with the achievement of a" exact="pCR" post="was analyzed in the TRYPHAENA study. Levels of HER2"/>
   <result pre="Levels of HER2 mRNA and protein were associated with the" exact="pCR" post="rates when data from all groups were pooled. These"/>
   <result pre="the combination of pertuzumab and trastuzumab was well tolerated, and" exact="adverse events" post="were mild or moderate, the most frequent being diarrhea"/>
   <result pre="30%, and 15% versus 24.9%, respectively). The incidence of cardiac" exact="adverse events" post="was slightly higher in the control group (16.4%) compared"/>
   <result pre="observed in combinations of trastuzumab plus standard chemotherapy. 29 A" exact="meta-analysis" post="of six randomized trials evaluating the cardiac toxicity between"/>
   <result pre="HER2 blockade does not significantly increase the risk of cardiac" exact="adverse events" post="compared with anti-HER2 monotherapy. 33 Congestive heart failure grade"/>
   <result pre="neoadjuvant treatment for breast cancer showed that patients who attain" exact="pCR" post="defined as ypT0, ypN0 or ypT0/is, and ypN0 have"/>
   <result pre="ypN0: HR 0.36, 95% CI 0.31–0.42). 36 The association between" exact="pCR" post="and OS was strongest in patients with triple-negative and"/>
   <result pre="profile NeoSphere 28 (N=417) II Neoadjuvant T+Doc P+T+Doc P+T P+Doc" exact="pCR" post="pCR improvement in the P+T+Doc group (45.8%) Other: similar"/>
   <result pre="NeoSphere 28 (N=417) II Neoadjuvant T+Doc P+T+Doc P+T P+Doc pCR" exact="pCR" post="improvement in the P+T+Doc group (45.8%) Other: similar safety"/>
   <result pre="of symptomatic LVSD and significant declines in LVEF Other: similar" exact="pCR" post="rates across groups (57.3%–66.2%) Abbreviations: P, pertuzumab; T, trastuzumab;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4447178/results/search/cochrane/results.xml">
   <result pre="headache (9%) and fatigue (4.5%) were the most frequent severe" exact="adverse events." post="Onartuzumab is a recombinant, fully humanized, monoclonal anti-MET antibody."/>
   <result pre="with advanced gastroesophageal cancer were enrolled from 25 centers; key" exact="eligibility" post="criteria included no previous treatments for metastatic disease, Eastern"/>
   <result pre="was not beneficial, regardless of patients’ race, and produced more" exact="adverse events." post="It is unclear whether these negative results suggest a"/>
   <result pre="was to analyze the relationship between PD-L1 expression and clinical" exact="outcome" post="in patients with advanced disease treated with pembrolizumab. 15"/>
   <result pre="the toxicity profile appears a bit challenging, with five severe" exact="adverse events" post="(peripheral sensory neuropathy, fatigue, decreased appetite, hypoxia, and pneumonitis)"/>
   <result pre="trial, AFP baseline levels seemed to be correlated with clinical" exact="outcome" post="during ramucirumab treatment. Hopefully, the impact of this novel"/>
   <result pre="acneiform rash, fatigue, and arthralgia being the most frequent treatment-related" exact="adverse events." post="On the basis of the same assumption that activation"/>
   <result pre="Database. 45 A significant relationship between time delay (TD) and" exact="pCR" post="was demonstrated ( P=0.0002). At TD &amp;lt;30 days, 4.0%"/>
   <result pre="4.0% of patients achieved pCR, while 9.3% of patients achieved" exact="pCR" post="by 75 days. At TD &amp;gt;75 days, the rate"/>
   <result pre="by 75 days. At TD &amp;gt;75 days, the rate of" exact="pCR" post="decreased. However, TD of &amp;gt;60 days was associated with"/>
   <result pre="greater risk of mortality (95% CI: 1.07–1.36). Direct correlation between" exact="pCR" post="and survival does not seem very strong in rectal"/>
   <result pre="G Scarpi E et al. eNOS polymorphisms in relation to" exact="outcome" post="in advanced HCC patients receiving sorafenib J Clin Oncol"/>
   <result pre="al. VEGF and VEGFR genotyping in the prediction of clinical" exact="outcome" post="for HCC patients receiving sorafenib: the ALICE-1 study Int"/>
   <result pre="receptor (EGFR) and its network in the prediction of clinical" exact="outcome" post="during anti-EGFR treatment in colorectal cancer patients Curr Drug"/>
   <result pre="carcinomas Authors Phase Treatment line Design Primary end point Trial" exact="outcome" post="Kwak et al 7 I Refractory AMG 337, single"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4453607/results/search/cochrane/results.xml">
   <result pre="examined the correlations between EGFR overexpression, trastuzumab response and clinical" exact="outcome" post="in 447 primary, and 112 metastatic HER2-positive breast cancer"/>
   <result pre="negativity, large tumour size, high histologic grade and poor clinical" exact="outcome" post="( DiGiovanna et al, 2005 ; Nieto et al,"/>
   <result pre="the correlation of EGFR expression with trastuzumab response and clinical" exact="outcome" post="in HER2-positive primary and metastatic breast cancer patients treated"/>
   <result pre="treated with adjuvant trastuzumab. Correlation between EGFR overexpression and clinical" exact="outcome" post="in HER2-positive primary breast cancer patients treated with adjuvant"/>
   <result pre="trastuzuamb. Therefore, the association of EGFR overexpression with poor clinical" exact="outcome" post="in patients receiving adjuvant trastuzuamb cannot be solely explained"/>
   <result pre="large studies. There are treatments that may improve the clinical" exact="outcome" post="of patients with HER2-positive breast cancers overexpressing EGFR. A"/>
   <result pre="pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical" exact="outcome" post="in HER2-positive metastatic breast cancer patients treated with trastuzumab"/>
   <result pre="Park SY 2014 High EGFR gene copy number predicts poor" exact="outcome" post="in triple-negative breast cancer Mod Pathol 27 1212 1222"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4456592/results/search/cochrane/results.xml">
   <result pre="analyses showing the association of preoperative sHER2 with adverse patient" exact="outcome" post="in two cohorts using recurrence-free survival as clinical endpoints"/>
   <result pre="to prevail as a standard clinical screening test to determine" exact="eligibility" post="of HER2 targeted therapies, many studies have shown the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4457853/results/search/cochrane/results.xml">
   <result pre="the utility of TOS by correlating the score to the" exact="outcome" post="of recent clinical trials evaluating trastuzumab, an effective anticancer"/>
   <result pre="show that there is a correlation between TOS and the" exact="outcome" post="of recent clinical trials where trastuzumab was used in"/>
   <result pre="of various drug combinations. 2.4. TOS shows correlation with the" exact="outcome" post="of clinical trials In a clinical trial (also called"/>
   <result pre="the statistical dependence between the TOS score and the clinical" exact="outcome" post="measures. Table 2 shows that the TOS score shows"/>
   <result pre="axes, the clinical outcome, Overall Response (for the definition of" exact="outcome" post="measures see the RECIST [ 35]) are on the"/>
   <result pre="and Methods. 10.1371/journal.pone.0129267.t002 Table 2 Spearman correlation between the clinical" exact="outcome" post="measures and the generalized TOS scores of multicomponent combinations."/>
   <result pre="measures and the generalized TOS scores of multicomponent combinations. Clinical" exact="outcome" post="1 r 2 p-val. 3 OR 4 0.6453 0.0028"/>
   <result pre="0.8440 0.0021 median PFS 7 0.3784 0.4008 1All the clinical" exact="outcome" post="measures were recorded based on the Response Evaluation Criteria"/>
   <result pre="is a significant correlation between the TOS scores and the" exact="outcome" post="of clinical trials. Discussion The TOS score is based"/>
   <result pre="Supporting Information S1 Table Clinical Trial Data. 1All the clinical" exact="outcome" post="measures were recorded based on the Response Evaluation Criteria"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4464713/results/search/cochrane/results.xml">
   <result pre="of local recurrence but an especially low risk of lethal" exact="outcome" post="from the disease [ 27]. However, an increasing rate"/>
   <result pre="intervention predominantly used in our cohort. Compared to mastectomy, the" exact="outcome" post="following this surgical approach requires higher accuracy in pre-surgical"/>
   <result pre="between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient" exact="outcome" post="Diagn Mol Pathol 2009 18 88 95 10.1097/PDM.0b013e31816f6374 19430296"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4465168/results/search/cochrane/results.xml">
   <result pre="to be cost-effective in health economic studies. In fact, a" exact="meta-analysis" post="of clinical and safety data from randomized trials in"/>
   <result pre="Patients receiving protocol-specified dose (%) Efficacy outcomes Select grade 3/4" exact="adverse events" post="(%) ORR (%) PFS (months) OS (months) Neutropenia Neuropathy"/>
   <result pre="Patients receiving protocol-specified dose (%) Efficacy outcomes Select grade 3/4" exact="adverse events" post="(%) ORR (%) PFS (months) OS (months) Neutropenia Neuropathy"/>
   <result pre="in a favorable safety profile: the most common grade 3" exact="adverse events" post="were pain (11 %), infection (9 %), neutropenia (8"/>
   <result pre="primarily due to nonhematologic toxicity. The most common grade 3/4" exact="adverse events" post="were diarrhea (22 %) and neutropenia (22 %). A"/>
   <result pre="Patients receiving protocol-specified dose (%) Efficacy outcomes Select grade 3/4" exact="adverse events" post="(%) pCR in breast and LNs (%) Other parameters"/>
   <result pre="dose (%) Efficacy outcomes Select grade 3/4 adverse events (%)" exact="pCR" post="in breast and LNs (%) Other parameters Neutropenia Neuropathy"/>
   <result pre="Long-term follow-up would be necessary to confirm whether the higher" exact="pCR" post="translates into improved survival. Also in the neoadjuvant setting,"/>
   <result pre="37]. The addition of bevacizumab resulted in a significantly higher" exact="pCR" post="rate (primary endpoint 36 % vs 21 % in"/>
   <result pre="of the planned nab-paclitaxel doses were reduced or skipped. A" exact="pCR" post="was observed in 58 % of patients with HER2-positive"/>
   <result pre="and trastuzumab. This treatment resulted in a high rate of" exact="pCR" post="(48 %) and was well tolerated, with low rates"/>
   <result pre="2 to 125 mg/m 2, resulting in a 38 %" exact="pCR" post="rate and grade 3/4 sensory neuropathy in 10 %"/>
   <result pre="Metastatic breast cancer ORR Overall response rate OS Overall survival" exact="pCR" post="Pathologic complete response PFS Progression-free survival q2w Every 2"/>
   <result pre="Harris LN et al. Failure of higher-dose paclitaxel to improve" exact="outcome" post="in patients with metastatic breast cancer: Cancer and Leukemia"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467394/results/search/cochrane/results.xml">
   <result pre="cancer patients and correlates with adverse prognosis and poor clinical" exact="outcome" post="[ 3, 4]. HER2 overexpression correlates with tumour size,"/>
   <result pre="B-41 [ 19] and neoALTTO trials [ 20]. Recently, a" exact="meta-analysis" post="of six randomised trials had concluded that lapatinib in"/>
   <result pre="concluded that lapatinib in combination with chemotherapy achieved a lower" exact="pCR" post="and higher risk of toxicity compared to trastuzumab with"/>
   <result pre="nuclear HER4 but not cytoplasmic HER4 is associated with poor" exact="outcome" post="in HER2-positive breast cancer [ 40]. Therefore, further analysis"/>
   <result pre="mAbs monoclonal antibodies TKIs tyrosine kinase inhibitors T-DM1 Trastuzumab emtansine" exact="pCR" post="pathological complete response FDA Food and Drug Administration TKD"/>
   <result pre="the combination added to preoperative chemotherapy for breast cancer: a" exact="meta-analysis" post="of randomized evidence Breast cancer research and treatment 2012"/>
   <result pre="mediates acquired resistance to trastuzumab and is associated with poor" exact="outcome" post="in HER2 positive breast cancer Oncotarget 2014 5 5934"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467661/results/search/cochrane/results.xml">
   <result pre="64 Patients with hormone receptor-positive/HER2-positive disease also had a higher" exact="pCR" post="rate with the addition of neratinib (30% vs 17%)."/>
   <result pre="higher score than the previous median MammaPrint score had a" exact="pCR" post="of 47.5% if treated with a neratinib-containing regimen in"/>
   <result pre="to 93%), especially during the first week of treatment; other" exact="adverse events" post="included nausea, fatigue, vomiting, neutropenia, and anorexia. 79, 81"/>
   <result pre="mediates acquired resistance to trastuzumab and is associated with poor" exact="outcome" post="in HER2 positive breast cancer Oncotarget 2014 5 15"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467984/results/search/cochrane/results.xml">
   <result pre="the cases ( Fig 2B, lower graph). The percentage of" exact="pCR" post="in the DM group (50%) was not statistically different"/>
   <result pre="cases (8 with DM and 8 with HSR amplification) without" exact="pCR" post="were analyzed pre- and post treatment. The average amplification"/>
   <result pre="showing that the cases with DM that did not achieve" exact="pCR" post="did not tend to lose HER2 gene copies. In"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4469402/results/search/cochrane/results.xml">
   <result pre="often diagnosed an advanced disease stage and have a poor" exact="outcome" post="with systemic therapy. Recent efforts towards molecular characterization have"/>
   <result pre="presentation, early occurrence of liver and peritoneal metastases, and poor" exact="outcome" post="with standard chemotherapy contribute to the poor prognosis of"/>
   <result pre="molecular characterization of this disease may help alter the dismal" exact="outcome" post="with targeted therapeutics [ 1, 2]. An estimated 12–15"/>
   <result pre="activation in sensitivity to trastuzumab in HER2-positive breast cancer: a" exact="meta-analysis" post="Curr Med Res Opin 2013 29 6 633 642"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4470009/results/search/cochrane/results.xml">
   <result pre="still under debate.[ 9] Dendukuri et al.[ 10] performed a" exact="meta-analysis" post="and found that the strategy with the lowest cost-effectiveness"/>
   <result pre="and time in laboratory diagnosis, but also will improve patient" exact="outcome" post="by introducing appropriate cases to trastuzumab therapy. Available FREE"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471111/results/search/cochrane/results.xml">
   <result pre="in the first follow-up visit were also predictive of patient" exact="outcome" post="[ 9]. Besides CTC detection, significant effort has been"/>
   <result pre="hormonal therapy and their persistence is associated with poor clinical" exact="outcome" post="[ 19– 21]. Targeting these CTCs could be beneficial"/>
   <result pre="after the completion of prior therapy for advanced disease. Other" exact="eligibility" post="criteria were: age &amp;gt;18 years old, adequate bone marrow,"/>
   <result pre="value (Whiskers: Tukey). Effect of lapatinib on CTCs according to" exact="outcome" post="A total of 120 treatment cycles were administered (median"/>
   <result pre="Toxicity Twenty-two patients were evaluable for toxicity. The most common" exact="adverse events" post="of any grade were fatigue, diarrhoea and rash reported"/>
   <result pre="sampling whereas HER2-positive CTCs have been associated with poor clinical" exact="outcome" post="in early breast cancer [ 17, 28, 29]. We"/>
   <result pre="observed in the negative control. Moreover, the cut-off for patient" exact="eligibility" post="was arbitrarily set as the detection of at least"/>
   <result pre="al. ( 2006) HER2-positive circulating tumor cells indicate poor clinical" exact="outcome" post="in stage I to III breast cancer patients ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471791/results/search/cochrane/results.xml">
   <result pre="tumor stage, it is currently difficult to predict the clinical" exact="outcome" post="for individual patients with early-stage tumors. The endoplasmic reticulum"/>
   <result pre="Millar EK Graham PH McNeil CM et al. Prediction of" exact="outcome" post="of early ER+ breast cancer is improved using a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4472207/results/search/cochrane/results.xml">
   <result pre="this population. Finally, we believe that exploratory analysis regarding clinical" exact="outcome" post="or other clinical parameter will not produce reliable results."/>
   <result pre="J Saint F Cordon-Cardo C Defining molecular profiles of poor" exact="outcome" post="in patients with invasive bladder cancer using oligonucleotide microarrays"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4484424/results/search/cochrane/results.xml">
   <result pre="cause of cancer-related death by 2030 [ 3]. This dramatic" exact="outcome" post="is related to a lack of efficient therapeutic tools"/>
   <result pre="number of chromosome 17 but not HER2 amplification predicts clinical" exact="outcome" post="of patients with pancreatic ductal adenocarcinoma J Clin Oncol"/>
   <result pre="nuclear envelope of breast carcinoma cells correlates with poor clinical" exact="outcome" post="Pathol Oncol Res 2012 18 331 342 21986666 35"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4488128/results/search/cochrane/results.xml">
   <result pre="improved prognosis. We examined differences in anti-HER2 Th1 responses between" exact="pCR" post="and non-pCR patients to identify modifiable immune correlates to"/>
   <result pre="associated with higher anti-HER2 Th1 repertoire (p = 0.048). While" exact="pCR" post="(n = 16) and non-pCR (n = 24) patients"/>
   <result pre="= 24) patients did not differ substantially in demographic/clinical characteristics," exact="pCR" post="patients demonstrated dramatically higher anti-HER2 Th1 responsivity (94 %"/>
   <result pre="response (pCR) [ 5– 7]; compared with incomplete response (non-pCR)," exact="pCR" post="is associated with decreased recurrence and improved long-term survival"/>
   <result pre="absent estrogen/progesterone receptor (ER/PR) expression appears to reproducibly correlate with" exact="pCR" post="[ 8, 9], there are a paucity of modifiable"/>
   <result pre="+ Th1 response as a novel systemic immune correlate to" exact="pCR" post="following neoadjuvant T + C in patients with HER2"/>
   <result pre="of chemotherapy (i.e., neoadjuvant versus adjuvant), and further sub-stratified by" exact="pCR" post="and non-pCR status within the neoadjuvant cohort (Fig. 1)."/>
   <result pre="pCR and non-pCR status within the neoadjuvant cohort (Fig. 1)." exact="pCR" post="was defined as absence of residual invasive cancer on"/>
   <result pre="chemotherapy ( T + C) was 26 (IQR 16.5–31.0) months." exact="pCR" post="pathologic complete response, DCI type 1-polarized dendritic cell, Adj"/>
   <result pre="(categorical data) were used for two-group and univariate comparisons between" exact="pCR" post="and non-pCR cohorts. To determine independent correlates of pCR,"/>
   <result pre="in 40 patients (61.5 %); 16 patients (40.0 %) achieved" exact="pCR" post="whereas 24 (60.0 %) had residual disease at surgery"/>
   <result pre="spot-forming cells Anti-HER2 T cell immune responses correlate strongly with" exact="pCR" post="In the cohort receiving neoadjuvant T + C, patients"/>
   <result pre="In the cohort receiving neoadjuvant T + C, patients achieving" exact="pCR" post="( cohort E; Fig. 1) demonstrated dramatically higher IFN-γ"/>
   <result pre="T + C to study enrollment did not differ between" exact="pCR" post="and non-pCR cohorts (23.5 vs 26.5 months, p ="/>
   <result pre="observed in patients with HER2 pos invasive breast cancer achieving" exact="pCR" post="(n = 16) following neoadjuvant trastuzumab and chemotherapy (T"/>
   <result pre="= 24). Peripheral blood mononuclear cells (PBMC) from patients with" exact="pCR" post="and non-pCR were stimulated ex vivo with six HER2-derived"/>
   <result pre="cumulative response. b Evaluable HLA-A2.1 pos PBMC from patients with" exact="pCR" post="(n = 6; black bars) and non-pCR (n ="/>
   <result pre="standard error of the mean Evaluable PBMC from HLA-A2.1 pos" exact="pCR" post="and non-pCR patients were stimulated ex vivo with two"/>
   <result pre="+ CD8 + T cell responses were significantly higher in" exact="pCR" post="patients upon stimulation with the immunodominant HER2 369–377 (72.1"/>
   <result pre="epitope (Fig. 3b). Anti-HER2 Th1 responsivity is independently associated with" exact="pCR" post="following multivariable analysis The independent association between IFN-γ +"/>
   <result pre="The independent association between IFN-γ + anti-HER2 Th1 responses and" exact="pCR" post="was evaluated by controlling for confounding from relevant demographic"/>
   <result pre="confounding from relevant demographic and clinicopathologic characteristics. Upon univariate testing," exact="pCR" post="and non-pCR cohorts did not differ significantly by age,"/>
   <result pre="LVI, nuclear grade, or utilized T + C regimens. However," exact="pCR" post="patients were more likely to have ER/PR neg tumors"/>
   <result pre="non-pCR (68.8 % vs 29.2 %, p = 0.02). Although" exact="pCR" post="patients demonstrated a trend toward presentation at lower (i.e.,"/>
   <result pre="Table 2 Univariate comparison of demographic and tumor-related characteristics between" exact="pCR" post="and non-pCR patients Characteristic Patients with pCR, number (%)"/>
   <result pre="multivariable logistic regression analysis to determine independent correlates to pCR." exact="pCR" post="pathologic complete response, BMI body mass index, AJCC American"/>
   <result pre="CI 1.03, 21.58, p = 0.046) remained independently associated with" exact="pCR" post="status. Due to persistence of the association between ER/PR"/>
   <result pre="Due to persistence of the association between ER/PR status and" exact="pCR" post="on multivariable analysis, anti-HER2 Th1 responses were stratified by"/>
   <result pre="[ 17]), and intracellular IFN-γ by flow cytometry. Patients with" exact="pCR" post="demonstrated a significantly greater proportion of HER2-specific CD4 +T-bet"/>
   <result pre="+ cells in peripheral blood mononuclear cells ( PBMC) from" exact="pCR" post="and non-pCR patients. Representative stains within groups are shown"/>
   <result pre="indicated. b Circulating HER2-specific IL-4 production does not vary between" exact="pCR" post="and non-pCR patients, when assessed by responsivity, repertoire, and"/>
   <result pre="6 cells) across six HER2 class II peptides compared in" exact="pCR" post="and non-pCR patients. Relative HER2-specific IFN-γ:IL-4 proportions (% depicted"/>
   <result pre="IFN-γ:IL-4 proportions (% depicted in graph) was significantly higher in" exact="pCR" post="(IFN-γ/(IFN-γ + IL-4) = 73.9 %:IL-4/(IFN-γ + IL-4) ="/>
   <result pre="bottom right panel). c HER2-specific IL-10 production is similar between" exact="pCR" post="and non-pCR patients across all Th1 metrics. Results are"/>
   <result pre="top panel). Relative HER2-specific IFN-γ:IL-10 production was significantly higher in" exact="pCR" post="(62.0:38.0 %) compared with non-pCR (23.8:76.2 %) patients. Absolute"/>
   <result pre="pos responsivity, repertoire, and cumulative response did not differ between" exact="pCR" post="and non-pCR cohorts, donor-matched HER2-specific IFN-γ:IL-4 production ratios shifted"/>
   <result pre="IFN-γ:IL-4 production ratios shifted from 2.8:1 (relative Th1-favoring phenotype) in" exact="pCR" post="to 0.5:1 (relative Th2-favoring) in non-pCR patients ( p"/>
   <result pre="overall anti-HER2 IL-10 pos immune metrics did not differ between" exact="pCR" post="and non-pCR patients; however, relative anti-HER2 IFN-γ:IL-10 contributions shifted"/>
   <result pre="however, relative anti-HER2 IFN-γ:IL-10 contributions shifted from 1.6:1 (Th1-favoring) in" exact="pCR" post="to 0.3:1 (T reg-favoring) in non-pCR patients ( p"/>
   <result pre="host-level T cell anergy or immunosuppressive phenotypes Immune competence in" exact="pCR" post="and non-pCR subgroups was assessed by anti-CD3/anti-CD28-stimulated Th1 responses"/>
   <result pre="70.7 SFC/2 × 10 5 cells, p = 0.23) between" exact="pCR" post="and non-pCR cohorts. Furthermore, IFN-γ production following recall stimuli"/>
   <result pre="181 ± 9.0 SFC/2 × 10 5)) were similar between" exact="pCR" post="and non-pCR groups, respectively (Fig. 5a). Collectively, these data"/>
   <result pre="in immunosuppressive phenotypes. Peripheral blood mononuclear cells ( PBMC) from" exact="pCR" post="and non-pCR patients did not differ significantly in ("/>
   <result pre="p = 0.67) cells did not differ between PBMCs from" exact="pCR" post="and non-pCR patients, respectively (Fig. 5b). Proportions of B"/>
   <result pre="± 0.3 %, p = 0.34) did not differ between" exact="pCR" post="and non-pCR subgroups, respectively (Fig. 5c). Anti-HER2 Th1 deficit"/>
   <result pre="autologous HER2-targeted DC1 vaccination resulted in durable anti-HER2 Th1 immunity;" exact="pCR" post="rates approached 25 % with substantial loss of target"/>
   <result pre="CD4 + T-cell immunity is more robust in patients achieving" exact="pCR" post="compared with their non-pCR counterparts despite controlling for relevant"/>
   <result pre="8]; in fact, the Food and Drug Administration (FDA) supports" exact="pCR" post="as a trial endpoint for drug approval [ 20]."/>
   <result pre="369–377-specific CD8 + T-cell immune responses and tumor eradication in" exact="pCR" post="patients may reflect the ready availability of CD4 +"/>
   <result pre="GeparQuattro trial suggested that tumor-infiltrating lymphocyte (TIL) density correlates with" exact="pCR" post="following neoadjuvant T + C; for every 10 %"/>
   <result pre="% increase in TIL levels, a 16 % increase in" exact="pCR" post="rates was observed [ 27]. The sizeable increase in"/>
   <result pre="27]. The sizeable increase in circulating anti-HER2 Th1 populations in" exact="pCR" post="patients in the present study may represent a systemic"/>
   <result pre="analysis, however, is whether the heightened anti-HER2 Th1 responses in" exact="pCR" post="patients represent preservation of erstwhile immunity, or immune restoration"/>
   <result pre="a critical association between anti-HER2 CD4 + Th1 immunity and" exact="pCR" post="following neoadjuvant T + C in HER2 pos IBC"/>
   <result pre="the six tested peptides - in this example, both the" exact="pCR" post="and non-pCR patients were responsive. Th1 repertoire represents the"/>
   <result pre="represents the number of reactive peptides - in this example," exact="pCR" post="donor: 4; non-pCR donor: 1. Th1 cumulative response is"/>
   <result pre="and standardizing to 10 6 cells - in this example," exact="pCR" post="donor: 197.5 SFC/10 6; non-pCR donor: 29.1 SFC/10 6."/>
   <result pre="odds ratio PBMC peripheral blood mononuclear cells PBS phosphate-buffered saline" exact="pCR" post="pathologic complete response PMA phorbol-12-myristate 13-acetate PR progesterone receptor"/>
   <result pre="reveals that immune function genes are strongly linked to clinical" exact="outcome" post="in the North Central Cancer Treatment Group N9831 Adjuvant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4491676/results/search/cochrane/results.xml">
   <result pre="PP2A inhibitor which when over expressed, is associated with poor" exact="outcome" post="[ 75, 76]. Specifically, CIP2A inhibits the activity of"/>
   <result pre="Overexpression of SET is a recurrent event associated with poor" exact="outcome" post="and contributes to protein phosphatase 2A inhibition in acute"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494975/results/search/cochrane/results.xml">
   <result pre="in two patients (Fig. 1). Table 1 THERAPY clinical trial:" exact="eligibility" post="criteria Inclusion criteria previous failure of gemcitabine-based chemotherapy (in"/>
   <result pre="in Table 3. No toxicity-related death was reported and most" exact="adverse events" post="were grade 1 or 2. The most commonly reported"/>
   <result pre="grade 1 or 2. The most commonly reported grade 3" exact="adverse events" post="were cutaneous toxicities ( n=19). Other non-cutaneous grade 3"/>
   <result pre="to cutaneous toxicity, although disease was stabilized. Moreover, such cutaneous" exact="adverse events" post="might be more frequent and severe in patients who"/>
   <result pre="the correlation between response or survival and severity of cutaneous" exact="adverse events," post="as observed in our study, has already been reported."/>
   <result pre="documented, unresectable pancreatic adenocarcinoma were enrolled (Fig. 1). The other" exact="eligibility" post="criteria are listed in Table 1. Phase 1 trial"/>
   <result pre="Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical" exact="outcome" post="of patients with metastatic colorectal cancer treated with cetuximab"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4495150/results/search/cochrane/results.xml">
   <result pre="ER and had HER2 overexpression. Their findings revealed a superior" exact="outcome" post="to that after endocrine therapy alone (progression-free survival: 4.8"/>
   <result pre="O et al. Molecular subtype can predict the response and" exact="outcome" post="of Chinese locally advanced breast cancer patients treated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4496366/results/search/cochrane/results.xml">
   <result pre="IA Park SY High EGFR gene copy number predicts poor" exact="outcome" post="in triple-negative breast cancer Mod Pathol 2014 27 1212"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4501549/results/search/cochrane/results.xml">
   <result pre="caveolin-1 protein may be an effective predictor for determining the" exact="outcome" post="of T-DM1 treatment in breast cancer patients. Funding This"/>
   <result pre="invasive breast cancers and is a predictor of poor clinical" exact="outcome" post="[ 1, 2]. The humanized monoclonal antibody, trastuzumab (Herceptin),"/>
   <result pre="63× objective (1.4 oil). Cell viability using a trypan blue" exact="exclusion" post="assay Cells were seeded into 24 well plates at"/>
   <result pre="pattern in primary colorectal carcinomas and their metastases reflects disease" exact="outcome" post=". World J Gastroenterol. 2006; 12( 27): 4304– 9."/>
   <result pre="MA , et al. Stromal cell expression of caveolin-1 predicts" exact="outcome" post="in breast cancer. Am J Pathol. 2009; 174( 6):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506361/results/search/cochrane/results.xml">
   <result pre="prognostic value of HER2 overexpression in CRC, although a recent" exact="meta-analysis" post="found no significant effect on survival [ 10]. ERBB2"/>
   <result pre="backbone. Thus, this case illustrates a much better than expected" exact="outcome" post="given failure of standard treatments, and in comparison to"/>
   <result pre="Chen L HER-2 overexpression and survival in colorectal cancer: a" exact="meta-analysis" post="J Zhejiang Univ Sci B 2014 6 15 6"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4511219/results/search/cochrane/results.xml">
   <result pre="its trend to less extensive surgery without compromise of the" exact="outcome" post="[ 6, 7], but recent radiotherapy trials in node-positive"/>
   <result pre="based on BRCA 1 or BRCA 2 mutation showed high" exact="pCR" post="rates to platinum salts [ 61, 62], and carboplatin"/>
   <result pre="to be no optimal cut point, at least to predict" exact="pCR" post="along the continuum of Ki-67 levels [ 71, 72]."/>
   <result pre="to reduce variability [ 74]. Neoadjuvant systemic therapies An improved" exact="pCR" post="rate was observed with carboplatin for patients with triple-negative"/>
   <result pre="not observed for HER2-positive disease [ 50, 76]. An improved" exact="pCR" post="rate was also observed in triple-negative breast cancer using"/>
   <result pre="breast cancer using nab-paclitaxel instead of solvent-based paclitaxel [ 50]." exact="pCR" post="rates were higher in patients with lymphocyte predominant breast"/>
   <result pre="with carboplatin [ 77]. PIK3CA mutation was associated with inferior" exact="pCR" post="rates to anti-HER2 therapies in several neoadjuvant studies ["/>
   <result pre="endocrine therapies usually take longer to achieve tumor response and" exact="pCR" post="rates are generally low. Treatment may continue until maximal"/>
   <result pre="and accurate after neoadjuvant chemotherapy and allows precise assessment of" exact="pCR" post="[ 92– 95]. In patients with nodal involvement at"/>
   <result pre="study of adjuvant paclitaxel and trastuzumab, without anthracycline, showed excellent" exact="outcome" post="in node-negative, HER2-positive, pT1b and pT1c tumors. Despite the"/>
   <result pre="al. Ki-67 as prognostic marker in early breast cancer: a" exact="meta-analysis" post="of published studies involving 12 155 patients . Br"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="in 100,000 randomised women in 123 randomised trials ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524128/results/search/cochrane/results.xml">
   <result pre="bleeding in 12 patients (80 %). There were no severe" exact="adverse events" post="attributable to radiotherapy. Conclusions Palliative radiotherapy for gastric bleeding"/>
   <result pre="EY Wong LC Lim K Lu JJ Koh WY Clinical" exact="outcome" post="of palliative radiotherapy for locally advanced symptomatic gastric cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524286/results/search/cochrane/results.xml">
   <result pre="and small molecule tyrosine-kinase inhibitors has significantly improved the clinical" exact="outcome" post="for HER2-positive breast-cancer patients. However, only a fraction of"/>
   <result pre="novel drug targets for improved therapeutic action, and/or predict therapeutic" exact="outcome" post="[ 11]. Mass-spectrometry based proteomics methods, such as label-free"/>
   <result pre="dissociation (CID) fragmented in the linear ion trap. A dynamic" exact="exclusion" post="window was applied within 40 s. All tandem mass"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4525792/results/search/cochrane/results.xml">
   <result pre="this comes the potential for added cardiotoxicity. 22 A recent" exact="meta-analysis" post="has shown limited cardiac toxicity, with dual therapy, though"/>
   <result pre="to narrow the gaps between preclinical safety evaluation and clinical" exact="outcome" post="J Appl Toxicol 2012 32 945 51 22961481 37"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4529453/results/search/cochrane/results.xml">
   <result pre="Tibiletti MG Genetic heterogeneity in HER2 testing may influence therapy" exact="eligibility" post="Breast Cancer Res Treat 2012 133 1 161 168"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4534500/results/search/cochrane/results.xml">
   <result pre="the combination of cisplatin and gemcitabine [ 29]. A subsequent" exact="meta-analysis" post="concluded that BTC patients treated with gemcitabine combined with"/>
   <result pre="months. The treatment was overall tolerable with some EGFR-related skin" exact="adverse events" post="[ 51]. Sohal et al. reported data involving yet"/>
   <result pre="Wolk A Obesity and the risk of gallbladder cancer: a" exact="meta-analysis" post="Br J Cancer 2007 96 9 1457 61 17375043"/>
   <result pre="Hepatitis B virus infection increases the risk of cholangiocarcinoma: a" exact="meta-analysis" post="and systematic review J Gastroenterol Hepatol 2012 27 10"/>
   <result pre="21. Farges O et al. Influence of surgical margins on" exact="outcome" post="in patients with intrahepatic cholangiocarcinoma: a multicenter study by"/>
   <result pre="of gemcitabine plus platinum agents for biliary tract cancers: a" exact="meta-analysis" post="Anti-Cancer Drugs 2013 24 8 871 7 10.1097/CAD.0b013e3283637292 23799294"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538762/results/search/cochrane/results.xml">
   <result pre="and brain metastasis), palliative care and medicines for management of" exact="adverse events" post="and side effects were not included in our study,"/>
   <result pre="cancer in indigenous populations in Africa: a systematic review and" exact="meta-analysis" post="PLoS Med 2014 11 9 e1001720 10.1371/journal.pmed.1001720 25202974 44."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538915/results/search/cochrane/results.xml">
   <result pre="P = 0.001) and OS (HR, 0.64; P = 0.03) [ 26]. The EBCTCG" exact="meta-analysis" post="found that adjuvant CMF reduced the risk of recurrence"/>
   <result pre="AC in patients with node-negative disease [ 74]. The EBCTCG" exact="meta-analysis" post="found that comparison of CMF with AC yielded similar"/>
   <result pre="only marginally improved (HR, 0.83; P = 0.057) [ 23]. The EBCTCG" exact="meta-analysis" post="found that breast cancer mortality rates were reduced more"/>
   <result pre="follow-up of 62 months, there was no significant difference in" exact="outcome" post="between the arms [ 94]. In the GEICAM 9906"/>
   <result pre="of a taxane was also addressed in the 2012 EBCTCG" exact="meta-analysis" post="[ 16]. In trials adding four separate cycles of"/>
   <result pre="ER-negative disease but not ER-positive disease. A systemic review and" exact="meta-analysis" post="identified 10 trials that met the inclusion criteria for"/>
   <result pre="and DFS (HR, 0.81; P &amp;lt;0.001). The rate of non-hematological" exact="adverse events" post="was higher in the dose-dense chemotherapy arms than in"/>
   <result pre="Breast Cancer Trialists’ Collaborative Group Tamoxifen for early breast cancer" exact="Cochrane" post="Database Syst Rev 2001 1 CD000486 11279694 14. collab:"/>
   <result pre="and other factors to the efficacy of adjuvant tamoxifen: patient-level" exact="meta-analysis" post="of randomised trials Lancet 2011 378 771 84 21802721"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="among 100,000 women in 123 randomised trials Lancet 2012"/>
   <result pre="Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and" exact="meta-analysis" post="of randomized controlled trials J Natl Cancer Inst. 2010"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4541732/results/search/cochrane/results.xml">
   <result pre="presence of HER2-positive CTCs has been associated with poor clinical" exact="outcome" post="in early breast cancer [ 16– 18]. Finally, we"/>
   <result pre="expressing the truncated HER2 receptor. CTCs' phenotypic profile and clinical" exact="outcome" post="After a median follow-up period of 29 months (range,"/>
   <result pre="the completion of adjuvant chemotherapy is associated with poor clinical" exact="outcome" post="[ 22– 24]. The same observation applies to metastatic"/>
   <result pre="primary tumors [ 13– 15]. HER2-targeted therapies have changed the" exact="outcome" post="of patients with HER2-positive primary tumors [ 6]. We"/>
   <result pre="but also the p95HER2 truncated receptor is crucial for the" exact="outcome" post="of patients with breast cancer. p95HER2 lacks the extracellular"/>
   <result pre="as an independent prognostic factor associated with a poor clinical" exact="outcome" post="[ 2]. Moreover, in patients with metastatic breast cancer"/>
   <result pre="expressing the p95HER2 phenotype is associated with a poor clinical" exact="outcome" post="in terms of OS suggesting that the expression of"/>
   <result pre="F Keenan EJ Albanell J et al. p95HER-2 predicts worse" exact="outcome" post="in patients with HER-2-positive breast cancer Clin Cancer Res."/>
   <result pre="L et al. HER2-positive circulating tumor cells indicate poor clinical" exact="outcome" post="in stage I to III breast cancer patients Clin"/>
   <result pre="paraffin sections by using a p95-specific antibody and correlation with" exact="outcome" post="in a cohort of trastuzumab-treated breast cancer patients Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4542411/results/search/cochrane/results.xml">
   <result pre="properly attributed. Abstract Hypoxic tumors are associated with poor clinical" exact="outcome" post="for multiple types of human cancer. This may be"/>
   <result pre="Mayer A Hypoxia in cancer: significance and impact on clinical" exact="outcome" post="Cancer Metastasis Rev 2007 26 2 225 239 17440684"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4548203/results/search/cochrane/results.xml">
   <result pre="Silva A. ( 2013). Beta blockers for peripheral arterial disease." exact="Cochrane" post="Database Syst. Rev. 9, CD005508. 10.1002/14651858.CD005508.pub3 24027118 Pardi D."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4550185/results/search/cochrane/results.xml">
   <result pre="(physician perceived or actual) and the impact of comorbidities on" exact="eligibility" post="for entering trials, despite the fact that there is"/>
   <result pre="by a patient is an important predictor of risk for" exact="adverse events" post="(AEs) and treatment outcome because AEs may limit treatment"/>
   <result pre="important predictor of risk for adverse events (AEs) and treatment" exact="outcome" post="because AEs may limit treatment duration and benefits. 35"/>
   <result pre="Diab SG Elledge RM Clark GM Tumor characteristics and clinical" exact="outcome" post="of elderly women with breast cancer J Natl Cancer"/>
   <result pre="BM Woodward WA Buchholz TA The impact of age on" exact="outcome" post="in early-stage breast cancer Semin Radiat Oncol 2011 21"/>
   <result pre="cancer in elderly women: biological profile and relation with clinical" exact="outcome" post="Crit Rev Oncol Hematol 2003 45 3 313 25"/>
   <result pre="inhibitors for treatment of advanced breast cancer in postmenopausal women" exact="Cochrane" post="Database Syst Rev 2009 4 CD003370 19821307 60 Riemsma"/>
   <result pre="and inactivators versus standard hormonal therapy in advanced breast cancer:" exact="meta-analysis" post="J Natl Cancer Inst 2006 98 18 1285 91"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4553016/results/search/cochrane/results.xml">
   <result pre="amplification or protein overexpression. All HER2-directed therapies can cause severe" exact="adverse events" post="and have a heightened risk of causing significant patient"/>
   <result pre="basis for selecting subsequent therapy for the patient, whose treatment" exact="outcome" post="and safety ultimately depend on the result of this"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558136/results/search/cochrane/results.xml">
   <result pre="Correlation of HER-2 and HER-3 expression with clinical parameters and" exact="outcome" post="HER-2 and HER-3 expression analyses were correlated with clinico-pathological"/>
   <result pre="had prognostic implications however with ambiguous findings regarding the clinical" exact="outcome" post="[ 29][ 34][ 44][ 45]. In line with several"/>
   <result pre="that HER-3 proved to be a predictive factor for clinical" exact="outcome" post="in wild-type KRAS CRC patients treated with cetuximab. Currently,"/>
   <result pre="constitution and comorbidity and risk of further damage with fatal" exact="outcome" post="(e.g. hepatitis, hepatic failure). Major surgery involved resection of"/>
   <result pre="colonic cancer: complete mesocolic excision and central ligation–technical notes and" exact="outcome" post="Colorectal Dis 2009 11 354 64 19016817 7 Sauer"/>
   <result pre="colorectal cancer and corresponding lymph node metastases related to clinical" exact="outcome" post="Eur J Cancer 2014 50 656 62 24300455 30"/>
   <result pre="The role of HER-3 expression in the prediction of clinical" exact="outcome" post="for advanced colorectal cancer patients receiving irinotecan and cetuximab"/>
   <result pre="et al. HER3 overexpression and survival in solid tumors: a" exact="meta-analysis" post="J Natl Cancer Inst 2013 105 266 73 23221996"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558517/results/search/cochrane/results.xml">
   <result pre="lead either to a cytoprotective or cytotoxic autophagy response. The" exact="outcome" post="is clearly dependent on the stage and type of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4570757/results/search/cochrane/results.xml">
   <result pre="is a humanized monoclonal IgG1 antibody which has revolutionized the" exact="outcome" post="of patients with HER-2 overexpressing breast cancer. Traditionally, HER-2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4574060/results/search/cochrane/results.xml">
   <result pre="disease) was found to be associated with a significantly better" exact="outcome" post="(HR = 0.54, P = 0.006). 10.1371/journal.pone.0138229.t003 Table 3"/>
   <result pre="Discussion This retrospective cohort study suggests a significantly better survival" exact="outcome" post="in HER2-positive MBC patients treated with TBP, rather than"/>
   <result pre="affect overall survival and skew the results. In addition, the" exact="outcome" post="endpoint has some weaknesses, as OS is not disease-specific,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4578850/results/search/cochrane/results.xml">
   <result pre="be present on individual trial level analysis, when correlating improved" exact="outcome" post="for the investigational arm for the primary endpoint (pathological"/>
   <result pre="[ 2– 4]. The relationship between pathological response and longer-term" exact="outcome" post="in women with early breast cancer receiving neoadjuvant systemic"/>
   <result pre="opinion article discusses the relationship between the two. A recent" exact="meta-analysis" post="of neoadjuvant breast cancer trials [ 5] and a"/>
   <result pre="on an individual trial level analysis, any correlation between improved" exact="outcome" post="for the investigational trial arm—in terms of the primary"/>
   <result pre="when we say pathological complete response? Neoadjuvant clinical trials, using" exact="pCR" post="as an evaluable endpoint, have gained acceptance as a"/>
   <result pre="trials looked at response in the breast only, and defined" exact="pCR" post="as no residual invasive disease in the breast, irrespective"/>
   <result pre="invasive disease and DCIS in the breast (ypT0 ypN0). A" exact="meta-analysis" post="of 12 major neoadjuvant randomised trials involving 11,955 patients"/>
   <result pre="5]. They examined the different definitions of pCR, with overall" exact="pCR" post="rates of 22 % for ypT0/is ypNx, 18 %"/>
   <result pre="of either ypT0 ypN0 or ypT0/is ypN0 as definitions of" exact="pCR" post="in their guidance on the use of pCR as"/>
   <result pre="definitions of pCR in their guidance on the use of" exact="pCR" post="as an endpoint for accelerated approval for agents in"/>
   <result pre="Number 3666940645625) There is general consensus that the definition of" exact="pCR" post="should include axillary lymph node status, because several studies"/>
   <result pre="nodes indicates a worse prognosis, even in the presence of" exact="pCR" post="in the breast [ 13– 15]. In both the"/>
   <result pre="of whether DCIS should be included in the definition of" exact="pCR" post="is more contentious. A single-institution cohort study of patients"/>
   <result pre="patients with and without residual DCIS, similar to the CTNeoBC" exact="meta-analysis" post="[ 5, 17]. However, a pooled analysis of seven"/>
   <result pre="increased OS (HR 1.41, p = 0.166) [ 18]. The definition of" exact="pCR" post="used should be clearly stated in the pathology report."/>
   <result pre="assessment and quantification of residual disease important? The likelihood of" exact="pCR" post="in breast cancer is heavily influenced by the biological"/>
   <result pre="growth factor receptor 2 (HER2)-negative have the lowest rates of" exact="pCR" post="(&amp;lt;10 %), with a weaker association between not achieving"/>
   <result pre="(&amp;lt;10 %), with a weaker association between not achieving a" exact="pCR" post="and survival outcomes. In contrast, HER2-positive/ER-negative and triple-negative (ER/PR/HER2-negative)"/>
   <result pre="of pCR, with a stronger association between not achieving a" exact="pCR" post="and poorer outcome (Fig. 3). Fig. 3 Percentage of"/>
   <result pre="a stronger association between not achieving a pCR and poorer" exact="outcome" post="(Fig. 3). Fig. 3 Percentage of patients achieving pathological"/>
   <result pre="4. Few modifications of tumour appearance Sataloff Tumour: T-A includes" exact="pCR" post="and minimal residual disease  T-A. Total or near total"/>
   <result pre="Grade 1. No reduction in overall cellularity DCIS allowed for" exact="pCR" post="Grade 2. Minor loss of tumour cells (up to"/>
   <result pre="identifiable; DCIS may be present Pinder Breast: DCIS allowed for" exact="pCR" post=" 1. pCR: (1) no residual carcinoma or (2) no"/>
   <result pre="over long term follow up DCIS ducal carcinoma in situ," exact="pCR" post="complete pathological response The Residual Cancer Burden score (RCB)"/>
   <result pre="between pathological residual disease and clinical outcomes than looking at" exact="pCR" post="alone. To illustrate how the different definitions of pathological"/>
   <result pre="The most important difference may be for those patients with" exact="pCR" post="in the breast but with disease in axillary lymph"/>
   <result pre="keeping with those of patients who do not achieve a" exact="pCR" post="in the breast. This means that if they are"/>
   <result pre="breast. This means that if they are included in the" exact="pCR" post="longer-term outcome correlation an additional bias will be introduced."/>
   <result pre="means that if they are included in the pCR longer-term" exact="outcome" post="correlation an additional bias will be introduced. Table 2"/>
   <result pre="(95 % CI) % (95 % CI) p value a" exact="pCR" post="in all breast tumours and absence of disease in"/>
   <result pre="positive (Allred 6–8) (n = 466) 7 % (4–11) 6 % (3–10)" exact="pCR" post="in all breast tumours (ypT0/Tis) (n = 76/394) (n = 99/388) 0.02 19"/>
   <result pre="positive (Allred 6–8) (n = 466) 9 % (5–13) 8 % (5–12)" exact="pCR" post="or minimal residual disease in all breast tumours (n = 114/394)"/>
   <result pre="bPrimary endpoint for the ARTemis trial In summary, in the" exact="meta-analysis" post="of neoadjuvant chemotherapy trials carried out by the US"/>
   <result pre="trials carried out by the US FDA, the definition of" exact="pCR" post="that is endorsed is absence of residual invasive disease"/>
   <result pre="here is being increasingly used. What influences the relationship between" exact="pCR" post="and longer-term outcomes in neoadjuvant breast cancer? Definition of"/>
   <result pre="pCR and longer-term outcomes in neoadjuvant breast cancer? Definition of" exact="pCR" post="and review How the definition of pathological response used"/>
   <result pre="confident that this is a robust enough strategy for determining" exact="pCR" post="for each patient. We will have the opportunity to"/>
   <result pre="in progress. It is essential to include the definition of" exact="pCR" post="that was used within a trial in the paper,"/>
   <result pre="(residual DCIS and axillary node status). This will allow accurate" exact="meta-analysis" post="with reference to the different definitions, even if the"/>
   <result pre="type of breast cancer (e.g. ER-positive HER2-positive) will influence the" exact="pCR" post="rate and often the effect size between a control"/>
   <result pre="size between a control arm and an experimental arm. The" exact="meta-analysis" post="manuscript [ 5] shows clearly that the pCR rate"/>
   <result pre="arm. The meta-analysis manuscript [ 5] shows clearly that the" exact="pCR" post="rate increases the higher the biological risk (Fig. 3)."/>
   <result pre="biological risk (Fig. 3). In ER-positive low-grade cancers, achieving a" exact="pCR" post="predicts an excellent outcome as it does in high-risk"/>
   <result pre="In ER-positive low-grade cancers, achieving a pCR predicts an excellent" exact="outcome" post="as it does in high-risk disease/biology, however, varying degrees"/>
   <result pre="As an example, the HR for OS for those achieving" exact="pCR" post="is 0.16 (95 % confidence interval [CI] 0.11–0.25) in"/>
   <result pre="numbers Neoadjuvant trials are powered for the primary endpoint of" exact="pCR" post="and not for secondary endpoints such as relapse-free survival"/>
   <result pre="OS. On a purely statistical basis, unless the benefit in" exact="pCR" post="rate is very large, there is unlikely to be"/>
   <result pre="will be greatest in patients who have not achieved a" exact="pCR" post="at the time of surgery. Adjuvant treatments include 5–10"/>
   <result pre="in the adjuvant setting will also confound the relationship between" exact="pCR" post="and longer-term outcomes, particularly if used to treat exclusively"/>
   <result pre="if used to treat exclusively the non-pCR group. However, the" exact="outcome" post="to be achieved here is for maximum patient benefit"/>
   <result pre="30], and the same arguments would hold for correlation between" exact="pCR" post="and longer-term outcomes. In trials including both patients with"/>
   <result pre="the time of analysis can influence the observed relationship between" exact="pCR" post="and RFS and OS; more importantly, for a given"/>
   <result pre="RFS and OS; more importantly, for a given improvement in" exact="pCR" post="rate between trial arms, the magnitude and direction of"/>
   <result pre="new second malignancy. For neoadjuvant trials and for correlation of" exact="pCR" post="we are most interested in distant metastases free survival"/>
   <result pre="a special case?: exploring the effect on the relationship between" exact="pCR" post="and long-term cancer-related outcomes for a ‘pure’ angiogenesis inhibition"/>
   <result pre="cancer have produced added complexity when examining the correlation between" exact="pCR" post="and longer-term cancer-related outcomes. Four neoadjuvant trials, GeparQuinto ["/>
   <result pre="and ARTemis [ 4], all show a significant improvement in" exact="pCR" post="with bevacizumab. For the purposes of comparative analysis, these"/>
   <result pre="OS [ 8] and shows no correlation between the improved" exact="pCR" post="rates and longer-term outcomes. In addition, two large adjuvant"/>
   <result pre="‘pure’ angiogenesis inhibitor, has the potential to improve rates of" exact="pCR" post="in the primary tumour, which is angiogenesis-dependent, but has"/>
   <result pre="important additional factor, with potential influence on the relationship between" exact="pCR" post="and longer-term outcomes in neoadjuvant trials. Do the challenges"/>
   <result pre="in neoadjuvant trials. Do the challenges to the correlation of" exact="pCR" post="to longer-term outcomes invalidate neoadjuvant trials? Clearly our answer"/>
   <result pre="tumour biology, is unlikely ever to achieve statistical correlation between" exact="pCR" post="and longer-term outcomes because they are more likely to"/>
   <result pre="(even in high-risk groups) in terms of good correlation between" exact="pCR" post="and longer-term outcomes is the NOAH trial [ 6,"/>
   <result pre="event, Neo-ALLTO showed an absolute improvement of 20 % in" exact="pCR" post="rates, and ALLTO narrowly missed statistical significance with an"/>
   <result pre="some intuitive sense and implies that even large increases in" exact="pCR" post="rate will translate into very modest improvement in survival"/>
   <result pre="long-term survival outcome. In other words, to detect a long-term" exact="outcome" post="effect between treatment arms with credible power, an unrealistically"/>
   <result pre="effect between treatment arms with credible power, an unrealistically high" exact="pCR" post="rate in the experimental arm would be required, as"/>
   <result pre="model the effect of using a primary endpoint that combines" exact="pCR" post="with RCB down-staging as a more sensitive primary endpoint."/>
   <result pre="long-term outcomes? In neoadjuvant trials of high-risk breast cancer, although" exact="pCR" post="rates are relatively high, there will still be a"/>
   <result pre="succeed, then we remove any possibility of the correlation between" exact="pCR" post="and longer-term outcome being significant. Would it go against"/>
   <result pre="remove any possibility of the correlation between pCR and longer-term" exact="outcome" post="being significant. Would it go against good trial design"/>
   <result pre="to do so? Our view is that the most important" exact="outcome" post="from a neoadjuvant trial in high-risk early breast cancer"/>
   <result pre="Pathologic complete response as a potential surrogate for the clinical" exact="outcome" post="in patients with breast cancer after neoadjuvant therapy: a"/>
   <result pre="breast cancer after neoadjuvant chemotherapy does not adversely affect patient" exact="outcome" post="J Clin Oncol 2007 25 2650 5 10.1200/JCO.2006.08.2271 17602071"/>
   <result pre="in locally advanced carcinoma of the breast: a determinant of" exact="outcome" post="J Am Coll Surg 1995 180 297 306 7874340"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586465/results/search/cochrane/results.xml">
   <result pre="I.A. et al. High EGFR gene copy number predicts poor" exact="outcome" post="in triple-negative breast cancer Mod. Pathol. 2014 27 1212"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586793/results/search/cochrane/results.xml">
   <result pre="overexpression in node-positive breast cancer identifies patients with poor clinical" exact="outcome" post="independent of Her2/neu Int. J. Cancer 2005 113 678"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4588449/results/search/cochrane/results.xml">
   <result pre="a booster, at week 6. During the 6-month follow-up period," exact="adverse events" post="(AEs), pharmacokinetics and pharmacodynamics, and HER2-specific cellular and humoral"/>
   <result pre="decline in left ventricle ejection fraction below 50% and cardiac-related" exact="adverse events" post="(AEs), often observed in subjects using trastuzumab. As shown"/>
   <result pre="The VM206RY was injected into brachial and deltoid muscle. Subject" exact="eligibility" post="This study ( http://www.clinicaltrials.gov registration number: NCT01895491) was conducted"/>
   <result pre="with 3 × 10 9 VP of Ad-HM at week 6. All" exact="adverse events" post="were monitored at every visit and evaluated during the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589126/results/search/cochrane/results.xml">
   <result pre="Summaries of these trials are shown in Table 1. A" exact="meta-analysis" post="of these trials showed a significant reduction in the"/>
   <result pre="safety profile that was similar to bevacizumab with grade 3" exact="adverse events" post="that included hypertension, deep venous thrombosis, vomiting, and proteinuria."/>
   <result pre="ramucirumab versus placebo, the most frequent grade 3 or above" exact="adverse events" post="were hypertension (8% vs 3%), abdominal pain (6% vs"/>
   <result pre="ramucirumab versus paclitaxel, the most frequent grade 3 or above" exact="adverse events" post="were neutropenia (41% vs 19%), leucopenia (17% vs 7%),"/>
   <result pre="reported outcomes Quality of life was examined as a secondary" exact="outcome" post="in the REGARD study. 33 The European Organization for"/>
   <result pre="primary manuscript of the RAINBOW study which was a secondary" exact="outcome" post="measure of the study. 34 The EORTC QLQ-C30 version"/>
   <result pre="al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a" exact="meta-analysis" post="JAMA 2010 303 1729 1737 20442389 6 Macdonald JS"/>
   <result pre="S Grothe W et al. Chemotherapy for advanced gastric cancer" exact="Cochrane" post="Database Syst Rev 2010 CD004064 20238327 8 Cunningham D"/>
   <result pre="al. Chemotherapy in advanced gastric cancer: a systematic review and" exact="meta-analysis" post="based on aggregate data J Clin Oncol 2006 24"/>
   <result pre="The_GASTRIC_Group Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data" exact="meta-analysis" post="Eur J Cancer 2013 49 1565 1577 23352439 17"/>
   <result pre="chemotherapy versus supportive cancer treatment in advanced gastric cancer: a" exact="meta-analysis" post="Ann Oncol 2013 24 2850 2854 23942775 22 Hironaka"/>
   <result pre="factor receptor (EGFR) is an independent prognostic indicator of worse" exact="outcome" post="in gastric cancer patients Ann Surg Oncol 2008 15"/>
   <result pre="(12%) 116 (35%) 128 (39%) 27 (8%) 51 (16%) Non-haematological" exact="adverse events" post=" Fatigue * 147 (45%) 39 (12%) 0 0 126"/>
   <result pre="0 0 0 21 (6%) 1 (&amp;lt;1%) 0 0 Haematological" exact="adverse events" post=" Neutropenia * 45 (14%) 71 (22%) 62 (19%) 0"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589954/results/search/cochrane/results.xml">
   <result pre="require validation of HER2 positivity by the central laboratory for" exact="eligibility" post="and study participation [ 32]. When the central laboratory’s"/>
   <result pre="will determine whether the addition of trastuzumab to chemotherapy improves" exact="outcome" post="in women with resected node-positive or high-risk node-negative breast"/>
   <result pre="NE et al. HER2 and chromosome 17 effect on patient" exact="outcome" post="in the N9831 adjuvant trastuzumab trial J Clin Oncol."/>
   <result pre="reveals that immune function genes are strongly linked to clinical" exact="outcome" post="in the North Central Cancer Treatment Group n9831 adjuvant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4590321/results/search/cochrane/results.xml">
   <result pre="which seems to correlate with improved disease outcomes, suggesting that" exact="pCR" post="may serve as a surrogate marker of clinical benefit."/>
   <result pre="pathway in the neoadjuvant setting. The odds ratio (OR) for" exact="pCR" post="in the combination group relative to the trastuzumab-alone group"/>
   <result pre="group was 2.6 ( P=0.0001). Also, no significant difference in" exact="pCR" post="was seen between the lapatinib and trastuzumab-alone groups (29.5%"/>
   <result pre="trastuzumab-alone groups (29.5% vs 24.7%). An improvement was seen in" exact="pCR" post="rate in breast and axilla in the dual therapy"/>
   <result pre="based on anti-HER2 therapy alone. Subgroup analysis consistently showed higher" exact="pCR" post="rates for dual therapy when patients were stratified by"/>
   <result pre="of conversion to BCS across treatment arms. Interestingly, the higher" exact="pCR" post="rates in the combination arm of approximately 50% did"/>
   <result pre="into a correspondingly higher rate of BCS. However, a similar" exact="outcome" post="has been noted in many other modern trials of"/>
   <result pre="major determinant of type of surgery. 31 The correlation of" exact="pCR" post="with event-free survival (EFS) and OS in the NeoALTTO"/>
   <result pre="improvement in both EFS and OS in women who achieved" exact="pCR" post="compared with those who did not (hazard ratio [HR]"/>
   <result pre="blockade therapy versus either lapatinib or trastuzumab alone. The best" exact="outcome" post="was noted in patients with HER2+, hormone receptor-negative (ER−)"/>
   <result pre="differences in therapy regimens, CHER-LOB also demonstrated significant improvement in" exact="pCR" post="(breast and axilla) with dual therapy compared to trastuzumab"/>
   <result pre="25% vs 26.3%, respectively; P=0.019) demonstrating an 80% increase in" exact="pCR" post="rate. The rate of node negativity at surgery was"/>
   <result pre="the combination of trastuzumab and lapatinib and its effect on" exact="pCR" post="when given with an anthracycline–taxane-based neoadjuvant chemotherapy regimen. 34"/>
   <result pre="30 while there was a trend toward benefit (numerically higher" exact="pCR" post="rates), there was no statistically significant difference in either"/>
   <result pre="49.4%, P=0.056, breast + lymph nodes). Subgroup analysis showed that" exact="pCR" post="improvement with the addition of lapatinib to trastuzumab occurred"/>
   <result pre="a recommended 1-year treatment of trastuzumab. Numerically higher rates of" exact="pCR" post="(breast) were observed in patients treated with combined trastuzumab"/>
   <result pre="with the assigned HER2 therapy. 37 The primary endpoint of" exact="pCR" post="(breast and axilla) was reported to be 52% in"/>
   <result pre="DCTL arms were able to adhere to therapy. Rates of" exact="pCR" post="were higher in the ER− subgroup (67% DCTL vs"/>
   <result pre="vs 11% DCL vs 40% DCT). Another smaller study evaluating" exact="pCR" post="rates from lapatinib and trastuzumab combination randomized 100 patients"/>
   <result pre="in whom the paired biopsies were analyzed, and hence, the" exact="pCR" post="rates presented may not be representative of the entire"/>
   <result pre="entire population. Although the trial was not powered to compare" exact="pCR" post="rates across arms, a higher pCR (breast) rate was"/>
   <result pre="not powered to compare pCR rates across arms, a higher" exact="pCR" post="(breast) rate was seen in the combination arm (74%)"/>
   <result pre="patients) without chemotherapy in the neoadjuvant setting, and demonstrated a" exact="pCR" post="(breast) rate of 27% (17/64 patients), suggesting that this"/>
   <result pre="carefully selected groups of patients. 39 In the ER+ group," exact="pCR" post="rate was predictably higher at 36% as compared to"/>
   <result pre="of the addition of lapatinib to trastuzumab and neoadjuvant chemotherapy," exact="pCR" post="(breast and lymph nodes) rate was 38.36% in the"/>
   <result pre="95% CI 1.44–2.6; P&amp;lt;0.0001). 40 The three trials that evaluated" exact="pCR" post="(breast) for the combination of lapatinib and trastuzumab resulted"/>
   <result pre="the combination of lapatinib and trastuzumab resulted in a superior" exact="pCR" post="rate of 55.01% vs 40.70% in the trastuzumab-alone arm"/>
   <result pre="(OR 1.78; 95% CI 1.27–2.50; P=0.0007). The odds of achieving" exact="pCR" post="were 2.06 times higher in the ER− subgroup and"/>
   <result pre="1.76 times higher in the ER+ subgroup. In a similar" exact="meta-analysis" post="of 779 patients enrolled in NSABP-B41, 30 CHER-LOB, 33"/>
   <result pre="the addition of lapatinib to neoadjuvant chemotherapy resulted in a" exact="pCR" post="(breast and axilla) rate of 56.7% as compared to"/>
   <result pre="30 Azim et al 42 reported further analyses on lapatinib-specific" exact="adverse events" post="(AEs). Due to the design of the trial, with"/>
   <result pre="(within 6 weeks of starting therapy) was associated with improved" exact="pCR" post="in patients &amp;gt;50 years of age, but not in"/>
   <result pre="given pertuzumab and trastuzumab plus docetaxel had a significantly improved" exact="pCR" post="(45.8%) compared with those given trastuzumab with docetaxel (29%)"/>
   <result pre="the dual anti-HER2 therapy without chemotherapy arm resulted in a" exact="pCR" post="rate of 16.8%, which could suggest a potential role"/>
   <result pre="and 0.54 (95% CI 0.29–1.00), respectively, for those who achieved" exact="pCR" post="compared to those who did not. All patients were"/>
   <result pre="all concurrently with trastuzumab/pertuzumab (FEC-TP → DTP), resulting in a" exact="pCR" post="(breast) rate of 61.6%, 57.3%, and 66.2%, respectively. Following"/>
   <result pre="to complete a total of 1 year of therapy. The" exact="pCR" post="rate was higher in patients with ER− tumors compared"/>
   <result pre="interpretation of efficacy results is limited, albeit encouraging, with high" exact="pCR" post="rates seen in all arms. 47 The Investigation of"/>
   <result pre="trastuzumab to neoadjuvant taxaneanthracycline was reported to have an estimated" exact="pCR" post="rate of 55% (range, 46%–64%) versus 32% (range, 22%–43%)"/>
   <result pre="HER2-targeted therapy. For example, the correlation of ER status and" exact="pCR" post="rate has been evaluated in multiple studies. 30, 32–"/>
   <result pre="were then able to demonstrate that ER− patients experienced increased" exact="pCR" post="rates, despite the addition of letrozole to ER+ tumors."/>
   <result pre="despite the addition of letrozole to ER+ tumors. 39 Increased" exact="pCR" post="in ER− tumors was also seen in NeoALTTO 30"/>
   <result pre="NeoALTTO 30 and the NSABP-B41 trial. 34 In NeoALTTO, the" exact="pCR" post="rate was 61.3% in the ER− group vs 41.6%"/>
   <result pre="group. There was an impressive 18.9% and 24.8% difference in" exact="pCR" post="between docetaxel plus lapatinib and docetaxel alone in the"/>
   <result pre="ER+ group and ER− subgroups, respectively. 30 In CHER-LOB, the" exact="pCR" post="rate was also higher in the ER− group (41.3%"/>
   <result pre="more likely to respond to therapy. 35, 52 Numerically higher" exact="pCR" post="rates were observed in the ER− subsets (77% in"/>
   <result pre="studies, patients with ER− disease were more likely to achieve" exact="pCR" post="in all arms tested, a finding consistent with previous"/>
   <result pre="the dual anti-HER2 therapy and docetaxel arm resulted in a" exact="pCR" post="rate of 63.2% in the ER− subgroup when compared"/>
   <result pre="to determine HER2 expression. 53, 54 This analysis showed that" exact="pCR" post="rate increases with increasing HER2 levels, predominantly in the"/>
   <result pre="the combination therapy arm where HER2 expression strongly correlated with" exact="pCR" post="in both ER+ (ratio of 3.1; P=0.001) and ER−"/>
   <result pre="and lapatinib monotherapy arms, HER2 expression did not predict for" exact="pCR" post="in the ER− patients and weakly predicted for pCR"/>
   <result pre="for pCR in the ER− patients and weakly predicted for" exact="pCR" post="in the ER+ patients. This study also evaluated p95HER2,"/>
   <result pre="mediating trastuzumab resistance. 12, 55– 57 A positive correlation of" exact="pCR" post="with p95HER2 levels was noted only in the trastuzumab"/>
   <result pre="the trastuzumab arms. Expression of p95HER2 was mainly predictive for" exact="pCR" post="in ER+ patients treated with either trastuzumab or the"/>
   <result pre="combination of lapatinib plus trastuzumab, but did not predict for" exact="pCR" post="in ER− patients. Higher HER2 and p95HER2 levels were"/>
   <result pre="neoadjuvant treatment was demonstrated. 58 A hypothesis of the higher" exact="pCR" post="rate observed in ER− tumors is that HER2+/ER− tumors"/>
   <result pre="Overall, HER2-enriched subtype tumors were significantly more likely to achieve" exact="pCR" post="(70%) as compared to luminal A (34%) or B"/>
   <result pre="B (36%) subtypes. Among HER2-enriched, taxane plus trastuzumab alone produced" exact="pCR" post="rates in excess of 70%, which suggests that dual"/>
   <result pre="presence of PIK3CA mutations in breast tumors results in lower" exact="pCR" post="after treatment with HER2-targeted therapy. The pCR rate decreased"/>
   <result pre="results in lower pCR after treatment with HER2-targeted therapy. The" exact="pCR" post="rate decreased from 34.5% in wild-type to 21.3% in"/>
   <result pre="presence of PI3K mutations were much less likely to achieve" exact="pCR" post="compared to those with high PTEN expression or absence"/>
   <result pre="who received dual anti-HER2 therapy were more likely to achieve" exact="pCR" post="(48.5% vs 12.5%; P=0.06), although there was no difference"/>
   <result pre="(48.5% vs 12.5%; P=0.06), although there was no difference in" exact="pCR" post="rates between wild-type and mutated status across all treatment"/>
   <result pre="detected CTCs at baseline (≥1 CTC/22.5 mL) had numerically lower" exact="pCR" post="rates compared to those with no CTCs, but the"/>
   <result pre="study need to be validated in larger studies or a" exact="meta-analysis" post="of studies performed in a similar setting. These data"/>
   <result pre="trial 36 allow us to question both the utility of" exact="pCR" post="as a surrogate marker for improved survival outcomes and"/>
   <result pre="facilitate a better understanding of the overall failure of improved" exact="outcome" post="with dual HER2 blockade, to assess whether there are"/>
   <result pre="phase III CLEOPATRA trial, 25 as well as in a" exact="meta-analysis" post="of patients treated with combination pertuzumab/trastuzumab. 70 In the"/>
   <result pre="the DCTL arm). 37 Valachis et al 71 conducted a" exact="meta-analysis" post="to evaluate the cardiac toxicity of dual anti-HER2 agents"/>
   <result pre="blockade in the neoadjuvant setting was pCR. The use of" exact="pCR" post="instead of PFS or OS as an endpoint carries"/>
   <result pre="time with fewer patients, thereby considerably reducing the trial cost." exact="pCR" post="has also been proposed to be a viable surrogate"/>
   <result pre="gross invasive residual disease, in that order. 72 Achievement of" exact="pCR" post="was associated with improved outcomes in patients with triple-negative,"/>
   <result pre="triple-negative, HER2+, and luminal B/HER2–BC, and the authors concluded that" exact="pCR" post="can be used as a surrogate marker of DFS"/>
   <result pre="level, little association was noted between increase in frequency of" exact="pCR" post="and EFS or OS. 73 It is important to"/>
   <result pre="important to note that the variation in the definition of" exact="pCR" post="across trials makes the interpretation of individual trial results"/>
   <result pre="of individual trial results more challenging, and that standardization of" exact="pCR" post="definition may help with this issue. In May 2012,"/>
   <result pre="with this issue. In May 2012, the FDA advised that" exact="pCR" post="(absence of invasive disease in breast and axillary lymph"/>
   <result pre="based on the results of the NeoSphere study in which" exact="pCR" post="was utilized as a surrogate endpoint of survival outcomes."/>
   <result pre="trials reported thus far have shown a numerical improvement in" exact="pCR" post="with dual HER2 blockade (trastuzumab plus lapatinib, or trastuzumab"/>
   <result pre="highly variable across the trials. Possible reasons include differences in" exact="pCR" post="definitions, tumor size, backbone of chemotherapy regimen, duration of"/>
   <result pre="ER+ disease differed across trials, which may have influenced the" exact="pCR" post="rate. For example, the NeoALTTO 30 and NeoSphere 45"/>
   <result pre="Regardless of the differences in the absolute improvement in the" exact="pCR" post="rate, these neoadjuvant studies have successfully proven the utility"/>
   <result pre="in the treatment landscape of HER2+ BC. A recent literature-based" exact="meta-analysis" post="demonstrated a statistically significant improvement in pCR rate with"/>
   <result pre="A recent literature-based meta-analysis demonstrated a statistically significant improvement in" exact="pCR" post="rate with dual HER2 inhibition in the range of"/>
   <result pre="compared to single HER2 inhibition. 80 Consistent with individual studies," exact="pCR" post="was noted to be significantly higher in the ER−"/>
   <result pre="CJ Preoperative chemotherapy for women with operable breast cancer [review]" exact="Cochrane" post="Database Syst Rev 2007 2 CD005002 17443564 27 Mauri"/>
   <result pre="JP Neoadjuvant versus adjuvant systemic treatment in breast cancer: a" exact="meta-analysis" post="J Natl Cancer Inst 2005 97 3 188 194"/>
   <result pre="response in patients with early stage HER2-positive breast cancer: a" exact="meta-analysis" post="of randomized prospective clinical trials Oncologist 2015 20 4"/>
   <result pre="with human epidermal growth factor receptor 2-positive breast cancer: A" exact="meta-analysis" post="of randomized controlled trials Oncol Lett 2015 9 3"/>
   <result pre="patients with non-small cell lung cancer: a systematic review and" exact="meta-analysis" post="Kuwano M PLoS ONE 2013 8 1 e55128 23383079"/>
   <result pre="setting for HER2 positive breast cancer Study/phase Therapy Patients enrolled" exact="pCR" post="rate (breast only) pCR (breast + LN) Rate of"/>
   <result pre="breast cancer Study/phase Therapy Patients enrolled pCR rate (breast only)" exact="pCR" post="(breast + LN) Rate of discontinuation ORR NeoALTTO/III 30"/>
   <result pre="setting for HER2 positive breast cancer Study/phase Therapy Patients enrolled" exact="pCR" post="(breast only) pCR (breast + LN) Rate of discontinuation"/>
   <result pre="positive breast cancer Study/phase Therapy Patients enrolled pCR (breast only)" exact="pCR" post="(breast + LN) Rate of discontinuation ORR NeoSphere/II 45"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4591587/results/search/cochrane/results.xml">
   <result pre="care—have also occurred. The objective of this systematic review and" exact="meta-analysis" post="is to determine whether there has been a cumulative"/>
   <result pre="studies. Methods/Design A systematic search of Medline, EMBASE, and the" exact="Cochrane Central Register of Controlled Trials" post="will be performed. Two investigators will independently assess each"/>
   <result pre="breast cancer from 1987 onwards will be considered. The primary" exact="outcome" post="of interest is overall survival; secondary outcomes include progression-free"/>
   <result pre="the authors for this study. Standard and cumulative random effects" exact="meta-analysis" post="will be performed to derive pooled risk estimates, both"/>
   <result pre="in randomized clinical trials and other interventional trials, inclusion and" exact="exclusion" post="criteria are applied. This can result in patient populations"/>
   <result pre="II/III clinical trials. Outcomes of interest Primary outcome: The primary" exact="outcome" post="of interest is OS in patients with HER2-positive advanced"/>
   <result pre="studies. Secondary outcomes: PFS. Safety: The proportion of patients experiencing" exact="adverse events" post="and serious adverse events, the types of adverse events"/>
   <result pre="Safety: The proportion of patients experiencing adverse events and serious" exact="adverse events," post="the types of adverse events reported, and the proportion"/>
   <result pre="experiencing adverse events and serious adverse events, the types of" exact="adverse events" post="reported, and the proportion of patients experiencing adverse events"/>
   <result pre="of adverse events reported, and the proportion of patients experiencing" exact="adverse events" post="of particular interest as reported in prior studies (e.g.,"/>
   <result pre="We will conduct a systematic search of Medline, EMBASE, and" exact="Cochrane Central Register of Controlled Trials" post="to identify relevant studies published between 1 January 1987"/>
   <result pre="who dropped out or who were lost to follow-up. Efficacy/effectiveness" exact="outcome" post="variables: Number of deaths, median OS, median PFS, and"/>
   <result pre="based on treatment/intervention type or lack of active treatment/intervention. Safety" exact="outcome" post="variables: Proportion of patients experiencing adverse events and serious"/>
   <result pre="of active treatment/intervention. Safety outcome variables: Proportion of patients experiencing" exact="adverse events" post="and serious adverse events, types of adverse events reported,"/>
   <result pre="outcome variables: Proportion of patients experiencing adverse events and serious" exact="adverse events," post="types of adverse events reported, and proportion of patients"/>
   <result pre="patients experiencing adverse events and serious adverse events, types of" exact="adverse events" post="reported, and proportion of patients experiencing adverse events of"/>
   <result pre="types of adverse events reported, and proportion of patients experiencing" exact="adverse events" post="of particular interest as reported in prior studies (e.g.,"/>
   <result pre="[ 29], the Newcastle-Ottawa Quality Assessment Scale [ 30], the" exact="Cochrane" post="Collaboration risk of bias criteria [ 31], and other"/>
   <result pre="Is attrition balanced across outcomes or characteristics of interest?); (3)" exact="outcome" post="measurement (i.e., Is the outcome of interest measured appropriately?);"/>
   <result pre="or characteristics of interest?); (3) outcome measurement (i.e., Is the" exact="outcome" post="of interest measured appropriately?); and (4) data analysis and"/>
   <result pre="biases due to design, representativeness, comparability of groups, exposure, and" exact="outcome" post="measure and attrition. Study design: We will note the"/>
   <result pre="and an outcome. We will also record whether exposure and" exact="outcome" post="were registered concurrently (retrospective or prospective data collection; follow-up"/>
   <result pre="study inclusion (i.e., consecutive or random inclusion), criteria for justified" exact="exclusion" post="of participants for analysis, and whether the results are"/>
   <result pre="exposure groups, comparability will be determined by applying inclusion and/or" exact="exclusion" post="criteria equally to all groups and inclusion of all"/>
   <result pre="follow-up was similar between the groups [ 37]. Biases in" exact="outcome" post="measurement: We will assess this by using an explicit"/>
   <result pre="We will assess this by using an explicit definition of" exact="outcome" post="and by considering potential confounders in the study and"/>
   <result pre="Individual study characteristics will be described and summarized separately. The" exact="outcome" post="data will be analyzed using random effects meta-analysis ["/>
   <result pre="separately. The outcome data will be analyzed using random effects" exact="meta-analysis" post="[ 41]. Random effects meta-regression models will be used"/>
   <result pre="region, post-progression therapy, and relevant methodological quality parameters. A cumulative" exact="meta-analysis" post="will be performed to assess the potential shift in"/>
   <result pre="meta-analysis will be performed to assess the potential shift in" exact="outcome" post="values over time. A cumulative meta-analysis will be performed"/>
   <result pre="the potential shift in outcome values over time. A cumulative" exact="meta-analysis" post="will be performed regardless of type of treatment/intervention (including"/>
   <result pre="standard errors [ 44]. All analyses will be performed using" exact="STATA" post="13.1 (Stata, College Station, TX, USA). Role of the"/>
   <result pre="the aberrant data. The selection of OS as the primary" exact="outcome" post="of interest is a strength of our study. OS,"/>
   <result pre="using interventional controlled trials, minimizing biases by providing a direct" exact="outcome" post="comparison group [ 23]. However, PFS is a tumor"/>
   <result pre="comparison group [ 23]. However, PFS is a tumor assessment" exact="outcome" post="that does not require a large sample size, is"/>
   <result pre="and biologics. http://www.fda.gov/downloads/Drugs/%E2%80%A6/%20Guidances/ucm071590.pdf. Accessed 25 Mar 2015. 24. Balduzzi S" exact="Cochrane" post="review—Trastuzumab-containing regimens for metastatic breast cancer J Evid Based"/>
   <result pre="non-small cell lung cancer without treatment: a systematic review and" exact="meta-analysis" post="Syst Rev 2013 2 2 11 10.1186/2046-4053-2-10 23302739 28."/>
   <result pre="25 603 5 10.1007/s10654-010-9491-z 20652370 31. Higgins JPT, Green S." exact="Cochrane" post="Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated"/>
   <result pre="Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The" exact="Cochrane" post="Collaboration. 2009. Available from www.cochrane-handbook.org. 32. Hudak PL Cole"/>
   <result pre="JL Sutton AJ Jones DR Abrams KR Rushton L Contour-enhanced" exact="meta-analysis" post="funnel plots help distinguish publication bias from other causes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4593385/results/search/cochrane/results.xml">
   <result pre="the ALK inhibitor was able to significantly improve the clinical" exact="outcome" post="of NSCLC patients with a RR of 60% and"/>
   <result pre="in 25–30% of breast cancer patients, predicting a poor clinical" exact="outcome" post="in the absence of targeted therapy [ 27, 28]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4600684/results/search/cochrane/results.xml">
   <result pre="a principal cause of undertreatment and clearly affects the survival" exact="outcome" post="[ 23]. Moreover, the uncertainty of whether elderly women"/>
   <result pre="enables clinicians to assess these characteristics and to predict the" exact="outcome" post="after treatment interventions [ 31]. In particular, CGA incorporates"/>
   <result pre="in patients over 80 years old. Furthermore, according to a" exact="meta-analysis" post="of 17 trials of breast-conserving therapy, radiotherapy after surgery"/>
   <result pre="the adjuvant setting remains controversial [ 8]. According to the" exact="meta-analysis" post="by Early Breast Cancer Trialists' Collaborative Group et al."/>
   <result pre="been treated with tamoxifen alone [ 34 76 77]. The" exact="Cochrane" post="review, which included patients over 70 years old with"/>
   <result pre="HERA trial did not demonstrate a significant difference in cardiac" exact="adverse events" post="between patients older or younger than 60 years of"/>
   <result pre="older women treated by surgery: with correlation with long-term clinical" exact="outcome" post="and comparison with their younger counterparts Br J Cancer"/>
   <result pre="cancer in elderly women: biological profile and relation with clinical" exact="outcome" post="Crit Rev Oncol Hematol 2003 45 313 325 12633842"/>
   <result pre="and other factors to the efficacy of adjuvant tamoxifen: patient-level" exact="meta-analysis" post="of randomised trials Lancet 2011 378 771 784 21802721"/>
   <result pre="breast-conserving surgery on 10-year recurrence and 15-year breast cancer death:" exact="meta-analysis" post="of individual patient data for 10,801 women in 17"/>
   <result pre="FA Beitsch P Haffty B Keisch M Lyden M Five-year" exact="outcome" post="of patients classified using the American Society for Radiation"/>
   <result pre="operable primary breast cancer in elderly women (70 years plus)" exact="Cochrane" post="Database Syst Rev 2006 1 CD004272 16437480 79 Chakrabarti"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="among 100,000 women in 123 randomised trials Lancet 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4609140/results/search/cochrane/results.xml">
   <result pre="number of chromosome 17 but not HER2 amplification predicts clinical" exact="outcome" post="of patients with pancreatic ductal adenocarcinoma J Clin Oncol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612451/results/search/cochrane/results.xml">
   <result pre="taxane treatments. 39,40 It should also be noted that patient" exact="outcome" post="is statistically better and patients exhibit fewer side-effects when"/>
   <result pre="we also evaluated PRP4K as a potential prognostic biomarker for" exact="outcome" post="in ovarian cancer patients treated with taxane-containing therapies. Although"/>
   <result pre=", Clarke R . Multidrug resistance in breast cancer: a" exact="meta-analysis" post="of MDR1/gp170 expression and its possible functional significance ."/>
   <result pre="amplification is superior to protein expression status in predicting patient" exact="outcome" post="in serous ovarian carcinoma . Gynecol Oncol 2004; 92:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4621756/results/search/cochrane/results.xml">
   <result pre="high risk for recurrence after hormone therapy [ 24]. A" exact="meta-analysis" post="of gene expression datasets suggested that BST2 in breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4624825/results/search/cochrane/results.xml">
   <result pre="result in irreversible CV damage or reversible cardiac dysfunction. These" exact="adverse events" post="may be related to direct effects on myocytes or"/>
   <result pre="risk of complications [ 68]. Risk factors for chemotherapy associated" exact="adverse events" post="involve a combination of underlying comorbidities (renal insufficiency, lung"/>
   <result pre="therapy with cardiovascular death in patients with prostate cancer: a" exact="meta-analysis" post="of randomized trials JAMA 2011 306 2359 66 10.1001/jama.2011.1745"/>
   <result pre="J Varenne O Zuber B et al. Short- and long-term" exact="outcome" post="in elderly patients after out-of-hospital cardiac arrest: a cohort"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627342/results/search/cochrane/results.xml">
   <result pre="39 patients with HER2-overexpressing metastatic breast cancer, we analyzed the" exact="adverse events" post="in hepatobiliary system from the start of the medication"/>
   <result pre="of the concomitantly administered chemotherapeutic drugs is needed to avoid" exact="adverse events" post="including hepatotoxicity in combination regiment involving ABC transporter inhibitor."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627999/results/search/cochrane/results.xml">
   <result pre="was evaluated as the number of grade 3 and 4" exact="adverse events." post="Of the 293 patients analyzed, 66 received eribulin (eribulin"/>
   <result pre="cancer Safety outcomes No patient discontinued eribulin therapy due to" exact="adverse events." post="No grade 3 or 4 neuropathy was documented. Grade"/>
   <result pre="late-line therapy. Moreover, no patient discontinued eribulin therapy due to" exact="adverse events." post="The median OS for eribulin-treated patients was 72.1 months,"/>
   <result pre="study. In addition, no patient discontinued eribulin therapy due to" exact="adverse events." post="Based on the low incidence of adverse events and"/>
   <result pre="due to adverse events. Based on the low incidence of" exact="adverse events" post="and no treatment discontinuation, the safety profile of eribulin"/>
   <result pre="lower dose intensity and no unexpected grade 3 and 4" exact="adverse events." post="The survival benefit of eribulin was regardless of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4637019/results/search/cochrane/results.xml">
   <result pre="E. Chiorrini S. et al. Arterial hypertension correlates with clinical" exact="outcome" post="in colorectal cancer patients treated with first-line bevacizumab Annals"/>
   <result pre="Kremer L. C. Cardioprotective interventions for cancer patients receiving anthracyclines" exact="Cochrane" post="Database of Systematic Reviews 2011 6 10.1002/14651858.CD003917.pub3 148 Cardinale"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648606/results/search/cochrane/results.xml">
   <result pre="ott-8-3337 : Original Research Hormone receptor status predicts the clinical" exact="outcome" post="of human epidermal growth factor 2-positive metastatic breast cancer"/>
   <result pre="in HER2-positive breast cancer according to HR status, and the" exact="pCR" post="rates were 1.5- to 2-fold lower in ER-positive than"/>
   <result pre="and TBCRC 006 37 further confirmed these findings, showing that" exact="pCR" post="rates were lower in HER2+/HR+ patients, regardless of the"/>
   <result pre="also revealed that HR status as an independent predictor of" exact="pCR" post="and trastuzumab therapy resulted in a smaller benefit in"/>
   <result pre="we evaluated the impact of HR status on the clinical" exact="outcome" post="of trastuzumab therapy for Chinese MBC patients. Our data"/>
   <result pre="local laboratories and with potential variation. Considering the relatively lower" exact="pCR" post="rate and smaller prognostic impact in HER2+/HR+ patients, we"/>
   <result pre="status. 51 However, the impact of receptor conversion on clinical" exact="outcome" post="remains unclear; in a pooled analysis, only a minority"/>
   <result pre="the genes involved in the PI3K and estrogen-receptor pathways influence" exact="outcome" post="in human epidermal growth factor receptor 2-positive and hormone"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648969/results/search/cochrane/results.xml">
   <result pre="EGFR and has a relatively mild toxicity profile with main" exact="adverse events" post="consisting of diarrhea and rash [ 10– 12]. Importantly,"/>
   <result pre="approved by the local ethical review board. Patient selection and" exact="eligibility" post="This study was performed at the Netherlands Cancer Institute"/>
   <result pre="additional patients, none of whom experienced DLTs. Adverse events Treatment-related" exact="adverse events" post="(TRAEs) observed in ≥ 10 % of patients in this study"/>
   <result pre="this study are presented in Table 3. Table 3 Treatment-related" exact="adverse events" post="Adverse event Dose-level Total 1 2 3 7 5"/>
   <result pre="(21) Grade ≥3 0 0 0 0 0 0 Treatment-related" exact="adverse events" post="per dose-level. *includes desquamation, acneiform, erythema. # both clinical"/>
   <result pre="study, which could explain the persisting toxicity. The most common" exact="adverse events" post="seen with lapatinib, diarrhea and rash (42 and 31"/>
   <result pre="elevated ASAT/ALAT and anorexia were the most frequent non-hematological grade ≥ 2" exact="adverse events." post="Unfortunately, the combination failed to improve the overall survival"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650737/results/search/cochrane/results.xml">
   <result pre="suggests that miR-205-5p could be an important target to improve" exact="outcome" post="of patients with Her2-overexpressing breast cancer. In conclusion, we"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650834/results/search/cochrane/results.xml">
   <result pre="(mBC). Methods A bibliographic search was conducted in PubMed and" exact="Cochrane" post="databases. Only phase III randomized controlled trials (RCTs) including"/>
   <result pre="first-line setting. OS improved from 20.3 months in the first" exact="RCT" post="(standard chemotherapy; Slamon et al. (N Engl J Med"/>
   <result pre="A bibliographic search was conducted in the PubMed and in" exact="Cochrane Central Register of Controlled Trials" post="databases (updated October 2015). The search equation comprised terms"/>
   <result pre="of the target population, and efficacy outcomes. The primary efficacy" exact="outcome" post="was OS (defined as the time from random assignment"/>
   <result pre="random assignment until death from any cause), while the secondary" exact="outcome" post="was progression-free survival (PFS, defined as the time from"/>
   <result pre="outcomes OS and PFS, based on the ITT analysis. Where" exact="outcome" post="measures were not reported, we contacted the investigators to"/>
   <result pre="Hurwitz et al. [ 32]). The main results of each" exact="RCT" post="are shown in Table 1. Figure 2 presents the"/>
   <result pre="overall survival, PFS progression-free survival Chemotherapy ± trastuzumab or lapatinib The first" exact="RCT" post="assessing a therapy against HER2 for metastatic BC that"/>
   <result pre="or lapatinib The TAnDEM study was the first phase III" exact="RCT" post="combining a hormonal agent and trastuzumab without chemotherapy as"/>
   <result pre="Further, everolimus was associated with an increased risk for serious" exact="adverse events," post="such as neutropenia, leucopenia, anemia, febrile neutropenia, stomatitis, and"/>
   <result pre="of everolimus was associated with a high incidence of serious" exact="adverse events," post="exhibiting a similar safety profile to that seen in"/>
   <result pre="evaluated in RCTs, as it was noted in a previous" exact="meta-analysis" post="(Harris et al. [ 44]), but it would be"/>
   <result pre="45]). HER2-targeted therapies have an undeniable favorable impact in the" exact="outcome" post="of patients with HER2+ metastatic BC. Integration of trastuzumab"/>
   <result pre="Search strategies used to retrieve randomized controlled trials from the" exact="Cochrane Library" post="and PubMed (Updated, 6 October 2015). (DOCX 12 kb)"/>
   <result pre="V Muehlbauer S et al. Longer-term assessment of trastuzumab-related cardiac" exact="adverse events" post="in the Herceptin Adjuvant (HERA) trial J Clin Oncol"/>
   <result pre="the adjuvant treatment of HER2-positive early breast cancer patients: a" exact="meta-analysis" post="of published randomized controlled trials PLoS One 2011 6"/>
   <result pre="The efficacy of HER2-targeted agents in metastatic breast cancer: a" exact="meta-analysis" post="Ann Oncol 2011 22 1308 17 10.1093/annonc/mdq593 21119031 45."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650980/results/search/cochrane/results.xml">
   <result pre="56]. Importantly, the criteria for HER2 overexpression in determining the" exact="eligibility" post="of anti-HER2 therapy differ from those used in breast"/>
   <result pre="IHC was also performed, but was not used to determine" exact="eligibility" post="for the trial. The results showed a non-significant trend"/>
   <result pre="better applied to precision oncology, hopefully translating into improved clinical" exact="outcome" post="for this complex and heterogenous group of patients. Funding"/>
   <result pre="with focus on light-drinkers and never-smokers: a systematic review and" exact="meta-analysis" post=". Int J Cancer 2011; 129 : 2473 –"/>
   <result pre="ML Gallegos-Ruiz MI Rodriguez JA et al. Predictive factors for" exact="outcome" post="in a phase II study of gefitinib in second-line"/>
   <result pre="61 Lordick F Kang YK Salman P et al. Clinical" exact="outcome" post="according to tumor HER2 status and EGFR expression in"/>
   <result pre="capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a" exact="meta-analysis" post=". PLoS One 2013; 8 : e82798. 24349363 70"/>
   <result pre="factor receptor (EGFR) is an independent prognostic indicator of worse" exact="outcome" post="in gastric cancer patients . Ann Surg Oncol 2008;"/>
   <result pre="in cancer patients treated with aflibercept: a systematic review and" exact="meta-analysis" post=". Tumour Biol 2014; 35 : 10715 – 22."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4656949/results/search/cochrane/results.xml">
   <result pre="a significant change in invasion area suggests that the main" exact="outcome" post="of ranibizumab treatment is to induce the narrowing of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657380/results/search/cochrane/results.xml">
   <result pre="alone [ 41, 42]. These results were confirmed in a" exact="meta-analysis" post="[ 43]. A recent non-randomized non-inferiority trial showed the"/>
   <result pre="10.1016/S1470-2045(09)70263-3 19801201 43. Tsao M Xu W Sahgal A A" exact="meta-analysis" post="evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients"/>
   <result pre="M Stocchi L Vidiri A Giannarelli D et al. Clinical" exact="outcome" post="of patients with brain metastases from HER2-positive breast cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4665969/results/search/cochrane/results.xml">
   <result pre="as well as a prognostic factor associated with poor clinical" exact="outcome" post="( 4– 6). Trastuzumab (Herceptin), the first anti-HER2 agent,"/>
   <result pre="6). Trastuzumab (Herceptin), the first anti-HER2 agent, improved the clinical" exact="outcome" post="of HER2-positive breast cancer when used in the metastatic"/>
   <result pre="combination of pertuzumab and trastuzumab was well tolerated, and the" exact="adverse events" post="were mild to moderate. Cardiac toxicity was minimal, and"/>
   <result pre="minimal, and no patients withdrew as a result of cardiac-related" exact="adverse events." post="Therefore, the combination of pertuzumab and trastuzumab was effective"/>
   <result pre="pertuzumab group (HR=0.66, 95% CI: 0.52–0.84; P=0.0008) ( 21). The" exact="adverse events" post="were similar to those reported at the primary analysis"/>
   <result pre="Asian patients compared with patients from other regions. However, the" exact="adverse events" post="did not result in a reduction in the median"/>
   <result pre="( 24). The reason for the discrepancy in the clinical" exact="outcome" post="among regions is unclear. One possible explanation may be"/>
   <result pre="(Arm C). Moreover, no new or unexpected cardiac or other" exact="adverse events" post="were observed in any of the study arms. The"/>
   <result pre="events were observed in any of the study arms. The" exact="adverse events" post="observed were consistent with those reported in previous studies"/>
   <result pre="performed by an independent review facility, and the incidence of" exact="adverse events." post="Japanese patients were enrolled in this study. F. Hoffmann-La"/>
   <result pre="( 34). This study is a multicenter, single-arm trial. The" exact="eligibility" post="and exclusion criteria for this study were almost identical"/>
   <result pre="This study is a multicenter, single-arm trial. The eligibility and" exact="exclusion" post="criteria for this study were almost identical to those"/>
   <result pre="occurrence of distant breast cancer recurrence), OS and incidence of" exact="adverse events." post="This study is currently recruiting participants. Japanese patients were"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4666271/results/search/cochrane/results.xml">
   <result pre="AUC of paclitaxel, were increased when combined. The most common" exact="adverse events" post="(AEs) related to the study treatment were alopecia, diarrhea"/>
   <result pre="%, if unavailable); adequate renal, hepatic and hematologic functions. Major" exact="exclusion" post="criteria were: prior therapy with an EGFR and/or HER2"/>
   <result pre="event, neutropenia, occurred in 2 patients. Table 2 Summary of" exact="adverse events" post="with at least 50 % occurrence Adverse event, n"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4669075/results/search/cochrane/results.xml">
   <result pre="single genomic locus. This is conducted by the inclusion or" exact="exclusion" post="of specific exons in pre-mRNA processing. It occurs in"/>
   <result pre="cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic" exact="outcome" post="for breast cancer patients Clin Cancer Res 2008 14"/>
   <result pre="precision of microarray-based predictors of breast cancer biology and clinical" exact="outcome" post="J Clin Oncol 2010 28 2198 2206 20368555 141"/>
   <result pre="human mammary stem cells and a predictor of poor clinical" exact="outcome" post="Cell Stem Cell 2007 1 555 567 18371393 143"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4678619/results/search/cochrane/results.xml">
   <result pre="head/neck. The introduction of HER2-directed therapies has dramatically influenced the" exact="outcome" post="of patients with HER2-positive breast and gastric/gastroesophageal cancers; however,"/>
   <result pre="trial is PFS at 12 months, and secondary endpoints include" exact="adverse events," post="duration of PFS and OS, and tumor response. IHC"/>
   <result pre="Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and" exact="meta-analysis" post="of randomized-controlled trials Anticancer Drugs 2015 26 894 901"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4679405/results/search/cochrane/results.xml">
   <result pre="versus 5.7 months). Multivariate analyses demonstrated similar results. Grade ≥3" exact="adverse events" post="were reported in 48.8% and 63.3% of patients with"/>
   <result pre="discontinuation was collected. The primary results of EMILIA, including detailed" exact="eligibility" post="criteria and methodology, have been published [ 25]. As"/>
   <result pre="population. In patients with CNS metastases at baseline, grade ≥3" exact="adverse events" post="(AEs; 48.8% versus 63.3%), serious AEs (18.6% versus 26.5%),"/>
   <result pre="radiotherapy for the treatment of newly diagnosed multiple brain metastases" exact="Cochrane" post="Database Syst Rev 2012 4 CD003869 22513917 13 Polli"/>
   <result pre="18 Metro G Foglietta J Russillo M et al. Clinical" exact="outcome" post="of patients with brain metastases from HER2-positive breast cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4682234/results/search/cochrane/results.xml">
   <result pre="for 80 % of EC is associated with better clinical" exact="outcome" post="than type II EC. However, a substantial number of"/>
   <result pre="Homesley HD et al. Relationship between surgical-pathological risk factors and" exact="outcome" post="in clinical stage I and II carcinoma of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687700/results/search/cochrane/results.xml">
   <result pre="were invested on the HER‐2 targeted agents, and significantly improved" exact="outcome" post="and prolonged the survival of patients. However, some patients"/>
   <result pre="of HER‐2 positive patients expressing p95HER‐2 that have a worse" exact="outcome" post="while on trastuzumab. Some other variants of HER‐2 Other"/>
   <result pre="have achieved disease control with anti‐HER‐2 therapy 108, 109. Similar" exact="outcome" post="of HER‐2‐targeted therapy has also been achieved in breast"/>
   <result pre="metastatic breast cancer for HER‐2 mutation and investigate the clinical" exact="outcome" post="of HER‐2 targeted therapy (NCT01670877). Previous researches have revealed"/>
   <result pre="no inhibitors were directly targeted against p95HER‐2. To improve the" exact="outcome" post="of patients harbouring these two variants, new researches are"/>
   <result pre="of trastuzumab, which targeted against HER‐2, has significantly improved the" exact="outcome" post="and prognosis of HER‐2‐overexpressing breast cancer. However, despite the"/>
   <result pre="paraffin sections by using a p95‐specific antibody and correlation with" exact="outcome" post="in a cohort of trastuzumab‐treated breast cancer patients ."/>
   <result pre="MA , Ramsey EE , et al p95HER‐2 predicts worse" exact="outcome" post="in patients with HER‐2‐positive breast cancer. Clin Cancer Res."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687715/results/search/cochrane/results.xml">
   <result pre="feasibility of detecting cardiotoxicity with the blood-drived marker S100A1. This" exact="outcome" post="has important implications from the perspective of clinical practice,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689767/results/search/cochrane/results.xml">
   <result pre="However, the majority of TNBC patients do not achieve a" exact="pCR" post="and have a high risk of early relapse and"/>
   <result pre="monotherapy in BRCA1 mutation-breast cancer patients is highly effective with" exact="pCR" post="rates of 72–83 %. BRCAness and basal-like subtype may"/>
   <result pre="randomized phase II neoadjuvant trials [ 41, 42] and a" exact="meta-analysis" post="[ 43] have assessed the addition of carboplatin to"/>
   <result pre="the GeparSixto trial, the addition of carboplatin significantly increased the" exact="pCR" post="rate in TNBC patients treated with weekly paclitaxel and"/>
   <result pre="followed by AC every 2 weeks, increased the rate of" exact="pCR" post="as well. Nevertheless, the addition of platinum results in"/>
   <result pre="patients. Regarding the type of taxane and outcome, an improved" exact="pCR" post="was observed with Nab-paclitaxel compared to solvent-based weekly paclitaxel"/>
   <result pre="+ lapatinib, trastuzumab +pertuzumab) has led to improvements in the" exact="pCR" post="rate when compared with chemotherapy associated with trastuzumab agent,"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="among 100,000 women in 123 randomised trials Lancet 2012"/>
   <result pre="in early breast cancer (Recurrence Score, Central Grade, Ki67): early" exact="outcome" post="analysis from the prospective Pahase III WSG-PlanB Trial. San"/>
   <result pre="and other factors to the efficacy of adjuvant tamoxifen: patient-level" exact="meta-analysis" post="of randomised trials. Early Breast Cancer Trialists’ Collaborative Group"/>
   <result pre="neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and" exact="meta-analysis" post="Breast Cancer Res Treat 2014 144 223 232 10.1007/s10549-014-2876-z"/>
   <result pre="axillary surgery on 10-year recurrence and 20-year breast cancer mortality:" exact="meta-analysis" post="of individual patient data for 8135 women in 22"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689775/results/search/cochrane/results.xml">
   <result pre="in TNBC is under debate. These compounds significantly increase the" exact="pCR" post="rate in TNBC patients (regardless of BRCA status) when"/>
   <result pre="its paired metastasis: tumor biology or test artefact? Insights through" exact="meta-analysis" post="Breast Cancer Res Treat 2011 129 3 659 674"/>
   <result pre="Combination versus sequential single agent chemotherapy for metastatic breast cancer." exact="Cochrane" post="Database Syst. Rev. (Wiley). 2013. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008792.pub2/abstract. Accessed 11 October"/>
   <result pre="rate in neoadjuvant treatment of triple negative breast cancer: a" exact="meta-analysis" post="PLoS One 2014 9 9 e108405 10.1371/journal.pone.0108405 25247558 40."/>
   <result pre="of primary tumors in stage IV breast cancer: an updated" exact="meta-analysis" post="of published studies with meta-regression Med Oncol 2012 29"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694793/results/search/cochrane/results.xml">
   <result pre="is a heterogeneous disease, both histologically and genetically, and patient" exact="outcome" post="is difficult to predict using just the classical histologic"/>
   <result pre="targets for this disease. MANAGEMENT OF ADVANCED STAGE GC The" exact="outcome" post="for patients with GC is predicted based on the"/>
   <result pre="determination of tumor sensitivity to chemotherapy [ 12]. In a" exact="meta-analysis" post="conducted by the Global Advanced/Adjuvant Stomach Tumor Research International"/>
   <result pre="shown the benefit of palliative chemotherapy. For example, in a" exact="meta-analysis" post="of 35 clinical studies and a total of 5,726"/>
   <result pre="with hereditary diffuse GC, poorly differentiated phenotype and poor clinical" exact="outcome" post="[ 62]. In contrast, mutated RHOA interacts with other"/>
   <result pre="tolerated at the recommended single-agent dose of 15mg/kg without important" exact="adverse events." post="Furthermore, a phase I study using ABT-700 monotherapy showed"/>
   <result pre="300 mg and in regard to safety the most common" exact="adverse events" post="were nausea, vomiting and fatigue, and the only dose-limiting"/>
   <result pre="signaling) has been found to potentially correlate with poor clinical" exact="outcome" post="for cases of melanoma and GC [ 217]. Despite"/>
   <result pre="M Benefit of adjuvant chemotherapy for resectable gastric cancer: a" exact="meta-analysis" post="JAMA 2010 303 17 1729 1737 20442389 14 Sakuramoto"/>
   <result pre="A Haerting J Fleig WE Chemotherapy for advanced gastric cancer" exact="Cochrane" post="Database Syst Rev 2010 3 CD004064 17 Garrido M"/>
   <result pre="a prognostic marker in gastric cancer? A systematic review with" exact="meta-analysis" post="J Surg Oncol 2014 110 2 129 135 24737677"/>
   <result pre="Richel DJ Van Groeningen C Giaccone G Predictive factors for" exact="outcome" post="in a phase II study of gefitinib in second-line"/>
   <result pre="ZG Role of Notch signaling pathway in gastric cancer: a" exact="meta-analysis" post="of the literature World J Gastroenterol 2014 20 27"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694868/results/search/cochrane/results.xml">
   <result pre="and 10% are ER+/HER2+. The ER+/HER2+ patients have a worse" exact="outcome" post="compared to ER+/HER2- patients. Currently there is a lack"/>
   <result pre="a lack of effective prognosis biomarkers for the prediction of" exact="outcome" post="in ER+/HER2+ patients. Genome-wide differences in ER binding between"/>
   <result pre="direct ER target genes. These genes were correlated to survival" exact="outcome" post="using publicly available breast cancer patient cohorts. We found"/>
   <result pre="expression of SERPINA1 could be predictive for a better clinical" exact="outcome" post="of ER+ and ER+/HER2+ patients. estrogen receptor breast cancer"/>
   <result pre="cells requires HER2 and has significant association with better survival" exact="outcome" post="for ER+/HER2+ breast cancer. SERPINA1, also known as α1-AntiTrypsin"/>
   <result pre="patients. Patients with ER+/HER2+ breast cancer generally have a worse" exact="outcome" post="compared to ER+/HER2- patients [ 17, 18]. Currently there"/>
   <result pre="Currently there is no known predictive marker for the treatment" exact="outcome" post="of ER+/HER2+ breast cancers [ 19], thus the ability"/>
   <result pre="of SERPINA1 was found to associate with better patient survival" exact="outcome" post="in the TCGA large patient cohort, and validated using"/>
   <result pre="show that changes in ER binding is associated with clinical" exact="outcome" post="in breast cancer. There have been extensive studies of"/>
   <result pre="how we can correlate our ER binding data to patient" exact="outcome" post="information using bioinformatics analysis. Our attempts pointed out some"/>
   <result pre="need of large cohorts with detailed clincopathological features and treatment" exact="outcome" post="information for more meaningful prediction. Since the majority of"/>
   <result pre="cancer, but did not show statistical significant correlation with survival" exact="outcome" post="based on our analysis. In early stage breast cancer,"/>
   <result pre="Clinical data has shown that ER+/HER2+ patients generally have worse" exact="outcome" post="than ER-/HER2+ or ER+/HER2- patients [ 17, 18], and"/>
   <result pre="predictive marker to predict a subgroup of patients with better" exact="outcome" post="will be valuable. To investigate whether there are any"/>
   <result pre="good and bad responders, suggesting that SERPINA1 could be an" exact="outcome" post="predictor independent of treatment options. Chemotherapy and HER2-directed therapy"/>
   <result pre="translate results from ER ChIP-seq analysis to breast cancer patient" exact="outcome" post="information. Ross-Innes et al. [ 35] have provided a"/>
   <result pre="a strong precedence that differential ER-binding is associated with clinical" exact="outcome" post="in breast cancer. Based on our findings, we propose"/>
   <result pre="an ER and HER2 regulated gene, is linked to the" exact="outcome" post="of ER+ and ER+/HER2+ breast cancer. MATERIALS AND METHODS"/>
   <result pre="Carroll JS Differential oestrogen receptor binding is associated with clinical" exact="outcome" post="in breast cancer Nature 2012 481 389 393 22217937"/>
   <result pre="the genes involved in the PI3K and estrogen-receptor pathways influence" exact="outcome" post="in human epidermal growth factor receptor 2-positive and hormone"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4696215/results/search/cochrane/results.xml">
   <result pre="January 1, 2005, to September 30, 2012, and who met" exact="eligibility" post="criteria were selected from the Optum Research Database for"/>
   <result pre="16– 21]. Clinical trials target highly selected patients with restrictive" exact="eligibility" post="criteria, limiting the generalizability of outcomes. Therefore, we conducted"/>
   <result pre="date of nab-paclitaxel initiation. Patients who met the cohort entry" exact="eligibility" post="criteria were further categorized into 3 subgroups by line"/>
   <result pre="frequent ICD-9-CM diagnoses codes. The toxicities of interest included select" exact="adverse events" post="consistent with the known safety profile of nab-paclitaxel: neutropenia,"/>
   <result pre="2637 nab-paclitaxel initiators identified during the study period. After the" exact="eligibility" post="criteria were applied, a total of 664 patients remained"/>
   <result pre="receiving nab-paclitaxel in later lines of therapy. Table 4 Select" exact="adverse events" post="among nab-paclitaxel initiators by line of therapy during the"/>
   <result pre="carboplatin in patients with triple-negative MBC [ 29]. The common" exact="adverse events" post="identified in the clinical trials were also explored in"/>
   <result pre="Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a" exact="meta-analysis" post="of randomized trials J Clin Oncol 2008 26 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4700735/results/search/cochrane/results.xml">
   <result pre="cancer. Therefore, the identification of predictive markers of anti-EGFR treatment" exact="outcome" post="to determine the population that would most likely benefit"/>
   <result pre="addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer:" exact="meta-analysis" post="of randomized clinical trials J Exp Clin Cancer Res"/>
   <result pre="Zhu J Zhang J Chen H Chen X An updated" exact="meta-analysis" post="of fatal adverse events caused by bevacizumab therapy in"/>
   <result pre="J Chen H Chen X An updated meta-analysis of fatal" exact="adverse events" post="caused by bevacizumab therapy in cancer patients PLoS One"/>
   <result pre="Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a" exact="meta-analysis" post="Asian Pac J Cancer Prev 2012 13 2903 8"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4703392/results/search/cochrane/results.xml">
   <result pre="developed, and the HER2-specific antibody trastuzumab has profoundly improved treatment" exact="outcome" post="in HER2 overexpressing human breast cancer [ 3]. Nevertheless,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706127/results/search/cochrane/results.xml">
   <result pre="required EGFR expression by immunohistochemistry (IHC) as part of the" exact="eligibility" post="criteria for enrollment. However, in the BOND study, a"/>
   <result pre="of expanded RAS mutations needed or even acceptable? A recent" exact="meta-analysis" post="showed a correlation higher than 92% between KRAS mutations"/>
   <result pre="al. Epidermal growth factor receptor gene copy number and clinical" exact="outcome" post="of metastatic colorectal cancer treated with panitumumab J Clin"/>
   <result pre="Nicolantonio F et al. Association of KRAS p.G13D mutation with" exact="outcome" post="in patients with chemotherapy-refractory metastatic colorectal cancer treated with"/>
   <result pre="patients with advanced colorectal cancer receiving cetuximab and panitumumab: a" exact="meta-analysis" post="Eur J Cancer 2015 51 587 594 25673558 52"/>
   <result pre="anti-EGFR treatment in metastatic colorectal cancer: a systematic review and" exact="meta-analysis" post="Acta Oncol 2014 53 852 864 24666267 53 Prahallad"/>
   <result pre="al. KRASness and PIK3CAness in patients with advanced colorectal cancer:" exact="outcome" post="after treatment with early-phase trials with targeted pathway inhibitors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706528/results/search/cochrane/results.xml">
   <result pre="P=0.25] and was associated with more grade 3 or 4" exact="adverse events" post="(37% vs. 24%) 41 . The BOLERO-2 trial was"/>
   <result pre="failure of treatment with letrozole or anastrozole. The frequency of" exact="adverse events" post="such as stomatitis, fatigue, non-infectious pneumonitis and hyperglycemia, and"/>
   <result pre="highlighting the need for proactive monitoring and early management of" exact="adverse events." post="The median everolimus relative dose intensity of 0.54 (range,"/>
   <result pre="randomised to receive either paclitaxel alone, or paclitaxel plus everolimus." exact="pCR" post="was achieved in 3.6% of patients treated with paclitaxel"/>
   <result pre="should not be chewed or crushed; Advise patients on potential" exact="adverse events" post="including pneumonitis (cough, breathlessness), infections (fever, localising symptoms), hypersensitivity"/>
   <result pre="Clin Oncol 2014;32:abstr 645. 71 Peterson ME . Management of" exact="adverse events" post="in patients with hormone receptor-positive breast cancer treated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706584/results/search/cochrane/results.xml">
   <result pre="PK, efficacy [pathologic complete response (pCR)], and safety [grade ≥3" exact="adverse events" post="(AEs)]. Results Trastuzumab PK was described by a two-compartment"/>
   <result pre="was higher than the prespecified noninferiority margin of 0.80. The" exact="pCR" post="rates were 40.7 and 45.4 % in the IV"/>
   <result pre="explore the exposure–response relationship between PK, pCR, and grade ≥3" exact="adverse events" post="(AEs) for the SC regimen, and (4) to evaluate"/>
   <result pre="relevant covariates were collected. Efficacy data included in the analysis" exact="pCR" post="was defined as &quot;absence of invasive neoplastic cells in"/>
   <result pre="and random residual variability. PK exposure–response analysis The relationship between" exact="pCR" post="and C min,ss was assessed using a multiple logistic"/>
   <result pre="was assessed using a multiple logistic regression (MLR) analysis for" exact="pCR" post="with the covariates C min,ss, body weight, and treatment"/>
   <result pre="and 263 patients in the SC and IV arms, respectively." exact="pCR" post="rates were similar for the IV and SC arms"/>
   <result pre="second highest C min,ss quartile (≥61.5 μg/mL, &amp;lt;78.2 μg/mL), where" exact="pCR" post="rates [54 % ( n = 56) and 53"/>
   <result pre="is limited by the small sample sizes of the subgroups," exact="pCR" post="rates were similar across C min,ss and AUC ss"/>
   <result pre="safety (grade ≥3 AE) by body weight and exposure quartiles" exact="pCR" post="IV trastuzumab n = 263 SC trastuzumab n ="/>
   <result pre="interaction terms with treatment arm) impacted the primary efficacy endpoint," exact="pCR" post="( p &amp;gt; 0.1 for all, Online Resource 11)."/>
   <result pre="(46, 62, and 78 μg/mL). The estimated odds ratios for" exact="pCR" post="were similar in each subgroup, with overlapping CIs. Hence,"/>
   <result pre="relevant impact of predicted C min,ss or body weight on" exact="pCR" post="was observed. Fig. 4 Odds ratios for a pCR"/>
   <result pre="on pCR was observed. Fig. 4 Odds ratios for a" exact="pCR" post="subgroups of body weight and predicted C min,ss quartiles"/>
   <result pre="trastuzumab regimen and route of administration, or body weight and" exact="pCR" post="or AUC ss, trastuzumab regimen and route of administration,"/>
   <result pre="SC dose is further supported by the exposure–response analyses of" exact="pCR" post="and grade ≥3 AEs, which did not identify a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4707213/results/search/cochrane/results.xml">
   <result pre="patients with MBC [ 3], shows some benefits in survival" exact="outcome" post="by multidisciplinary therapies including local modalities. The disease status"/>
   <result pre="have been proved by phase III randomized trials and various" exact="outcome" post="analyses for intracranial metastasis [ 12 13 14]. However,"/>
   <result pre="5-year tumor LC rates were 69.6% and 66.1%, respectively. Our" exact="outcome" post="is comparable or superior to those of other studies."/>
   <result pre="therapy for treating locoregional recurrence in women with breast cancer" exact="Cochrane" post="Database Syst Rev 2001 4 CD002195 11687148 22 Chiang"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708174/results/search/cochrane/results.xml">
   <result pre="and alpelisib had favorable tolerability profiles, with the most common" exact="adverse events" post="consistent with &quot;on-target&quot; inhibition of PI3K; however, clinical efficacy"/>
   <result pre="in KRAS wild-type metastatic colorectal cancer: a systematic review and" exact="meta-analysis" post="Ann Oncol 2012 23 6 1518 1525 22039088 26"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4709394/results/search/cochrane/results.xml">
   <result pre="R Railton C Oren D Lishner M Koren G Pregnancy" exact="outcome" post="following non-obstetric surgical intervention Am J Surg 2005 190"/>
   <result pre="F Dewit M Trastuzumab in pregnancy associated with poor fetal" exact="outcome" post="Ann Oncol 2008 19 191 2 18084047 34 Morice"/>
   <result pre="R Railton C Oren D Lishner M Koren G Pregnancy" exact="outcome" post="following non-obstetric surgical intervention Am J Surg 2005 190"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717619/results/search/cochrane/results.xml">
   <result pre="organs, metastases developed only in specific organs, demonstrating that the" exact="outcome" post="of metastasis is dependent on the cross-talk between tumor"/>
   <result pre="barrier (BBB), and the presence of BM has been an" exact="exclusion" post="criterion for nearly all clinical trials on treatment in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4718910/results/search/cochrane/results.xml">
   <result pre="asthenia, rash, mucosal inflammation and nausea were the most frequent" exact="adverse events." post="In this small, exploratory study, afatinib combined with letrozole"/>
   <result pre="HER2 positivity was not a requirement for study entry. Further" exact="eligibility" post="criteria included: an Eastern Cooperative Oncology Group performance status"/>
   <result pre="Common Terminology Criteria for Adverse Events [NCI CTCAE] version 3.0)" exact="adverse events" post="(AEs) from previous treatment; documented menopause (estradiol level of"/>
   <result pre="than one AE leading to treatment discontinuation. Table 3 Treatment-related" exact="adverse events" post="by afatinib starting dose and reported as NCI CTCAE"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720061/results/search/cochrane/results.xml">
   <result pre="after NAC was also reported to indicate a better prognostic" exact="outcome" post="[ 6, 7]. ER, PR, and HER2 status are"/>
   <result pre="charge. 4. Statistical analysis All statistical analyses were performed using" exact="STATA" post="ver. 10 (StataCorp LP, College Station, TX). Differences in"/>
   <result pre="100 HER2+ tumors (31.1%), and 55 TN tumors (17.1%). A" exact="pCR" post="was achieved in 32 patients (9.9%); 6.6% in the"/>
   <result pre="to NAC, this change continued to demonstrate a significantly worse" exact="outcome" post="in terms of both RFS (hazard ratio, 3.54; 95%"/>
   <result pre="in breast cancer can be altered by neoadjuvant chemotherapy: a" exact="meta-analysis" post="Cancer Invest 2011 29 594 8 22011281 5 van"/>
   <result pre="administration of neoadjuvant chemotherapy and its impact on the long-term" exact="outcome" post="in patients with primary breast cancer Br J Cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720106/results/search/cochrane/results.xml">
   <result pre="R Uske A Mirimanoff RO et al. Diagnosis, treatment, and" exact="outcome" post="of pituitary tumors and other abnormal intrasellar masses. Retrospective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4728453/results/search/cochrane/results.xml">
   <result pre="89, 90, 94]. In FDA’s medical review at approval, a" exact="meta-analysis" post="of phase I studies ( n = 85, range"/>
   <result pre="these results were based on elderly patients who fulfilled the" exact="eligibility" post="criteria of the respective clinical trial, thus including a"/>
   <result pre="with a good performance status. Due to the inclusion and" exact="exclusion" post="criteria, these results cannot plainly be extrapolated to the"/>
   <result pre="on the influence of increasing age on treatment choice and" exact="outcome" post="is discernible in several recent guidelines [ 143, 147,"/>
   <result pre="van de Velde C.J.H. Liefers G.J. Impact of comorbidity on" exact="outcome" post="of older breast cancer patients: A FOCUS cohort study"/>
   <result pre="Smorenburg C.H. van Munster B.C. Frailty screening methods for predicting" exact="outcome" post="of a comprehensive geriatric assessment in elderly patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4729711/results/search/cochrane/results.xml">
   <result pre="cancer [ 2]. The risk of recurrence, disease management and" exact="outcome" post="of these major subtypes vary significantly. Anti-oestrogen therapy is"/>
   <result pre="as disease progression, alternative methods of measuring cavitary lesions (i.e." exact="exclusion" post="of the air component during measurement) have been described"/>
   <result pre="[ 38]. This contributes important prognostic information, as patients with" exact="pCR" post="have significantly higher disease-free and overall survival rates than"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4730993/results/search/cochrane/results.xml">
   <result pre="relapse-free survival, and shorter overall survival. 39, 44 This poorer" exact="outcome" post="extends to those patients with small (&amp;lt;1 cm), node-negative,"/>
   <result pre="in clinical decisions and treatment course do occur based on" exact="outcome" post="predictions from these assays, and thus are included and"/>
   <result pre="different polychemotherapy regimens for early breast cancer: meta-analyses of long-term" exact="outcome" post="among 100,000 women in 123 randomised trials Lancet 2012"/>
   <result pre="de Vijver MJ et al. Gene expression profiling predicts clinical" exact="outcome" post="of breast cancer Nature 2002 415 6871 530 536"/>
   <result pre="MK Viale G et al. The 70-gene prognosis-signature predicts disease" exact="outcome" post="in breast cancer patients with 1–3 positive lymph nodes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4734963/results/search/cochrane/results.xml">
   <result pre="other molecular subtypes in a TCGA study [ 20], a" exact="meta-analysis" post="[ 43] and a recent study regarding the molecular"/>
   <result pre="a prognostic marker in gastric cancer? A systematic review with" exact="meta-analysis" post="J Surg Oncol 2014 110 129 35 24737677 44"/>
   <result pre="71 Puzanov I Amaravadi RK McArthur GA et al. Long-term" exact="outcome" post="in BRAF(V600E) melanoma patients treated with vemurafenib: patterns of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4735094/results/search/cochrane/results.xml">
   <result pre="2, HR hormone receptor, NAT neoadjuvant therapy, OS overall survival," exact="pCR" post="pathological complete response, T- D target-directed therapy, T- DM1"/>
   <result pre="targeted by the investigational T-D agent cDepends on use of" exact="pCR" post="as surrogate for survival (pCR translates to disease-free survival"/>
   <result pre="in the adjuvant setting. Relative to drug development, improvements in" exact="pCR" post="have been correlated with survival outcomes in HER2-positive and"/>
   <result pre="Neosphere trial did not show a statistically significant association between" exact="pCR" post="and 3-year disease-free survival and progression-free survival (PFS) (Gianni"/>
   <result pre="Innovative approaches to neo-adjuvant research, using adaptive Bayesian designs and" exact="pCR" post="as the primary end-point, to rapidly select active novel"/>
   <result pre="arm, or with a primary completion date (date of primary" exact="outcome" post="data collection, or date expected) before January 2012, were"/>
   <result pre="hormone receptor mTOR mammalian target of rapamycin PARP poly(ADP-ribose) polymerase" exact="pCR" post="pathological complete response PI3K phosphoinositide 3-kinase PR progesterone receptor"/>
   <result pre="and other factors to the efficacy of adjuvant tamoxifen: patient-level" exact="meta-analysis" post="of randomised trials Lancet 2011 378 9793 771 784"/>
   <result pre="The efficacy of HER2-targeted agents in metastatic breast cancer: a" exact="meta-analysis" post="Ann Oncol 2011 22 6 1308 1317 10.1093/annonc/mdq593 21119031"/>
   <result pre="Association of genomic analysis of immune function genes and clinical" exact="outcome" post="in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. J"/>
   <result pre="PS Bernards R Friend SH Gene expression profiling predicts clinical" exact="outcome" post="of breast cancer Nature 2002 415 6871 530 536"/>
   <result pre="the adjuvant treatment of HER2-positive early breast cancer patients: a" exact="meta-analysis" post="of published randomized controlled trials PLoS ONE 2011 6"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4736909/results/search/cochrane/results.xml">
   <result pre="were HER2-positive (22.1%). The 594 patients who satisfied all the" exact="eligibility" post="criteria were randomly assigned in a 1 : 1 ratio to"/>
   <result pre="be clinically managed. The most common grades 3 to 4" exact="adverse events" post="were hand-foot syndrome and hypertension. Hematologic toxicities were moderate,"/>
   <result pre="with apatinib group was generally well tolerated. Most of the" exact="adverse events" post="could be controlled by dose interruptions or reductions. Grades"/>
   <result pre="by iv) and a placebo control group, and the primary" exact="outcome" post="was overall survival. The results showed that the median"/>
   <result pre="SOX regimen or the SOX regimen alone. The primary study" exact="outcome" post="was PFS. Their results showed that the PFS for"/>
   <result pre="experienced primary chemotherapy failure is good. But the drug-related sever" exact="adverse events" post="are big problem which may discount patients' quality of"/>
   <result pre="XP regimens or XP regimens alone. PFS was the primary" exact="outcome" post="for this study. The results showed that PFS was"/>
   <result pre="the tumor surface EGFR density of patients, and the low" exact="adverse events" post="rate allows patients who received nimotuzumab plus irinotecan to"/>
   <result pre="randomized to receive everolimus (10 mg/day) or placebo treatment. The main" exact="outcome" post="was overall survival. Their results demonstrated that the OS"/>
   <result pre="versus 10%). The conclusion is that there are no extra" exact="adverse events" post="and more antitumor activity in the treatment group with"/>
   <result pre="or a control group (receiving only ECX) treatment. The main" exact="outcome" post="was overall survival. It was found that the OS"/>
   <result pre="al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data" exact="meta-analysis" post="European Journal of Cancer 2013 49 7 1565 1577"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4738716/results/search/cochrane/results.xml">
   <result pre="possibly be synergistic to the chemotherapy, to improve the clinical" exact="outcome" post="of these patients. 1. Introduction Breast cancer, the most"/>
   <result pre="a result, TNBC subtype tends to have a poor clinical" exact="outcome" post="and an increased risk of recurrence and distant metastasis."/>
   <result pre="implicit necrosis. Tumor necrosis has been associated with a poor" exact="outcome" post="in breast carcinoma [ 34] and usually generates cytokine-like"/>
   <result pre="possibly be synergistic to the chemotherapy to improve the clinical" exact="outcome" post="of these patients. Supplementary Material The Additional file 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4741657/results/search/cochrane/results.xml">
   <result pre="JN et al. HER2 and chromosome 17 effect on patient" exact="outcome" post="in the N9831 adjuvant trastuzumab trial J Clin Oncol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4742525/results/search/cochrane/results.xml">
   <result pre="40] by a pathologist who was blinded to clinical and" exact="outcome" post="data. In cases with different expression between the two"/>
   <result pre="al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data" exact="meta-analysis" post=". European journal of cancer. 2013; 49( 7): 1565–"/>
   <result pre="growth factor receptor in gastric cancer: a systematic review and" exact="meta-analysis" post=". Archives of medical research. 2013; 44( 5): 380–"/>
   <result pre="in gastric carcinomas: HER2 and HER3 are predictors of poor" exact="outcome" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor" exact="outcome" post=". Cancer. 2007; 109( 4): 658– 67. doi: 10.1002/cncr.22445"/>
   <result pre="WL , Richel DJ , et al. Predictive factors for" exact="outcome" post="in a phase II study of gefitinib in second-line"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4743179/results/search/cochrane/results.xml">
   <result pre="been extensively investigated among women with metastatic breast cancer with" exact="meta-analysis" post="indicating that it may be particularly useful among women"/>
   <result pre="The introduction of anti-HER2 therapy has significantly improved the prognostic" exact="outcome" post="of this cohort in both the early stage and"/>
   <result pre="research efforts have focused on trying to improve further prognostic" exact="outcome" post="with the development of novel anti-HER2 agents and looking"/>
   <result pre="The addition of pertuzumab to TDM-1 did not improve prognostic" exact="outcome" post="over trastuzumab and taxane as demonstrated by MARIANNE, suggesting"/>
   <result pre="that may not only be associated with an increase in" exact="adverse events" post="but also would be associated with a significant financial"/>
   <result pre="the addition of 1 year of trastuzumab significantly improves prognostic" exact="outcome" post="among women with early stage HER2-positive breast cancer. The"/>
   <result pre="know that it not only associated with a worse prognostic" exact="outcome" post="but associated with early recurrence; in the clinic, it"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4745781/results/search/cochrane/results.xml">
   <result pre="with the aim of developing therapeutic strategies to improve disease" exact="outcome" post="[ 2]. Given the relevance of tyrosine kinases in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4747990/results/search/cochrane/results.xml">
   <result pre="Japanese medical circumstances. Literature search strategy A systematic review and" exact="meta-analysis" post="of the effectiveness of antiemetic therapy was performed by"/>
   <result pre="structured abstracts were generated for each of the manuscripts included." exact="MEDLINE" post="searches were also performed to identify other randomized controlled"/>
   <result pre="also performed to identify other randomized controlled trials, and the" exact="Cochrane" post="library was reviewed during 2008–2010 [ 5]. Materials from"/>
   <result pre="of formulations for oral, rectal, intravenous, and intramuscular administration. A" exact="meta-analysis" post="of randomized control trials showed equivalence of oral and"/>
   <result pre="during clinical evaluations (CQ14, 16). However, common terminology criteria for" exact="adverse events" post="(CTCAE) may remain useful when chemotherapeutic regimens are applied,"/>
   <result pre="recommendation, were made on the basis of systematic review and" exact="meta-analysis" post="of antiemetic therapy. Consequently, the CQs and their recommendations"/>
   <result pre="in oncology: update 4. www.agreetrust.org/resource-centre/agree-ii/. Accessed June 2009 5. The" exact="Cochrane Library" post="(2009) issue 3 6. Kimura K, Yamada K, Uzuka"/>
   <result pre="Contribution of dexamethasone to control chemotherapy-induced nausea and vomiting; a" exact="meta-analysis" post="of randomized evidence J Clin Oncol 2000 18 3409"/>
   <result pre="for prophylaxis of chemotherapy-induced nausea and vomiting: results of a" exact="meta-analysis" post="of randomized controlled trials Cancer 2000 89 2301 2308"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4750533/results/search/cochrane/results.xml">
   <result pre="Akt inhibitors have been shown to significantly improve the therapeutic" exact="outcome" post="of traditional anticancer drugs. The preclinical tests of several"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4751719/results/search/cochrane/results.xml">
   <result pre="with resistant tumor cell populations that might indicate a worse" exact="outcome" post="in the future. Thus, these patients might benefit from"/>
   <result pre="the neoadjuvant GeparQuattro Trial [ 43]. In a recently published" exact="meta-analysis" post="summarizing the results of several prospective randomized trials of"/>
   <result pre="loss of association between the decrease of CTC number and" exact="pCR" post="[ 44]. Despite the prognostic impact of CTC counts,"/>
   <result pre="89 % and 12 % for relapses. Eligibility criteria The" exact="eligibility" post="criteria were histologically proven BC, BM and blood samples"/>
   <result pre="3 = residual noninvasive tumor only; ductal carcinoma in situ (DCIS)], and" exact="pCR" post="(defined as no evidence of residual invasive cancer and"/>
   <result pre="scaled variables). In parallel, univariable logistic regression models regarding binary" exact="outcome" post="(yes or no) by factor were analyzed. Univariable Cox"/>
   <result pre="count information and missing significant effects for cell counts on" exact="outcome" post="measures in univariable analyses, a multivariable analysis was not"/>
   <result pre="response to NACT with regard to PFS when patients with" exact="pCR" post="or pPR were compared with nonresponders. For OS, no"/>
   <result pre="well as resistant tumor cell populations, which might indicate worse" exact="outcome" post="in the future. These findings underline our assumption that"/>
   <result pre="that DTCs persist after treatment and are associated with worse" exact="outcome" post="has already been described and is explained by a"/>
   <result pre="invasive and painful for monitoring purposes. Unfortunately, a recently published" exact="meta-analysis" post="confirmed that, although CTCs before NACT significantly correlated with"/>
   <result pre="associated NACT neoadjuvant chemotherapy OR odds ratio OS overall survival" exact="pCR" post="pathological complete response PFS progression-free survival PI3K phosphoinositide 3-kinase"/>
   <result pre="JP Neoadjuvant versus adjuvant systemic treatment in breast cancer: a" exact="meta-analysis" post="J Natl Cancer Inst. 2005 97 188 94 10.1093/jnci/dji021"/>
   <result pre="non-metastatic breast cancer after primary surgery are associated with inferior" exact="outcome" post="BMC Cancer. 2012 12 190 10.1186/1471-2407-12-190 22640166 11. Mathiesen"/>
   <result pre="response to neoadjuvant chemotherapy in local advanced breast cancer? A" exact="meta-analysis" post="Oncol Res Treat. 2014 37 250 4 10.1159/000362378 24853784"/>
   <result pre="categories of immunocytochemically positive cells have different impact on clinical" exact="outcome" post="Breast Cancer Res Treat. 2013 138 485 97 10.1007/s10549-013-2439-8"/>
   <result pre="cells in breast cancer may not be associated with clinical" exact="outcome" post="but may favor distant metastasis Clin Cancer Res. 2005"/>
   <result pre="RS Wiedswang G Weyde K Risberg T et al. Clinical" exact="outcome" post="with correlation to disseminated tumor cell (DTC) status after"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4752991/results/search/cochrane/results.xml">
   <result pre="A. P. Yee D. Brattain M. G. Phosphorylation and nuclear" exact="exclusion" post="of the forkhead transcription factor FKHR after epidermal growth"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4754120/results/search/cochrane/results.xml">
   <result pre="like growth factors (IGFs) increase breast cancer risk and poor" exact="outcome" post="in patients. This has led to the development of"/>
   <result pre="as a regular part of their clinical care. These patient-reported" exact="outcome" post="(PRO) instruments should be simple and user-friendly to facilitate"/>
   <result pre="Denosumab was safely administered ( Figure 3). No differences in" exact="adverse events" post="(AEs), serious AEs with denosumab versus placebo was seen."/>
   <result pre="association between the amount of TILs present at diagnosis and" exact="outcome" post="in various cancers. A pooled analysis of studies that"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758093/results/search/cochrane/results.xml">
   <result pre="dose modification was needed for lapatinib. The majority of reported" exact="adverse events" post="(AE) were grade 1 and 2 in severity with"/>
   <result pre="criteria v.1.1, and safety. Safety and Tolerability Safety parameters included" exact="adverse events" post="(AEs) and serious AEs (SAEs), hematology and clinical chemistry,"/>
   <result pre="patients from the others were identified. Safety In total, 117" exact="adverse events" post="have been reported in this study. The relationship to"/>
   <result pre="15.4 % related to both). The majority of the reported" exact="adverse events" post="( n = 105) were grade 1 and 2 in severity."/>
   <result pre="and 2 in severity. One patient experienced two grade 4" exact="adverse events" post="(hyperbilirubinemia and elevated level of GGT). For this patient,"/>
   <result pre="investigator to be unrelated to study treatment. Nine grade 3" exact="adverse events" post="were reported in 5 patients including neutropenia, diarrhea, hepatotoxicity,"/>
   <result pre="with the known lapatinib and vinorelbine safety profiles. Three serious" exact="adverse events" post="have been reported (humerus fracture, pulmonary embolism and hypertension),"/>
   <result pre="of them were considered unrelated to study treatment. Most common" exact="adverse events" post="are summarized in Table 2. Table 2 Most common"/>
   <result pre="events are summarized in Table 2. Table 2 Most common" exact="adverse events" post="Grade 1/2 n (%) Grade 3 n (%) Grade"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4764922/results/search/cochrane/results.xml">
   <result pre="Prevention (Atlanta, USA) for classical χ 2-tests and with the" exact="Stata" post="9.0 software package (StataCorp LP, College Station, USA) for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4769490/results/search/cochrane/results.xml">
   <result pre="therapeutic use of novel Mcl-1- targeting agents to improve patient" exact="outcome" post="in BC. Electronic supplementary material The online version of"/>
   <result pre="behavior; that is, increased rate of metastasis, and poor clinical" exact="outcome" post="without Her2-targeted treatment [ 10]. Unprecedented therapeutic advances have"/>
   <result pre="the therapeutic use of novel Mcl-1-targeting agents to improve patient" exact="outcome" post="in BC. Methods Materials Lapatinib ditosylate and ABT-199 were"/>
   <result pre="normoxic and hypoxic conditions in order to further improve patient" exact="outcome" post="in BC. Additional file LINK Additional file 1: Figure"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4772532/results/search/cochrane/results.xml">
   <result pre="individual needs) to treatments are well reflected in the disappointing" exact="outcome" post="of current chemotherapies, where drug agents directed at an"/>
   <result pre="development of molecular tools with better predictive power for patient" exact="outcome" post="and response to treatment has long been a subject"/>
   <result pre="and throughout treatment because the subclone that influences a disease" exact="outcome" post="may not be detectable in a single biopsy ["/>
   <result pre="inhibitor) and fulvestrant to treat advanced BCs has a better" exact="outcome" post="than fulvestrant used alone. Anastrozole and letrozole can be"/>
   <result pre="tumors in postmenopausal women. Endocrine therapy has significantly improved the" exact="outcome" post="of patients with early- and advanced-stage HR+ BCs. However"/>
   <result pre="knowledge is progressively integrated with patient therapy to improve disease" exact="outcome" post="considering features such as personal medical history, physiological index,"/>
   <result pre="for patient’s response to chemotherapy being positively correlated with clinical" exact="outcome" post="expectation. Since the oncogenesis process involves the dysregulation of"/>
   <result pre="correlated alterations in the expression of individual genes with disease" exact="outcome" post="according to contradicting results. Some important claims about markers"/>
   <result pre="%) of them reached the proliferative phenotype. The other significant" exact="outcome" post="of this modeling approach was that the monotherapies tested"/>
   <result pre="for adjuvant therapy of early breast cancer in premenopausal women" exact="Cochrane" post="Database Syst Rev 2009 4 CD004562 19821328 109. Diaby"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
